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Diabetes, a metabolic disorder characterised by chronic hyperglycaemia due 
to relative insulin deficiency, insulin resistance or both, is associated with micro- and 
macro- vascular complications. Diabetes mellitus and impaired glucose tolerance are 
linked to increase cardiovascular morbidity and mortality. Endothelial and smooth 
muscle cells are the major factors in the development of cardiovascular diseases.
Both diabetes and hypertension have been shown to produce tissue hypoxia -  
a reduction in the normal level of tissue oxygen -  that can occur from direct 
decreases in blood supply or from venous/arterial occlusion. Cellular responses to 
hypoxia include proliferation, angiogenesis, metabolism, apoptosis and migration. 
Therefore, we investigated the effects of hyperglycaemia on bovine aortic endothelial 
cell (BAEC) and bovine aortic smooth muscle cell (BASMC) growth (proliferation 
and apoptosis) under normoxic and hypoxic conditions.
Exposure of BAEC and BASMC to high glucose in media containing 10% 
fetal bovine serum (FBS) did not alter cell apoptosis and proliferation under 
normoxic conditions. Although serum deprivation (0.5% FBS containing media) 
significantly increased cell apoptosis and decreased cell proliferation under normoxic 
conditions, exposure to high glucose did not show any positive or negative effects. 
Mannitol, as controls for osmolarity, excluded the possibility of involvement of an 
osmotic effect on cells.
Hypoxia increased cell apoptosis and suppressed cell proliferation however; 
these effects on hypoxia-induced cell apoptosis and inhibition of proliferation were 
significantly reversed in the presence of high glucose.
The most evident response to hypoxia is via hypoxia-inducible factor 1 alpha 
(HIF-la). To investigate if hyperglycaemia modulated cell apoptosis and 
proliferation under hypoxic conditions through HIF-la; HIF-la expression was 
silenced following siRNA knockdown. Under these conditions, the hypoxia 
induced response was significantly impaired.
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Taken together, these studies suggest that hyperglycaemia has no effect on 
BAEC and BASMC cell fate under normoxic conditions; hyperglycaemia impairs 
hypoxia-induced apoptosis and hypoxia-induced inhibition of cell proliferation under 
hypoxic conditions which is via a HIF-la-dependent mechanism.
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Introduction
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Diabetes mellitus is a group of metabolic disease characterized by 
hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. 
The chronic hyperglycaemia of diabetes is associated with long-term damage, 
dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, 
and blood vessels (Association 2004).
The long-term mortality and morbidity rate for diabetic patients with a 
diabetic vascular disease are significantly elevated relative to that of the nondiabetic 
patients (Aronson et al. 1997). Endothelial Cell (EC) and Smooth Muscle Cell 
(SMC) dysfunctions are the key factors which result in atherosclerosis, thrombosis 
and hypertension.
It has become increasingly evident that hypoxia plays an important role in all 
diabetes complications (Cameron et al. 2001). Atherosclerosis, a major 
complication of diabetes, highlights the fact that the more deeply situated parts of the 
arterial wall depend on diffusion to satisfy their need for oxygen and nutrients. 
When atherosclerosis lesions develop, the arterial wall thickness increases and 
diffusion capacity is impaired. Simultaneously, oxygen consumption is augmented 
(Bjornheden and Bondjers 1987) and an energy imbalance may occur.
In addition to deficient blood supply as a consequence of micro- and 
macrovascular disease, it has been postulated that hyperglycaemia induces a 
pseudohypoxia states. This theory is based on the finding that hyperglycaemic 
concentrations induce a high NADH+/NAD+ ratio in cells even when the oxygen 
tension is normal (Williamson et al. 1993).
Hyperglycaemia and hypoxia are suggested to play essential 
pathophysiological roles in the complications of diabetes, which may result from a 
defective response of the tissues to low oxygen tension. The possibility that 
hyperglycaemia and hypoxia may interact via a common metabolic imbalance to 
initiate and/or exacerbate complications of diabetes is suggested by the 
correspondence of several redox, metabolic, and pathophysiological changes evoked 
by either condition alone (Nyengaard et al. 2004).
Adaptive responses of cells to hypoxia are mediated by various 
hypoxia-responsive transcription factors. Hypoxia-inducible factor (HIF) is a 
master regulator during hypoxic stress which binds to the hypoxia response elements
1.1 R esearch  A im s
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(HRE) in the promoter or enhancer of the target genes such as vascular endothelial 
growth factor (VEGF), platelet-derived growth factor (PDGF), glucose transporter-1 
(GLUT-1), p53 to induce angiogenesis, glycolysis, proliferation and apoptosis 
(Schofield and Ratcliffe 2004).
We are interested to study the interaction between these two denominators of 
the chronic complications of diabetes (hyperglycaemia and hypoxia) as well as the 
interactions between other factors suggested to play role in chronic complications of 
diabetes and hypoxia.
A im  1: To investigate the effects of high glucose (HG 25mM) on Bovine
Aortic Endothelial Cell (BAEC) and Bovine Aortic Smooth Muscle 
Cell (BASMC) growth (balance between proliferation and apoptosis).
A im  2 : To investigate the effects of hypoxia (2% O2) on BAEC and BASMC
growth (proliferation vs apoptosis) in the absence or presence of FIG 
(25mM).
A im  3 : To investigate the role of HIF-la as a target for hyperglycaemia
(25mM HG) in hypoxia-induced apoptosis and proliferation.
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Diabetes Mellitus (DM) is a disease in which the body does not produce or 
properly use insulin. Insulin is a hormone that transports glucose, converts starches 
and other food into energy needed for daily life. The cause of diabetes continues to 
be a mystesry, although both genetics and environmental factors such as obesity and 
lack of exercise appear to play roles.
Diabetes was recognized, and its clinical features were recorded, over 
thousands of years ago and our understanding of the disease has progressed and 
advanced greatly, especially during the last two decades, but many aspects of its 
management are still enigmatic. The goal of preventing diabetes and thus, the 
long-term complications, has become evermore important as the disease threatens to 
explode to epidemic proportions.
The number of patients with diabetes is increasing due to population growth, 
aging, urbanization and the increasing prevalence of obesity and physical inactivity. 
In the year 2000, the number of diabetes cases worldwide among adults > 20 years of 
age was estimated to be approximately 171 million; 11% higher than the 154 million 
previously reported by the WHO in 1990. The International Diabetes Federation 
has subsequently released estimates of the number of people with diabetes for 2003 
and 2025, at 194 million and 334 million respectively, indicating that DM will 
remain a global health threat.
In order to determine whether or not a patient has pre-diabetes or diabetes, 
there are several major symptoms which are clinically recognized namely: frequent 
urination; excessive thirst; extreme hunger; unusual weight loss; increased fatigue; 
irritability and blurred vision, in conjunction with any one of the following three 
criteria: a random plasma sugar level greater than 11 mmol/1; a fasting plasma sugar 
level greater than or equal to 7 mmol/1 (or 6.1 mmol/1 in whole blood); a plasma 
sugar level greater than 11 mmol/1 two hours after drinking 75 grams of glucose 
dissolved in water in an oral glucose tolerance test (OGTT).
1.2 Diabetes Mellitus (DM)
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1 .2 .1  C la s s i f ic a t io n  o f  D ia b e te s  M e l l i t u s
The vast majority of cases of diabetes fall into two broad etiopathogenetic 
categories which were given names descriptive of their clinical presentation: 
"insulin-dependent diabetes mellitus" (IDDM) and "non insulin-dependent diabetes 
mellitus" (NIDDM).
( a )  T y p e  1 D ia b e te s  M e l l i t u s  - This form of diabetes is characterized by 
(3-cell destruction, usually leading to absolute insulin deficiency.
The development of type 1 diabetes may be viewed as a two-step process. 
During the first step, presumed environmental triggers such as virus infection cause 
the destruction of beta cells. It is assumed that pancreatic antigen-presenting cells 
engulf dead beta cells. The antigen-presenting cells are thought to migrate to lymph 
nodes that drain the pancreas and in which islet-beta-cell-specific antigen 
presentation takes place (Kent et al. 2005). CD4+ T lymphocytes with T cell 
receptors that recognize beta-cell peptides lodged in a groove in the human leukocyte 
antigen (HLA) class II molecule may then be activated, which initiates an islet auto 
immune reaction. After auto-antibodies have developed, there is a second step, in 
which genetic as well as environmental factors may aggravate the islet autoimmunity. 
It is possible that CD8+ cytotoxic T cells are induced, leading to a rapid onslaught on 
beta cells (Pundziute-Lycka et al. 2002).
Onset is most common in childhood, thus the common term "juvenile-onset", 
but the onset up to age 40 is not uncommon and can even occur later. Patients are 
susceptible to diabetic ketoacidosis (DKA) which is a state of absolute or relative 
insulin deficiency aggravated by ensuing hyperglycaemia, dehydration, and 
acidosis-producing derangements in intermediary metabolism. This condition 
causes underlying infection, disruption of insulin treatment, and new onset of 
diabetes. DKA is typically characterized by hyperglycaemia over 300 mg/dL, low 
bicarbonate (<15 mEq/L), and acidosis (pH <7.30) with ketonemia (the presence of 
detectable levels of ketone bodies in the plasma) and ketonuria (an excessive 
concentration of ketone bodies in the urine).
( b )  T y p e  2  D ia b e te s  M e l l i t u s  - Type 2 diabetes is characterized by 
insulin resistance with relative insulin deficiency to predominatly an insulin 
secretory defect with insulin resistance.
Type 2 diabetics have a high (hyperinsulinemia) or normal basal insulin level 
and fewer insulin receptors on insulin-sensitive target tissues. The large majority of 
patients are overweight at onset. Most are over 40, hence the common terms 
"adult-onset", but onset can occur at any age. Patients are not susceptible to DKA 
(diabetic ketoacidosis).
There is a strong genetic tendency which is highly associated with a family 
history of diabetes, but not simple inheritance. Depending on the individual, 
treatment may be by diet, exercise weight loss, oral medications which stimulate the 
release of insulin, or the suppression of glucose production, or insulin injections. 
Patients are usually subjected to a combination of several of these treatments. 
Insulin resistance and hyperinsulinemia eventually lead to impaired glucose tolerance. 
Defective beta cells become exhausted, further fuelling the cycle of glucose 
intolerance and hyperglycaemia. The aetiology of type 2 diabetes mellitus is 
multifactorial and probably genetically based, but it also has strong behavioural 
components such as diet and exercise.
1.2.2 Clinical Complications of Diabetes Mellitus
The clinical complications of diabetes mellitus can be broadly classified into 
micro-vascular complications and macro-vascular complications.
Micro-vascular disease affects the retina which presents as diabetic retinopathy. 
Neuropathy presents with numbness and parasthesia, and often the formation of 
trophic ulceration on the feet secondary to reduced sensation. Diabetic nephropathy 
is the leading cause of kidney failure and presentation is determinant upon the stage 
of the disease ranging from mild proteinuria (protein in the urine) to renal failure or 
multi-system failure.
The macro-vascular disease is reflected in premature atherosclerosis, 
coronary heart disease and peripheral vascular disease. Abnormalities in vascular 
reactivity in both macro and micro-vascular disease are well established in diabetes 
(NDDG 1979; ECDM 1980; WHOTRS 1985; DCCT 1993). Macrovascular disease 
presents as premature atherosclerosis, stroke, coronary heart disease and poor 
perfusion to the distal limbs presenting as intermittent claudication secondary to 
ischaemia. Ulceration is also common.
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1.2.3 Diabetic Effects on the Vasculature
Angiopathy is the generic term for a disease of the blood vessels (arteries, 
veins, and capillaries). The best known and most prevalent angiopathy is diabetic 
angiopathy; a complication that may occur in chronic diabetes.
There are two types of angiopathy: macroangiopathy and microangiopathy. In 
macroangiopathy, fat and blood clots build up in the large blood vessels, stick to the 
vessel walls, and block the flow of blood. In microangiopathy, the walls of the 
smaller blood vessels become so thick and weak that they bleed, leak protein, and 
slow the flow of blood through the body. The decrease of blood flow through 
stenosis or clot formation impairs the flow of oxygen to cells and biological tissues 
and leads to their death (necrosis) which in turn may require amputation. Thus, 
tissues which are very sensitive to oxygen levels develop microangiopathy and may 
cause blindness. Damage to nerve cells may cause peripheral neuropathy, and to 
kidney cells, diabetic nephropathy.
Macroangiopathy, on the other hand, may cause other complications such as 
ischemic heart disease, stroke and peripheral vascular disease which contribute to 
diabetic foot ulcers and the risk of amputation.
The term ‘diabetic angiopathy’ suggests that the pathological processes 
involved in the development of micro- and macro-angiopathies are uniform, 
irrespective of the type of diabetes. However, both micro- and macroangiopathy 
exhibit specific stages in their development and there is emerging evidence that the 
pathophysiology of microangiopathy may differ between type 1 and type 2 diabetes 
(Tooke et al. 1996).
Type 1 diabetes is characterized by an early increase in microvascular 
pressure and flow. It is thought that this leads to endothelial injury and resultant 
capillary basement membrane thickening and microvascular sclerosis. This in turn 
limits maximum hyperaemia and impairs the autoregulatory capacity of the 
vasculature (Parving et al. 1983). In contrast, in type 2 diabetes in the absence of 
hypertension, microvascular pressure appears normal (Shore et al. 1992). There is 
however a profound early reduction in vasodilatory reserve and increasing evidence 
that this abnormality, which probably represents endothelial dysfunction, precedes 
the development of diabetes (Tooke and Goh 1999). Whether or not endothelial 
dysfunction is itself a cause of insulin resistance through impaired insulin-mediated 
vasodilation of skeletal muscle remains debatable.
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1.3 Vascular Disease
The metabolic abnormalities associated with DM result in vascular 
complications in multiple organ systems though it is the cardiovascular impact that 
accounts for the greatest morbidity and mortality associated with the disease. 
Cardiovascular diseases are any disease of the circulatory system, chief among which 
are myocardial infarction, cerebrovascular disease, and other peripheral vascular 
diseases. Cardiovascular diseases are the leading cause of death in the western 
world, accounting for 40% of all deaths in the United States. An estimated 17 million 
people die due to cardiovascular disease per annum, which translates into one death 
every 30 seconds. The incidence of cardiovascular disease in Ireland is the highest 
in the European Union (EU), with 53 deaths per 100,000 population compared to the 
EU average of 32. In addition, it is estimated that one quarter of people in the 
western world live with cardiovascular disease, resulting in a significant economic 
impact both in terms of health care expenditures and lost productivity (World Health 
Organization, American Heart Foundation). Therefore, an increased understanding of 
the mechanisms underlying the pathology of cardiovascular diseases is imperative 
both in the prevention and management of this condition.
A number of risk factors are associated with the development of 
cardiovascular diseases, including genetic pre-disposition, gender, age and race. 
Many factors, however, are lifestyle determined, such as poor nutrition, obesity, lack 
of exercise and smoking. A diet high in saturated fat and cholesterol can increase the 
risk of developing certain cardiovascular disorders. Whilst cholesterol has important 
functions in the body, such as the formation of cellular membranes, it is important 
that the correct ratio of cholesterols within the body is maintained. Cholesterol is 
insoluble in blood and is transported in the esterified form via plasma lipoproteins, 
namely high density lipoproteins (HDL), low density lipoproteins (LDL) and very 
low density lipoproteins (VLDL). The ratio of HDL to LDL is an important factor 
in determining the risk that cholesterol presents in the development of 
atherosclerosis.
8
1.3.1 Atherosclerosis
Atherosclerosis from the Greek athero (meaning gruel or paste) and sclerosis 
(hardness) is the process in which deposits of fatty substances, cholesterol, cellular 
waste products, calcium and other substances build up in the inner lining of an artery 
to form a plaque.
Atherosclerotic vascular disease, the primary cause of all cardiovascular 
diseases, is a systemic disease involving the intima of large and medium arteries 
including the aorta, carotid, coronary and peripheral arteries (Corti and Badimon 
2002). Atherosclerosis is characterized by a dysfunctional endothelium; chronic 
inflammation; lipid accumulation; aberrant regulation of vascular smooth muscle cell 
(VSMC) fate decisions; and often calcification, which clinically manifests as an 
atherosclerotic plaque. Key risk factors associated with the development of 
atherosclerosis include: elevated LDL and low HDL levels (Sharrett et al. 1994); an 
increased level of homocysteine in the blood due to dietary deficiencies in vitamins 
B6, B12 and folic acid (Boers 2000); obesity; and smoking.
Obesity is a considerable problem in Ireland, where 57% of people are 
considered overweight or obese (Livingstone et al. 2001). Regular exercise can 
help combat or prevent obesity, in addition to increasing HDL levels in the 
circulation (Irish Heart Foundation). Smoking directly damages the endothelium; 
increases vascular tone; increases platelet activation; and promotes LDL oxidation 
(Muscat et al. 1991). Smoking increases the risk of developing cardiovascular 
disease by 50% and contributes to one fifth of all cardiovascular related deaths 
(American Heart Association).
The generation of obstructive plaques can result in additional cardiovascular 
disorders, for example, an obstructive coronary plaque can cause a critical reduction 
in coronary blood flow, and subsequent myocardial ischaemia (Schroeder and Falk 
1995). Plaques can grow large enough to significantly reduce the blood's flow 
through an artery but most of the damage occurs when they become fragile and 
rupture. Ruptured plaques can result in the formation of a thrombus that can block 
blood flow or break off and travel to other parts of the body. If either happens and 
blocks a blood vessel that feed the heart, it causes a ‘heart attack’. If it blocks a blood 
vessel that feeds the brain, it causes a stroke. Reduced blood supply to the arms or 
legs can cause difficulty walking and eventually result in cellular necrosis which may 
require amputation of the limb.
Atherosclerotic plaques occur preferentially at bifurcations and curvatures of 
arterial blood vessels due to the presence of disturbed blood flow at these sites 
(Glagov et al. 1988). Atherosclerotic lesions form at distinct sites in the arterial tree, 
especially at or near branch points, bifurcations, and curvatures. This distribution 
pattern suggests that local factors, such as hemodynamic forces (shear stress) that can 
be sensed by endothelial cells lining the artery wall, influence the initiation of 
atherogenesis. Blood flow is disturbed at branch points, bifurcations, and curvatures, 
unlike straight segments where it tends to be laminar. Alterations in shear stress can 
alter endothelial cell gene expression and modulates the expression of adhesion 
molecules. Hemodynamic forces may also influence topographic variations in gene 
expression by endothelial cells in arteries and may predispose regions to 
atherosclerotic lesion formation if appropriate systemic risk factors are present.
1.3.2 Hypertension (high blood pressure)
Blood is carried from the heart to all the body's tissues and organs via arteries. 
Blood pressure is the force of the blood pushing against the walls of those arteries. 
Hypertension (high blood pressure) is defined as either a systolic pressure 
consistently at 140/mmHg or higher or a diastolic pressure consistently at 90/mmHg 
or higher comparing to normal blood pressure which is considered to be 120/80 
mmHg.
Hypertension can develop due to a genetic pre-disposition or may be 
environmentally induced due to poor diet, obesity, smoking and lack of exercise. In 
addition, the development of hypertension is itself a major risk factor in the 
development of cardiovascular diseases such as atherosclerosis, heart attack, stroke 
and enlarged heart. It also can result in VSMC hypertrophy and hyperplasia, and a 
subsequent increase in peripheral vascular resistance (Molloy et al. 1999).
The mechanisms behind the factors associated with secondary hypertension 
(hypertension that is secondary to another disease) are generally fully understood. 
However, those associated with essential hypertension are far less understood. 
What is known about inessential hypertension is that cardiac output is raised early in 
the disease course, with total peripheral resistance remaining normal; over time, 
cardiac output (the volume of blood being pumped by the heart in a minute; equal to 
the heart rate multiplied by the stroke volume) drops to normal levels but TPR 
(temperature, pulse, respiration) is increased. Three theories have been proposed to
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e x p la in  th is : (i) in a b ili ty  o f  th e  k id n e y s  to  e x c re te  so d iu tn , re s u lt in g  in  n a tr iu re tic  
f a c to r  b e in g  se c re te d  to  p ro m o te  s a lt e x c re t io n  w ith  th e  s id e -e f fe c t  o f  ra is in g  to ta l  
p e r ip h e ra l  re s is ta n c e ; ( ii)  a n  o v e ra c tiv e  r e n in  / A n g io te n s in  s y s te m  le a d s  to  
v a s o c o n s tr ic t io n  a n d  re te n tio n  o f  so d iu m  an d  w a te r. T h e  in c re a se  in  b lo o d  v o lu m e  
le a d s  to  h y p e r te n s io n ; ( iii)  a n  o v e ra c tiv e  s y m p a th e tic  n e rv o u s  sy s te m , le a d in g  to  
in c re a s e d  s tre ss  re sp o n se s .
M a lig n a n t h y p e r te n s io n  (o r  a c c e le ra te d  h y p e r te n s io n )  w h ic h  is a  c o m p lic a tio n  
o f  h y p e r te n s io n  c h a ra c te r iz e d  b y  v e ry  e le v a te d  b lo o d  p re s s u re  (> 2 4 0 /1 2 0  m m  H g ) is 
d is t in c t  a s  a  la te  p h a se  in  th e  c o n d itio n , a n d  m a y  p re s e n t  w ith  h e a d a c h e s , b lu rre d  
v is io n  a n d  e n d -o rg a n  d a m a g e .
E le v a te d  b lo o d  p re s s u re  is  k n o w n  to  c o n tr ib u te  to  d ia b e tic  m ic ro v a s c u la r  
c o m p lic a tio n s  su c h  as re n a l d is e a se , a u to n o m ic  n e u ro p a th y , re t in o p a th y  an d  
m a c ro v a s c u la r  c o m p lic a t io n s  su c h  as c a rd ia c  d ise a se , c e re b ro v a s c u la r  d is e a se  a n d  
p e r ip h e ra l  v a s c u la r  d is e a se  (U K P D S  1998; F in e b e rg  19 9 9 ; B a k r is  e t  al. 2 0 0 0 ).
H y p e r te n s io n  f re q u e n tly  c o e x is ts  w ith  d ia b e te s . T h e re  is  a n  in c re a s e d  
p re v a le n c e  o f  h y p e r te n s io n  a m o n g  d ia b e tic  p a tie n ts  (S o w e rs  e t al. 2 0 0 1 ) , b u t th e re  is 
a lso  a  h ig h e r  p ro p e n s ity  a m o n g  h y p e r te n s iv e  p a t ie n ts  to  d e v e lo p  ty p e  2 d ia b e te s  
(S to lk  e t  al. 1993 ; G re s s  e t al. 2 0 0 0 ) . W h e n  o c c u rr in g  to g e th e r , th e  tw o  d ise a se  
e n tit ie s  a p p e a r  to  a g g ra v a te  o n e  a n o th e r , w o rs e n in g  b o th  th e  d ia b e tic  an d  
c a rd io v a s c u la r  C V  e n d  p o in ts  (S ta m le r  e t al. 1993). T w e lv e -y e a r  fo l lo w -u p  d a ta  f ro m  
th e  la rg e  M u lt ip le  R isk  F a c to r  In te rv e n tio n  T ria l (M R F IT , 1971) s h o w e d  th a t 
a b s o lu te  r is k  o f  d e a th  f ro m  c a rd io v a s c u la r  d ise a se  a p p ro x im a te ly  t r ip le d  fo r  d ia b e tic  
c o m p a re d  w ith  n o n d ia b e tic  p a tie n ts . W ith  a  r is e  in  sy s to lic  b lo o d  p re s s u re , th e  
a b s o lu te  c a rd io v a s c u la r  r is k  fo r  d ia b e tic  p a tie n ts  in c re a se d  b e y o n d  th a t  o f  
n o n d ia b e tic  p a tie n ts  (S ta m le r  e t al. 1993). H y p e r te n s io n  a lso  a c c e le ra te s  k id n e y  
d a m a g e  a n d  m ic ro v a s c u la r  d is e a se  (A d le r  e t al. 2 0 0 0 ).
D y s re g u la te d  in s u lin  p ro d u c tio n  h a s  fu r th e r  c o n s e q u e n c e s . I t p ro m o te s  
v a s c u la r  s m o o th  m u s c le  c e ll  p ro life ra t io n  a n d  e x tra c e l lu la r  m a tr ix  d e p o s itio n . 
E le v a te d  b lo o d  g lu c o se  le v e ls  a lso  m e d ia te  s tru c tu ra l c h a n g e s  to  th e  v a sc u la tu re . It is 
th is  s tru c tu ra lly  c o m p ro m is e d  v a sc u la tu re , fo u n d  th ro u g h o u t th e  b o d y , w h ic h  a p p e a rs  
to  b e  p a r t ic u la r ly  s e n s itiv e  to  d a m a g e  b y  e le v a te d  b lo o d  p re s su re .
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Changes in the structure function and integrity o f arterial blood vessels is 
central to the pathogenesis o f many cardiovascular diseases. The arterial blood vessel 
is an active, integrated organ composed o f endothelial cells (EC), smooth muscle 
cells (SMC) and fibroblasts divided into three structural layers, termed the tunicas 
intima, media and adventitia (Fig 1.1).
1.4 The Vasculature
Endothelial cells 
Elastin
Smooth muscle
Loose fibrous 
connective tissue
Epithelial cells
LumenLumen
Tunica
Media
Artery Vein
runica
Adventitia
Tunica Intima Tunica Intima
Fig. 1.1 D iagram m atic Representation o f M acrovascular Vessel Structure
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T h e  in n e rm o s t  la y e r, th e  tu n ic a  in tim a , is  a  s im p le  s q u a m o u s  e p ith e liu m  
s u r ro u n d e d  b y  a c o n n e c tiv e  t is s u e  b a s e m e n t m e m b ra n e  w ith  e la s tic  f ib re s . T h e  
u n d e r ly in g  tu n ic a  m e d ia  is p r im a r i ly  c o m p r is e d  o f  s m o o th  m u s c le  c e lls , w h ic h  p la y  a  
k e y  ro le  in  m a in ta in in g  v a s c u la r  to n e  an d  fu n c tio n . S M C  a re  o r ie n ta te d
c irc u m fe re n tia l ly  in  th e  o u te r  m e d ia , b u t  c lo se r  to  th e  lu m e n  th e y  p re s e n t  in  a  m o re  
ra n d o m  fa s h io n  (G itte n b e rg e r -d e  G ro o t  e t al. 1 9 99 ). S e v e ra l s tu d ie s  h a v e  
d e m o n s tra te d  a  m a rk e d  h e te ro g e n e ity  o f  S M C  p h e n o ty p e s  in  th e  v e s se l w a ll o f  b o th  
h u m a n  a n d  a n im a l m o d e ls . T h e se  p h e n o ty p e s  a re  c la s s if ie d  as sy n th e tic  a n d  
c o n tra c tile , an d  a re  e v id e n t  e m b ry o n ic a lly  b u t b e c o m e  m o re  p ro m in e n t a s  th e  v e s se l 
m a tu re s . W h ils t  b o th  th e  in tim a l a n d  m e d ia l la y e rs  c o n ta in  a  m ix tu re  o f  b o th  
p h e n o ty p e s , th e  s y n th e tic  p h e n o ty p e  is  m o s t  c o m m o n ly  a s s o c ia te d  w ith  th e  in tim a l 
la y e r  a n d  w ith  v a s c u la r  re m o d e llin g . T h e  s y n th e tic  S M C s  re s e m b le  im m a tu re , 
d e d if fe re n tia te d  S M C  w ith  lo w e r  le v e ls  o f  c o n tra c ti le  p ro te in s  (a -a c tin ,  m y o s in , 
c a lp o n in , sm o o th e lin )  a n d  fe w e r  m y o f ila m e n ts  th a n  th e ir  m e d ia l  c o u n te rp a r ts  
(S h a n a h a n  e t a l. 19 9 3 ; B o c h a to n -P ia l la t  e t al. 1995 ; G itte n b e rg e r -d e  G ro o t e t al.
1 9 9 9 ). T h e s e  in tim a l c e lls  a re  sa id  to  b e  s im ila r  in  b o th  m o rp h o lo g y  an d  g e n e  
e x p re s s io n  to  fo e ta l o r  e m b ry o n ic  S M C , a n d  h a v e  b e e n  s h o w n  to  be  m o re  p ro n e  to  
b o th  p h y s io lo g ic a l  a n d  p a th o p h y s io lo g ic a l  a p o p to s is  th a n  th e  m e d ia l S M C  
(B o c h a to n -P ia l la t  e t al. 199 5 ; R a o  a n d  W h ite  19 9 7 ; S lo m p  e t al. 1 9 97). T h e  
c o n tra c ti le  S M C , o n  th e  o th e r  h a n d , a re  m o s t  c o m m o n ly  a s s o c ia te d  w ith  th e  tu n ic a  
m e d ia . T h e y  e x p re s s  d if fe re n tia te d  c e ll m a rk e rs  a s s o c ia te d  w ith  c o n tra c ti le  fu n c tio n  
a n d  a re  in v o lv e d  in  th e  sy n th e s is  a n d  m a in te n a n c e  o f  e x tra c e llu la r  c o m p o n e n ts  o f  th e  
v e s s e l w a ll. S m o o th  m u s c le  c o n tra c t io n  is  c a u se d  b y  th e  s lid in g  o f  m y o s in  an d  
a c tin  f ib re s  o v e r  e a c h  o th e r . T h e  e n e rg y  fo r  th is  to  h a p p e n  is  p ro v id e d  b y  h y d ro ly s is  
o f  A T P . M o v e m e n t o f  th e  f ib re s  o v e r  e a c h  o th e r  h a p p e n s  w h e n  h e a d s  o n  th e  
m y o s in  f ib re s  fo rm  c ro s s b r id g e s  w ith  th e  a c tin  f ib re . T h e se  h e a d s  t i l t  a n d  d ra g  th e  
a c tin  f ib re  a sm a ll d is ta n c e . T h e  h e a d s  th e n  re le a s e  th e  a c tin  f ib re  a n d  a d o p t th e ir  
o r ig in a l c o n fo rm a tio n . T h e y  c a n  th e n  re -b in d  to  a n o th e r  p a r t  o f  th e  a c tin  m o le c u le  
a n d  d ra g  it  a lo n g  fu r th e r . T h is  p ro c e s s  is  c a lle d  c ro s s b r id g e  c y c lin g  a n d  is th e  sam e  
fo r  a ll m u sc le .
C ro s s b r id g e  c y c lin g , th o u g h , c a n n o t o c c u r  u n til th e  m y o s in  h e a d s  h a v e  b e e n  
a c tiv a te d  to  a l lo w  c ro s s b r id g e s  to  fo rm . T h e  m y o s in  h e a d s  a re  m a d e  u p  o f  a  " lig h t"  
p ro te in  c h a in . W h e n  th is  is  p h o sp h o ry la te d  it b e c o m e s  a c tiv e  a n d  w ill a llo w  
c o n tra c t io n  to  o c c u r. T h e  e n z y m e  th a t  p h o s p h o ry la te s  th e  l ig h t c h a in  is  c a lle d  m y o s in
l ig h t c h a in  k in a se  (M L C K ). In  o rd e r  to  c o n tro l c o n tra c tio n , M L C K  w ill o n ly  w o rk  
w h e n  th e  m u s c le  is s tim u la te d  to  c o n tra c t. S t im u la tio n  w ill in c re a se  th e  in tra c e llu la r  
c o n c e n tra t io n  o f  c a lc iu m  io n s . T h e se  b in d  to  a  m o lc u le  c a lle d  c a lm o d u lin  a n d  fo rm  a 
c a lc iu m -c a lm o d u lin  c o m p le x . It is  th is  c o m p le x  th a t  w ill b in d  to  M L C K  to  a c tiv a te  it, 
a l lo w in g  th e  c h a in  o f  re a c tio n s  fo r  c o n tra c tio n  to  o ccu r.
M L C K  c a n  b e  in h ib ite d  to  p re v e n t  c ro s sb r id g e  c y c lin g : th is  c a u se s  re la x a tio n  
o f  th e  m u s c le . I t is  b y  c a u s in g  in h ib it io n  o f  M L C K  th o s e  v a s o d ila to rs  su ch  as 
e n d o th e liu m -d e r iv e d  re la x in g  fa c to r , o r  n itr ic  o x id e  (N O ), w o rk  to  d ila te  b lo o d  
v e sse ls . P ro d u c tio n  o f  c A M P  o r  c G M P  is s tim u la te d . T h is  b in d s  to  M L C K  a n d  
in h ib its  it, p re v e n tin g  it f ro m  a c tiv a tin g  th e  m y o s in  lig h t c h a in s .
T h e  o u te rm o s t lay e r, w h ic h  a tta c h e s  th e  v e sse l to  th e  s u r ro u n d in g  tis su e , is 
te rm e d  th e  tu n ic a  a d v e n tit ia . T h is  is  a  la y e r  o f  c o n n e c tiv e  t is s u e  w ith  v a ry in g  
a m o u n ts  o f  e la s tic  an d  c o lla g e n o u s  f ib re s . T h e  c o n n e c tiv e  t is s u e  is  d e n se  a d ja c e n t to  
th e  tu n ic a  m e d ia , b u t c h a n g e s  to  lo o s e  c o n n e c tiv e  t is s u e  n e a r  th e  p e r ip h e ry  o f  th e  
v e sse l.
1.4.1 The Vascular Endothelium
E n d o th e lia l  c e lls  (E C ) fu n c tio n  as a  s e m i-p e rm e a b le  b a rr ie r , a n d  a lso  a s  a  
d y n a m ic  p a ra c r in e  an d  e n d o c r in e  o rg a n , e x e r tin g  c o n s id e ra b le  in f lu e n c e  o n  th e  
u n d e r ly in g  V S M C  a n d  c irc u la t in g  b lo o d  e le m e n ts . E C  re g u la te  th e  m a in te n a n c e  o f  
s e le c tiv e  p e rm e a b il i ty ;  in te g ra t io n  a n d  tr a n s d u c tio n  o f  b lo o d -b o rn e  s ig n a ls ; 
re g u la t io n  o f  in f la m m a to ry  a n d  im m u n e  re a c tio n s ; re g u la t io n  o f  v a s c u la r  to n e ; 
m a in te n a n c e  o f  th ro m b o re s is ta n c e ;  m o d u la t io n  o f  le u k o c y te  in te ra c tio n s  w ith  tis su e s  
a n d  re g u la t io n  o f  v a s c u la r  g ro w th . N o rm a l e n d o th e lia l  fu n c tio n  p la y s  a  p iv o ta l  ro le  
in  v a s c u la r  h o m e o s ta s is , a n d  lim its  th e  d e v e lo p m e n t o f  a th e ro sc le ro s is . E n d o th e lia l  
d y s fu n c tio n , th e re fo re , is  a n  in itia l  p a th o lo g ic a l  s ig n  o f  a th e ro s c le ro s is . E C  a re  
in v o lv e d  in  m a in ta in in g  th e  n o n - th ro m b o g e n ic  b lo o d - tis su e  in te r fa c e  b y  re g u la tin g  
th ro m b o s is , th ro m b o ly s is , p la te le t  a d h e re n c e , v a s c u la r  to n e  a n d  b lo o d  flo w . T h is  is 
a c h ie v e d  th ro u g h  th e  p ro d u c tio n  o f  th ro m b o g e n ic  ( th ro m b o x a n e )  an d  
a n ti- th ro m b o g e n ic  ( th ro m b o m o d u lin )  fa c to rs , a n d  p ro -  a n d  a n ti- in f la m m a to ry  
m e d ia to rs , su c h  as le u k o c y te  a d h e s io n  m o le c u le s  an d  n itr ic  o x id e  re sp e c tiv e ly . In  
a d d itio n , th e  e n d o th e liu m  c a n  re le a s e  s u b s ta n c e s  th a t  a c t as  S M C  p ro m o te rs  a n d  
v a s o c o n s tr ic to rs , su c h  as a n g io te n s in  II, o r  as  S M C  in h ib ito rs  a n d  v a s o d ila to rs , su c h  
as p ro s ta c y c lin  (C o rti a n d  B a d im o n  2 0 0 2 ). T h e re fo re , e n d o th e lia l  d y s fu n c tio n  c a n
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r e s u lt  in  th e  a c c u m u la tio n  o f  c e l lu la r  c o m p o n e n ts , l ip id s  a n d  e x tra c e llu la r  m a tr ix  
(E C M ) to  y ie ld  a  f ib ro fa tty  p la q u e , w h ic h  c a n  u ltim a te ly  n a r ro w  th e  a r te r ia l  lu m e n  
(G e n g  a n d  L ib b y  2 0 0 2 ).
T h e  n o rm a l h e a lth y  e n d o th e liu m  re g u la te s  v a s c u la r  to n e  a n d  s tru c tu re  an d  
e x e r ts  a n tic o a g u la n t, a n tip la te le t , a n d  f ib r in o ly tic  p ro p e r tie s . T h e  m a in te n a n c e  o f  
v a s c u la r  to n e  is a c c o m p lis h e d  b y  th e  re le a s e  o f  n u m e ro u s  d i la to r  a n d  c o n s tr ic to r  
su b s ta n c e s . A  m a jo r  v a s o d ila tiv e  s u b s ta n c e  re le a s e d  b y  th e  e n d o th e liu m  is  n itr ic  
o x id e  (N O ), o r ig in a lly  id e n tif ie d  as e n d o th e liu m -d e r iv e d  re la x in g  fa c to r  (E D R F ). 
O th e r  e n d o th e liu m -d e r iv e d  v a s o d ila to rs  in c lu d e  p ro s ta c y c lin  a n d  b ra d y k in in  (D re x le r  
1 9 9 8 ). P ro s ta c y c lin  a c ts  s y n e rg is tic a lly  w ith  N O  to  in h ib it  p la te le t  a g g re g a tio n  
(L u s c h e r  a n d  B a r to n  1 997). B ra d y k in in  s tim u la te s  re le a s e  o f  N O , p ro s ta c y c lin , an d  
e n d o th e liu m -d e r iv e d  h y p e rp o la r iz in g  fa c to r, a n o th e r  v a so d ila to r , w h ic h  c o n tr ib u te s  
to  in h ib i t io n  o f  p la te le t  a g g re g a tio n  (D re x le r  1998). B ra d y k in in  a lso  s tim u la te s  
p ro d u c tio n  o f  t is s u e  p la s m in o g e n  a c tiv a to r  (t-P A ), a n d  th u s  m a y  p la y  a n  im p o r ta n t 
ro le  in  f ib r in o ly s is .
T h e  e n d o th e liu m  a lso  p ro d u c e s  v a s o c o n s tr ic to r  s u b s ta n c e s , su c h  as 
e n d o th e lin  ( th e  m o s t  p o te n t  e n d o g e n o u s  v a s o c o n s tr ic to r  id e n tif ie d  to  d a te )  a n d  
a n g io te n s in  II (A n g  II) . A n g  II n o t  o n ly  a c ts  as a  v a s o c o n s tr ic to r  b u t  is a lso  
p ro -o x id a n t  (S o w e rs  2 0 0 2 )  a n d  s t im u la te s  p ro d u c tio n  o f  e n d o th e lin . E n d o th e lin  an d  
A n g  II  p ro m o te  p ro life ra t io n  o f  s m o o th  m u s c le  c e lls  a n d  th e re b y  c o n tr ib u te  to  th e  
fo rm a tio n  o f  p la q u e s  (D re x le r  1 9 9 8 ). A c tiv a te d  m a c ro p h a g e s  a n d  v a s c u la r  sm o o th  
m u s c le  c e lls , c h a ra c te r is t ic  c e llu la r  c o m p o n e n ts  o f  a n  a th e ro s c le ro tic  p la q u e , p ro d u c e  
la rg e  a m o u n ts  o f  e n d o th e lin  (K in la y  e t al. 2 0 0 1 ).
D a m a g e  to  th e  e n d o th e liu m  u p s e ts  th e  b a la n c e  b e tw e e n  v a s o c o n s tr ic t io n  a n d  
v a s o d i la t io n  an d  in itia te s  a  n u m b e r  o f  e v e n ts /p ro c e s se s  th a t  p ro m o te  o r  e x a c e rb a te  
a th e ro s c le ro s is ;  th e se  in c lu d e  in c re a s e d  e n d o th e lia l  p e rm e a b ility , p la te le t  a g g re g a tio n , 
le u k o c y te  a d h e s io n , a n d  g e n e ra tio n  o f  c y to k in e s . D e c re a se d  p ro d u c tio n  o r  a c tiv ity  o f  
N O , m a n ife s te d  as im p a ire d  v a s o d ila t io n , m a y  b e  o n e  o f  th e  e a r lie s t  s ig n s  o f  
a th e ro s c le ro s is .
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1.4.2 Cellular Proliferation
In a normal resting cell the intracellular signalling proteins and genes that are 
normally activated by extracellular growth factors are inactive. When the normal cell 
is stimulated by an extracellular growth factor, these signalling proteins and genes 
become active and the cell proliferates (Fig. 1.2).
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Fig. 1.2 Cell Proliferation
Molecular Biology o f the Cell: Alberts, Johnson, Lewis, Raff, Roberts, Walter (1998)
Vascular proliferation contributes to the pathobiology o f atherosclerosis and 
is linked to other cellular processes such as inflammation, apoptosis and matrix 
alterations. The contribution o f vascular proliferation to the pathophysiology o f 
in-stent restenosis, transplant vasculopathy and vein bypass graft failure is 
particularly important. Thus, an emerging strategy for the treatment o f those 
conditions is to inhibit cellular proliferation by targeting cell cycle regulation. The 
understanding o f the pathophysiology o f atherosclerosis and related vascular diseases 
has changed over the last decade, providing new perspectives for preventive and 
therapeutic strategies (Dzau et al. 2002).
Recent studies have emphasized the involvement o f inflammation in 
mediating all stages o f atherosclerosis (Ross 1999; Libby et al. 2002). However, in
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a d d it io n  to  in f la m m a tio n , a  k e y  p ro c e s s  o f  a th e ro s c le ro s is  in v o lv e s  th e  p ro life ra tio n  
o f  v a s c u la r  sm o o th  m u s c le  c e lls  (V S M C s )  (R o ss  a n d  G lo m s e t  19 7 3 ; R o ss  1995; 
S c h w a r tz  e t al. 2 0 0 0 ).
U n d e rs ta n d in g  o f  th e  re s p o n s e s  o f  g ro w th  fa c to rs  a n d  V S M C  p ro life ra t io n  to  
v a s c u la r  in ju ry  is  d e r iv e d  m a in ly  f ro m  s tu d ie s  in v o lv in g  a n im a l m o d e ls  o f  a r te ria l 
in ju ry . D ire c t  d a ta  a re  d if f ic u lt  to  o b ta in  f ro m  h u m a n  d ise a se ; h o w e v e r , in  th e  ra t 
m o d e l, b a s ic  f ib ro b la s t  g ro w th  fa c to r , re le a s e d  f ro m  d y in g  v a s c u la r  c e lls , c a n  in itia te  
m e d ia l p ro li f e ra t io n  o f  V S M C s  (L in d n e r  a n d  R e id y  1 9 91), w h e re a s  p la te le t  d e r iv e d  
g ro w th  fa c to r  m a y  in d u c e  su b se q u e n t m ig ra t io n  o f  V S M C s  to w a rd  th e  in tim a  (F e rn s  
e t al. 1 9 9 1 ). In tim a i p ro life ra t io n  a n d  m a tr ix  a c c u m u la tio n  o c c u r  u n d e r  th e  in f lu e n c e  
o f  p la te le t-d e r iv e d  g ro w th  fa c to r  (P D G F ), tra n s fo rm in g  g ro w th  fa c to r-P  (T G F -P ), 
a n g io te n s in  II, e p id e rm a l g ro w th  fa c to r  (E G F ) an d  in s u lin - l ik e  g ro w th  fa c to r  1 
( IG F -1 )  (D z a u  e t al. 1991 ; M a je s k y  e t a l. 1991 ; N a b e l e t al. 1993 ; G ra n t  e t al. 1994). 
F u r th e rm o re , lo ss  o f  g ro w th - in h ib ito ry  fa c to rs , o c c u rr in g  as a re s u lt  o f  d e c re a se d  
e n d o th e lia l  c e ll s e c re tio n  o f  n itr ic  o x id e  (N O ), in a c tiv a tio n  o f  N O  b y  re a c tiv e  o x y g e n  
sp e c ie s  o r  a lte re d  h e p a r in  su lfa te  p ro te o g ly c a n  sy n th e s is , m a y  a lso  c o n tr ib u te  to  th e  
m ig ra tio n  a n d  p ro lif e ra t io n  o f  V S M C s  a n d  to  th e  in c re a se d  in f la m m a to ry  re sp o n se  
(K in s e lla  a n d  W ig h t 1986 ; Ig n a rro  e t a l. 1987). W ith  th e  re c o g n itio n  o f  th e  e s se n tia l 
in v o lv e m e n t o f  V S M C  p ro life ra t io n  in  th e  c o n d itio n s  d e s c r ib e d  a b o v e  a n d  th e  
im p ro v e d  u n d e rs ta n d in g  o f  th e  m o le c u la r  a n d  c e llu la r  m e c h a n is m s  o f  c e llu la r  
p ro life ra t io n , a n tip ro life ra t iv e  th e ra p e u tic  m o d a lit ie s  h a v e  b e c o m e  a  fo c u s  o f  
re s e a rc h  a n d  d e v e lo p m e n t.
T h e re  is  in c re a s in g  e v id e n c e  th a t  c o n n e c tio n s  e x is t  b e tw e e n  p ro life ra t io n  an d  
o th e r  c e l lu la r  p ro c e s s e s  th a t  a re  im p o r ta n t  fo r  th e  p a th o p h y s io lo g y  o f  v a sc u la r  
d ise a se . T h e  p ro c e s s e s  o f  p ro lif e ra t io n  a n d  in f la m m a tio n  a re  a lso  lin k ed . 
S u p p o r tin g  th is  l in k  o f  v a s c u la r  p ro lif e ra t io n  a n d  in f la m m a tio n  is  th e  o b s e rv a tio n  th a t 
im p a ire d  N O  b io a c tiv i ty  in  v a s c u la r  d is e a se  is a s s o c ia te d  w ith  V S M C  p ro life ra tio n  
a n d  in f la m m a tio n  (R o ss  1999). In v ivo  o v e re x p re s s io n  o f  N O  sy n th a s e  re s u lte d  in  
re d u c tio n  o f  a th e ro s c le ro tic  o r  re s te n o tic  le s io n  fo rm a tio n  in  ra b b its  th ro u g h  b o th  
in h ib i t io n  o f  V S M C  p ro life ra tio n  a n d  in h ib it io n  o f  a d h e s io n  m o le c u le  e x p re s s io n  
w ith  s u b s e q u e n t r e d u c tio n  o f  v a s c u la r  m o n o n u c le a r  ce ll in f i l t ra t io n  (v o n  d e r  L e y e n  e t 
al. 19 9 5 ; Q ia n  e t a l. 1 9 99).
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1.4.3 Vascular Remodelling
Remodelling is both a physiological and pathological process in the 
vasculature which can be defined as a change in the calibre o f the vessel, and can be 
sub-divided into hypertrophic, hypotrophic or eutrophic remodelling, due to an 
increase, decrease or no change in the overall tissue mass respectively. It can 
result in a decrease or increase in both wall: lumen ratio and vessel luminal diameter, 
termed inward and outward remodelling respectively (Mulvany 1999). The 
biological processes that can affect vascular remodelling include VSMC proliferation, 
apoptosis and migration, adventitial fibrosis and migration o f adventitial fibroblasts 
(Scott et al. 1996; Shi et al. 1996; Shi et al. 1997). These processes can exert major 
changes in  arterial architecture either alone, or in co-ordination w ith each other 
(Bennett 1999) (Fig. 1.3).
intima
Fig. 1.3 Endothelial Control of Vascular Structure
Physiological remodelling is evident during vascular remodelling after birth. 
Closure o f the ductus arteriosus, for example, is due to vascular remodelling 
accompanied by increased VSMC apoptosis, and concomitant changes in VSMC 
proliferation and matrix synthesis (Slomp et al. 1997). Inappropriate vascular 
remodelling, including its absence, is a prominent feature o f the pathogenesis of 
many vascular diseases. Many studies have demonstrated that changes in 
intravascular forces that occur in disease states, such as hypertension, result in a 
decreased lumen and increased media: lumen ratios in arterial blood vessels, as seen 
in essential hypertensive as compared to normotensive patients (Nordborg et al. 
1983).
18
1.4.4 Mechanical Forces
Shear stress is described as the dragging frictional force resulting from blood 
flow. Under normal physiological conditions, EC are primarily subjected to this 
haemodynamic shear stress. However, under conditions of endothelial dysfunction 
or denudation, shear stress can also exert its affect on the underlying VSMC. In 
arterial circulation, based on altering vessel wall diameters, the mean wall shear 
stress is 1 0 - 7 0  dyn/cm2. Changes in shear stress can result from changes in pulse 
pressure, which is defined as the difference between peak systolic and diastolic blood 
pressure. EC, which contain shear stress response elements, respond to 
physiological or pathological alterations in shear stress by releasing vasoactive 
agents and pro- or anti-atherogenic substances (Davies 1995; Traub and Berk 1998).
Shear
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Flow
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Fig. 1.4 Blood Vessels are Permanently Subjected to Mechanical Forces
Another well characterized haemodynamic force associated with the 
vasculature is cyclic circumferential strain (cyclic strain). Cyclic strain in arterial 
vessels is due to the repetitive pulsatile force on the vessel wall due to arterial blood 
pressure. Cyclic strain can be multi-dimensional as the pulsatile force acts 
perpendicular to the blood vessel, resulting in “stretching” o f the vascular cells in 
multiple planes. All cells of the vessel wall experience cyclic strain under normal 
physiological conditions. VSMC, which constitute the major component of the 
vessel wall, together with elastin and collagenous components, absorb most of the 
pressure-induced cyclic strain. Normal blood pressure is considered to be 120/80
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mmHg, whereas blood pressures of above 140/90 mmHg and below 90/60 mmHg are 
considered high and low respectively. Factors ranging from physical exertion to 
psychological stress can result in a transient rise in blood pressure, and a consequent 
transient increase in cyclic stress. Genetic predisposition to hypertension can lead 
to a chronic increase in cyclic stress, resulting in potentially serious clinical 
manifestations. Conversely, factors such as electrolyte imbalance, ischaemic heart 
disease and systemic sepsis can result in transient hypotension, and a consequent 
transient decrease in cyclic stress (Ikeda et al. 1999; Phillips et al. 2000; Lapinsky 
and Mehta 2005).
1.5 Atherosclerotic Plaque Formation
The damage to the normal endothelium results in the initiation of an 
inflammatory response. The endothelium expresses adhesion and chemoattractant 
molecules, that act to recruit inflammatory leukocytes such as monocytes and 
T-lymphocytes and, in addition, extra-cellular LDL begins to accumulate in the 
tunica intima, in part by binding to proteoglycans, and undergoes oxidative 
modification (Ananyeva et al. 1997; Williams and Tabas 1998). Accumulated 
monocytes in the arterial wall subsequently express scavenger receptors which bind 
to oxidized-LDL (ox-LDL), transforming them into lipid-laden foam cells, facilitated 
in part by macrophage colony-stimulating factor (MCSF) (Rolirer et al. 1990; Qiao et 
al. 1997), In addition, leukocytes and endogenous cells of the vascular wall can 
secrete inflammatory cytokines and growth factors that further amplify leukocyte 
recruitment and cause VSMC migration and proliferation (Fig. 1.5). The formation of 
this intimal macrophage-rich fatty streak, the precursor of an atherosclerotic lesion, 
appears to be ubiquitous in humans, and can develop over many years. In fact, these 
possible pre-cursors to atherosclerosis have been found in the intima of infants (Stary 
et al. 1994).
Lesion progression can occur due to the expression of tissue factor, a potent 
coagulant, and matrix-degrading proteinase that can act to weaken the integrity of the 
plaque. If the plaque subsequently ruptures, coagulation factors in the blood gain 
access to the thrombogenic, tissue factor-containing lipid core resulting in 
thrombosis (the formation of a clot or thrombus inside a blood vessel, obstructing the 
flow of blood through the circulatory system). Depending on the balance between
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pro-thrombogenic and fibrinolytic mechanisms, an occlusive thrombus could occur 
at this stage w ith deleterious clinical consequences or death. Alternatively, 
re-absorption o f  the throm bus results in  the release o f  throm bin and other mediators 
including PDGF and TGF-0 from  de-granulating platelets which results in collagen 
and SMC accumulation, and the progression o f  the lesion from a fibrofatty to an 
advanced fibrous and often calcified plaque, oftentimes causing significant stenosis 
o f  the vessel. In some cases, occlusive throm bi arise from superficial erosion o f  the 
endothelial layer and often complicate advanced stenotic lesions (Libby and 
Schonbeck2001).
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Fig. 1.5 Atherogenesis: Fibrous Plaque Formation
Tedgui A, Mallat Z: Atherosclerotic plaque formation; Rev /Vo/49(19):2081-6; (1999)
However, no t all fatty streaks evolve into advanced atherosclerotic lesions. 
The balance between pro- and anti-atherogenic factors determines w hether a fatty 
streak progresses to form  an atherosclerotic lesion or regresses. In addition to 
inflammatory cell infiltration, the progression o f  an atherosclerotic lesion requires 
the participation o f  VSM C, which are a principal source o f  the ECM  that constitutes 
a large volum e o f  an advanced atheroma (Geng and Libby 2002). Proliferation and 
migration o f  SMC plays an important role in the regulation o f  SMC number within 
an atherosclerotic plaque. However, the im portance o f  SMC apoptosis in the
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atherosclerotic plaque is being increasingly recognized. By counterbalancing 
proliferation, apoptosis may limit the cell accumulation in the intimal compartment, 
eliminate the lipid-laden foam cell, and decrease overall cell number, leading to 
regression of the fatty streak (Geng and Libby 2002).
1.6 Apoptosis
Apoptosis was first described in 1972 (Kerr et al. 1972) with the term 
originating from the Greek meaning falling (ptosis) off (apo). Apoptosis is described 
as a physiologically relevant and active form of cell death whose control and 
mediation is cell-specific and contextual, and is highly conserved throughout 
evolution (Hetts 1998; Bai et al. 1999). Apoptosis is recognized as an important 
physiological process, both during development and in the maintenance of 
homeostasis in the adult. This mode of cell death allows for the removal of 
damaged, injured, infected and incompetent cells from the body both quickly and 
efficiently.
Cells of multi-cellular organisms generally die in either one of two 
well-characterized ways, depending on the context and cause of death. These two 
forms of cell death, apoptosis and necrosis, can be defined and contrasted on the 
basis of their individual mechanisms, biochemistry, and altered cellular morphology 
(Hetts 1998).
Necrosis is an uncontrolled cell death characterized by cell swelling and 
mitochondrial damage leading to rapid depletion of energy levels; a breakdown of 
homeostatic control; cell membrane lysis and release o f the intracellular contents, 
leading to an inflammatory response, with oedema and damage to the surrounding 
cells. A classic example o f necrosis is ischemic necrosis of the cardiomyocyte during 
acute myocardial infarction (Yeh 1997). The release of extracellular components 
such as kinins incites localized inflammation, oedema, capillary dilation and 
macrophage aggregation (Yeh 1997; Hetts 1998; Kuan and Passaro 1998). The 
inflammatory response is lengthy and unpredictable in its timecourse, often taking 
hours to days to occur and subside (Kuan and Passaro 1998). Although necrosis 
may be important in acute injury and certain acute inflammatory responses, it is not 
the mechanism whereby cells normally die (Hetts 1998).
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In contrast, apoptosis is an active, contained process resulting from either 
external or internal stimuli (Kuan and Passaro 1998). It is a controlled cell death 
that keeps the intracellular content of the dying cell sequestered and is defined by a 
series of cellular change. Firstly the cell shrinks, looses contact with neighbouring 
cells or surrounding matrix and starts to display intracellular proteins on its surface. 
The chromatin in the nucleus condenses and the DNA is cleaved into small 
fragments of 180 base pairs (Steller 1995; Yeh 1997), which lead to characteristic 
DNA laddering when subjected to gel electrophoresis. The plasma membrane then 
begins to show a bubbled appearance and small membrane bound bodies break off 
containing intracellular material which can include nuclear matter and cellular 
organelles, which are usually unaffected. The fragments are known as apoptotic 
bodies and they are quickly removed by phagocytes or by neighbouring cells. As 
no cytosolic components are released into the extracellular space, an inflammatory 
response is not initiated (Hetts 1998; Kuan and Passaro 1998). Unlike necrosis, this 
process is relatively rapid, reaching completion in approximately two hours (Kuan 
and Passaro 1998).
If this does not occur quickly enough the plasma membrane and intracellular 
organelles can breakdown resulting in lysis of the fragments; a process called 
secondary necrosis.
The genetics and molecular mechanisms of apoptosis were first characterized 
during studies in C. elegans. Programmed cell death during the development of this 
nematode is highly precise and predictable, of the 1090 cells produced during 
development, 131 are destined to die (Ellis et al. 1991). Such studies have 
identified four sequential steps during the process of apoptosis: (1) commitment to 
cell death induced by extracellular or intracellular triggers; (2) activation of 
intracellular proteases; (3) engulfment of the apoptotic bodies by other cells; and (4) 
degradation of the apoptotic bodies within the lysosomes of the phagoctyotic cells 
(Steller 1995). Genetic analysis of factors involved in apoptosis in C. elegans 
implicated three main genes, cell death defective 3 (ced 3), ced 4 and ced 9. As the 
genetic control of apoptosis is conserved throughout evolution, human homologues 
of these genes have been identified, these are caspase 8, Apaf-1, and Bcl-2 
respectively (Hetts 1998).
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1.6.1 Triggers of apoptosis
Apoptosis-inducing stimuli can be either extrinsic or intrinsic and can cause 
apoptosis through the activation of a number of different pathways. In most cases, 
however, these pathways converge on the caspase system of enzymes to execute their 
function (Fig. 1.6). Extrinsic triggers of apoptosis include activation of 
receptor-mediated death-signalling pathways, such as Fas ligand activation, exposure 
to substances that cause DNA damage including chemotheraputic agents and ionizing 
radiation (Hetts 1998; Rich et al. 2000). Apoptosis can also be induced due to the 
removal of death-inhibiting (or survival-promoting) ligands, for example, vascular 
smooth muscle cells undergo apoptosis due to the withdrawal of growth factors such 
as IGF and PDGF (Best et al. 1999). In addition, intrinsic signals such as increased 
intracellular oxidative stress can cause the initiation of apoptosis within the cell, in 
which the mitochondria play a pivotal role (Desagher and Martinou 2000)
Fig. 1.6 Extrinsic and Intrinsic Activation of Apoptosis
Z ang , N ., H artig , H ., D zhagalov , I., D raper, D. and H e, Y-W.: T he  R o le  o f  A pop tosis  in the 
D ev e lo p m en t and F u n c tio n  o f  T  L ym phocy tes; C e l l  R e s  15: 749 -769 ; (2005)
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(a) Receptor-Mediated Death Signalling Pathways
Death receptors belong to the tum our necrosis factor (TNF) superfamily, and 
play a central role in  instructive apoptosis (Ashkenazi and D ixit 1998). Members o f 
the death receptor family contain one to five cysteine-rich repeats in their 
extracellular domain, and a death domain (DD) in their cytoplasmic tail (Fig. 1.7). 
This DD is essential for initiation o f  the apoptotic signal by these receptors. TNF 
receptor 1 and Fas (CD95) are two such receptors that initiate apoptosis when 
activated either by their respective ligands, T N F-a and Fas-L, or by agonist-like 
antibodies (M acLellan and Schneider 1997; Gupta 2003). Following 
receptor-ligand interaction, the receptor oligomerizes, recruits adaptor molecules 
forming a death inducing signalling complex (DISC), w hich recruits and activates 
the caspase cascade and can culminate in apoptosis o f  the cell (Yeh 1997; Gupta 
2003).
Fig. 1.7 Death Receptor Family Members
L avrik . I, G olks A . and  K ra m m e r P H : D ea th  R ecep to r S ignalling ; J C e l l  S c i  118: 2 65 -267  (2005)
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(b) Fas and Fas Ligand
Apoptosis following a cellular immune response is primarily mediated by 
Fas-Fas ligand (Fas-L) interaction (Krammer 2000). Fas is a type I transmembrane 
receptor, that is abundantly expressed in many tissues, including the heart, EC and 
VSMC (Gibbons and Pollman 2000). Fas-L however, displays a more restricted 
expression. Fas-L is a type II membrane protein, but is capable of undergoing 
cleavage by a metalloproteinase to generate a soluble but less biologically active 
form of the receptor (Tanaka et al. 1995). Both Fas and Fas-L expression can be 
upregulated by cytokines and stressful stimuli via nuclear factor-KB (NFkB) 
dependent mechanisms (Nagata 1999).
Fas receptor activation results in the trimerization of the receptor, and the 
formation of a signalling complex of molecules linked to the cytoplasmic portion of 
the receptor, as the cytoplasmic domain of the receptor does not have intrinsic 
enzymatic activity. The adaptor protein Fas-associated via death domain (FADD) is 
recruited to Fas through interactions between their respective death domains. In 
addition, FADD also contains a death effector domain (DED) at its N-terminus, 
which is responsible for binding to pro-caspase 8 (FLICE (FADD-like Interleukin 1 
beta converting enzyme)) to form a DISC. Subsequently, pro-caspase 8 is 
auto-proteolytically cleaved, triggering the cellular apoptosis cascade (Ashkenazi and 
Dixit 1998; Gibbons and Pollman 2000; Gupta 2003). In some cells, the levels of 
pro-caspase 8 is low, therefore the caspase cascade in this case must be amplified by 
the mitochondria to result in apoptosis (Li et al. 1998) (Fig. 1.8).
Fas-mediated apoptosis is regulated by FLICE-like inhibitory proteins (FLIP), 
a protein containing two DEDs. FLIP is present within the cell in two alternatively 
spliced isoforms, the long form (FLIPl) and the short form (FLIPs), and stable 
over-expression of these results in resistance to receptor-mediated apoptosis. FLIPl 
resembles caspase 8 and caspase 10, but lacks protease activity (Irmler et al. 1997), 
therefore effectively functioning as an endogenous inhibitor of apoptosis. In 
addition, FLIP also promotes the activation of the NFkB and extracellular signal 
regulated kinase ( ERK ) signalling pathways through the recruitment of adaptor 
proteins including receptor interacting protein (RIP) and receptor associated factors 
(Raf) (Kataoka et al. 2000).
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Fig. 1.8 The Fas-Fas Ligand Pathway of Apoptosis
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The induction o f  Fas-mediated apoptosis in VSM C has been the subject o f  a 
number o f  conflicting reports. Sata et al., (2000) report that soluble Fas-L and 
agonistic Fas antibodies fail to induce VSM C apoptosis. In contrast, however, viral 
over-expression o f  membrane-tethered Fas-L has been shown to promote VSMC 
apoptosis (Gibbons and Pollm an 2000; Sata et al. 2000). This discrepancy in 
VSM C response to Fas may be a consequence o f differing VSM C phenotype. Chan 
et al., (2000) has shown that the Fas-L resistant VSM C exhibit normal levels o f 
receptor expression and receptor engagement mechanisms. However, these cells 
display decreased expression o f  FADD, caspase 8 and caspase 3, and increased 
expression o f  FLIP w hen compared to Fas-L susceptible VSM C (Chan et al. 2000). 
This highlights the fact that the VSM C population is heterogeneous and as such, may 
respond differently to stimuli governing cell fate decisions.
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(c) A poptosis due to DNA D am age
Growth arrest, repair and apoptosis are all legitimate cellular responses to 
DNA damage. The choice of cell fate in each instance will depend on cell type, 
location, environment, and extent of damage.
p53 is a transcription factor that has been implicated in cell cycle arrest and in 
some, but not all, forms of apoptosis (MacLellan and Schneider 1997). The level of 
p53 activity within the cell is maintained at a low level, under normal conditions, due 
to interaction with the Mdm-2 protein, which marks it for ubiquitin-mediated 
destruction (Mayo et al. 1997). DNA damage-induced phosphorylation of either 
p53 or Mdm-2 prevents these two proteins from interacting, thus stabilizing and 
activating p53 (Evan and Littlewood 1998). p53 levels are reported to increase
within minutes of DNA damage, resulting in growth arrest or apoptosis of the cell 
(Lundberg and Weinberg 1999).
(d) M itochondria l P a thw ay  of A poptosis
A number of stimuli, including UV radiation, stress molecules (reactive 
oxygen and reactive nitrogen species), and growth factor withdrawal mediate 
apoptosis via the mitochondrial pathway (Gupta 2003). During the process of 
apoptosis the mitochondria undergo morphological and cellular re-distribution 
changes including a reduction in size and an increase in matrix density 
(mitochondrial pylcnosis). In addition, the mitochondria which are normally 
dispersed throughout the entire cell, display perinuclear clustering (Desagher and 
Martinou 2000).
Mitochondria are organelles comprising of a matrix surrounded by an inner 
membrane (IM), an inter-membrane space, and an outer membrane (OM). The IM 
contains molecules that contribute to the formation of an electrochemical gradient or 
membrane potential, including adenosine tri-phosphate (ATP) synthase and adenine
nucleotide translocator. The OM contains a voltage-dependent anion channel,
whilst the inter-membrane space contains proteins that, when activated, contribute to 
apoptosis, including holocytochrome c, some pro-caspases, and apoptosis-inducing 
factor (AIF) (Gupta 2003). At least three mechanisms contribute to 
mitochondrial-mediated apoptosis. These include disruption of electron transport, 
oxidative phosphorylation and ATP production, alteration of the cellular redox 
potential, and release of proteins such as cytochrome c, that trigger activation of the 
caspase family of proteases (Green and Reed 1998).
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1.6.2 The Caspase Cascade
Caspases are an evolutionally conserved family of cysteine proteases, which 
are viewed as the “central executioners” in apoptotic cell death. Caspases are 
synthesized as enzymatically inert zymogens, requiring proteolytic cleavage at an 
internal aspartate residue to induce their activation (Gibbons and Pollman 2000; 
Hengartner 2000). These zymogens are composed of three domains, an N-terminal 
pro-domain, and two domains termed plO and p20. The activation of caspases 
generally results in a serial sequence of caspase activation known as the caspase 
cascade, which is a common end pathway in apoptosis induced by many different 
stimuli. Three general mechanisms of caspase activation have been described to 
date, these are proximity-induced activation, processing by an upstream caspase, and 
association with a regulatory subunit (Hengartner 2000) (Fig. 1.9).
Proximity-induced activation occurs in the case of caspases 2 and 8. The 
aggregation of a number of caspase proteins via adaptor proteins renders the caspases 
capable of auto-proteolytic cleavage, and subsequent activation (Hengartner 2000). 
Most caspases are activated by cleavage between the plO and p20 domains, and 
between the p20 and N-terminal pro-domain. Activation of caspase 8 and caspase 9, 
known as initiator caspases, results in subsequent cleavage and activation of 
downstream effector caspases such as caspase 3, caspase 6 and caspase 7. The 
effector caspases are responsible for the induction of the biochemical and 
morphological changes associated with apoptosis, and are usually more abundant and 
active than the initiator caspases (Gibbons and Pollman 2000; Hengartner 2000).
Caspase 9 is activated through association with a regulatory subunit known as 
an apoptosome. The apoptosome consists of cytochrome c, an adapter molecule 
Apaf-1 (apoptosis protease-activating factor), and pro-caspase 9 (Hengartner 2000; 
Gupta 2003). Cytochrome c is a nuclear DNA encoded protein, its precursor, 
apocytochrome c, is synthesized on free ribosomes within the cytoplasm and can 
spontaneously insert into the mitochondrial outer membrane (Gonzales and Neupert 
1990; Stuart and Neupert 1990). This protein then incorporates a heme group, the 
protein re-folds, and is inserted into the inter-membrane space. The release of 
functional cytochrome c is reported to be an essential component for the formation of 
the apoptosome, and subsequent activation of caspases 9 and 3 (Liu et al. 1996). 
Apaf-1 is another essential component of the apoptosome, and appears to be 
activated by p53 and adenoviral early region 1A (E1A) (Fearnhead et al. 1998;
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M oroni et al. 2001). Apaf-1 has an N-terminal caspase recruitment domain 
(CARD), adjacent Walker’s A - and B -box sequences and C-terminal to this, twelve  
W D -40 repeats (Cai et al. 1998). The binding o f  cytochrome c to the W D-40  
repeats allows a conformational change o f  A paf-1, thus exposing the CARD domain. 
This conformational change is stabilized w ith the binding o f  ATP or dATP to the 
Walkers boxes. Pro-caspase 9 subsequently binds to the CARD domain, resulting 
in its activation. A s Apaf-1 does not have caspase activity, it is proposed that it 
facilitates caspase 9 auto-catalysis (Cai et al. 1998).
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Fig. 1.9 Activation of the Caspase Cascade
Caspase 9 subsequently cleaves and activates caspase 3, caspase 6 and a 
number o f  other substrates resulting in the biochemical and morphological
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characteristics of an apoptotic cell. These substrates include caspase-activated 
DNase (CAD), nuclear laminins, cytoskeletal proteins, and p21-activated kinase 2 
(PAK) among others. Activation of CAD within the cell results from the caspase 
3-mediated cleavage of the CAD inhibitory subunit. This active nuclease is 
subsequently responsible for the characteristic “DNA laddering” of apoptosis. 
Cleavage of cytoskeletal proteins, such as fodrin and gelsolin, results in an overall 
loss of cellular shape (Kothakota et al. 1997) whereas nuclear laminin cleavage is 
responsible for the characteristic nuclear shrinkage and budding seen in apoptosis 
(Rao et al. 1996). In addition, caspase-mediated cleavage of PAK 2, a member of 
the p21-activated kinase family, appears to mediate the distinctive blebbing of 
apoptotic cells (Rudel and Bokoch 1997).
Whilst caspase activation undoubtedly plays an important role in the 
initiation and execution of apoptosis, a number of caspase-independent inducers of 
apoptosis have also been identified. Reactive oxygen species (ROS) are associated 
with apoptosis (Suzuki et al. 1997). The generation of oxidants is involved in 
changes in mitochondrial permeability and release of molecules, other than 
cytochrome c, involved in the execution of apoptosis. Apoptosis inducing factor 
(AIF) is one such molecule that is released from the mitochondria and can induce 
caspase-independent apoptosis. AIF is transported to the nucleus where it causes 
ATP-independent large DNA fragmentation and chromatin condensation (Susin et al. 
1996; Gupta 2003). In addition, the release of Endo G nuclease from the 
mitochondrial inter-membrane space is thought to mediate nuclear DNA 
fragmentation (Li et al. 2001).
1.6.3 The Bcl-2 Family
Bcl-2 was initially identified as a frequent translocation occurring in human 
lymphoma and was found to function by promoting cell survival (Kirshenbaum 
2000). Bcl-2 is now recognized as being part of a large family of homologous 
proteins that can either promote or suppress apoptosis, known as the Bcl-2 family. 
The Bcl-2 family are considered the primary regulators of mitochondria-induced 
apoptosis, controlling mitochondrial membrane permeabilisation and cytochrome c 
release (Thompson 1995; Desagher and Martinou 2000; Marsden et al. 2002).
At least fifteen members of the Bcl-2 family have been identified, and these 
can be divided into two functional groups, pro-apoptotic and anti-apoptotic Bcl-2
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family members. Examples of family members that prevent apoptosis are Bcl-2, 
B c1-x l  and Bfl-1 among others, whilst Bcl-2 family members that promote apoptosis 
include Bad, Bax, Bid and Bik (Reed 1994; Sedlak et al. 1995; Green and Reed 
1998).
Structural analysis of the Bcl-2 family of proteins has identified four 
conserved regions within the family, known as the Bcl-2 homology domains 
(BH1-BH4) (Muchmore et al. 1996). All members of the Bcl-2 family contain at 
least one of these domains, which are formed by a-helices and thus enable different 
members of the family to form either homo- or heterodimers and regulate each other 
(Oltvai et al. 1993; Kelekar and Thompson 1998) (Table 1.1). The majority of 
Bcl-2 family members share sequence homology at the C-terminal region, with a 
~20-residue hydrophobic domain, which targets the Bcl-2 family of proteins to 
intracellular membranes. The principal membrane to which the Bcl-2 family 
members are directed is the outer mitochondrial membrane, therefore this C-terminal 
region is critical for the function of both the pro- and anti-apoptotic Bcl-2 family 
members (Goping et al. 1998; Kirshenbaum 2000). Variable sequence homology, 
however, exists between the BH1 to BH4 domains which implies that this variation 
in homology may determine whether the given Bcl-2 family member acts to promote 
or prevent cell death (Kirshenbaum 2000). The anti-apoptotic Bcl-2 family 
members such as Bcl-2 and B c1-x l , contain at least three BH domains and all contain 
the N-terminal BH4 domain. The BH4 domain is restricted to Bcl-2 family 
members with anti-apoptotic properties, therefore it is postulated that this domain is 
critical in preventing apoptosis. This is supported in a number of studies in which 
the deletion of the BH4 domain rendered the anti-apoptotic Bcl-2 protein defective in 
suppressing apoptosis (Hunter et al. 1996; Huang et al. 1998). Pro-apoptotic Bcl-2 
family members, such as Bax and Bak, have been identified as closely resembling 
Bcl-2, containing BH1-BH3 domains. Other pro-apoptotic members of this family 
are described as “BH3 only” as they contain the BH3 domain alone, which is 
therefore sufficient for the pro-apoptotic activity of these proteins (Kelekar and 
Thompson 1998) (Fig. 1.10). Cell fate is determined by the ratio of pro- and 
anti-apoptotic members of the Bcl-2 family within any given cell (Sedlak et al. 1995; 
Reed 1997).
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Inhibition  and P rom otion  o f  A poptosis by Bcl-2 Fam ily  Proteins
Protein Effect on Apoptosis Protein -Protein Interactions
Bcl-2 Bax, Bale
B cl-xL I Bax, Bale
Bcl-W I
Bax T Bcl-2, B el-xL
Bad t Bcl-2, Bel -xL
Bale t Bcl-2, Bel -x
«
Bcl-xs
*
t Bax, Bak
Table 1.1 Pro- and Anti-apoptotic Members of the Bcl-2 Family of Proteins
Table adapted from McLellan and Schneider, 1997
The Bcl-2 family can delay or prevent apoptosis by a diverse number of death 
signals thus suggesting that it influences a number of signalling factors that can lead 
to cell death. Bcl-2 has been shown to increase the anti-apoptotic NF-kB 
transactivation which can in turn, up-regulate anti-apoptotic Bfl-1 and Bcl-xL 
expression (Lee et al. 1999; Kirshenbaum 2000).
However, members of the Bcl-2 family primarily exert their pro- or 
anti-apoptotic influence through regulation of mitochondrial membrane potential and 
corresponding cytochrome c release. Upon stimulation of apoptosis, many 
members of the pro-apoptotic Bcl-2 family translocate from the cytoplasm to the 
mitochondria. Following a conformational change, these proteins can insert into the 
mitochondrial membranes, disrupting membrane integrity and increasing 
mitochondrial membrane potential. This results in the release of several 
mitochondrial proteins involved in caspase activation and other apoptotic events 
(Goping et al. 1998; Zamzami and Kroemer 2001). The pro-apoptotic protein, Bax, 
is normally present in the cell cytoplasm. Following stimulation of apoptosis, Bax 
migrates to the mitochondria where it inserts into the mitochondrial membrane and 
forms a homodimer, resulting in an increase in mitochondrial membrane potential, 
thus facilitating apoptosis. Similarly, the pro-apoptotic protein Bid is cleaved by 
caspase 8 and the resulting C-terminal fragment, tBid, translocates to the 
mitochondria.
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Fig. 1.10 Conserved Regions of Bcl-2 Family Proteins
Bid therefore mediates crosstalk between the death receptor and 
mitochondrial pathways of apoptosis. tBid facilitates insertion of other pro-apoptotic 
proteins into the mitochondrial membrane and promotes Bax dimerization (Eskes et 
al. 1998; Jurgensmeier et al. 1998; Ferri and Kroemer 2001). Conversely, many of 
the anti-apoptotic Bcl-2 family proteins are associated with the mitochondrial 
membrane where they act to inhibit increases in mitochondrial membrane potential, 
and prevent apoptosis by maintaining membrane integrity. Both the pro- and 
anti-apoptotic members of the Bcl-2 family appear, at least in part, to regulate each 
other. Bcl-2 can form a heterodimer with Bax, thus inhibiting the ability of Bax to 
increase mitochondrial membrane potential. Similarly, pro-apoptotic members can 
exert their effect by binding to their anti-apoptotic counterparts. Bad, binds to 
Bc1-xl thus inhibiting its anti-apoptotic function (Desagher and Martinou 2000; Ferri 
and Kroemer 2001; Zamzami and Kroemer 2001).
Bcl-2 family members also appear to modulate other cellular processes in 
addition to apoptosis however; this appears to be restricted to certain family 
members. Bfl-1 is an anti-apoptotic member of the Bcl-2 family that also exhibits
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proliferative and potent oncogene transforming activities (D'Sa-Eipper and 
Chinnadurai 1998). Therefore Bfl-1 communicates with both the apoptotic and 
proliferation cell machineries, suggesting a link between these two cellular 
processes.
The importance of the Bcl-2 family of proteins in normal physiology is 
highlighted by the fact that Bcl-2- and Bcl-XL-deficient mice die either at an 
embryonic stage or immediately post-natal due to increased apoptosis in multiple 
organs and tissues of the body (Veis et al. 1993; Motoyama et al. 1995).
The adenovirus E1B 19K protein is functionally similar to Bcl-2 as a survival 
factor (White 1996). A two hybrid screen of proteins that interact with E1B 19K in 
the yeast Saccharomyces cerevisiae identified several unique cDNAs named NIP 1 
(nineteen kD interacting protein-1), NIP 2 and NIP 3 (Boyd et al. 1994). All three 
proteins interact with discrete conserved domains of E1B 19K protein and Bcl-2 that 
are involved in suppression of cell death, although a function was not identified 
(Chen et al. 1997).
Bcl-2/ElB 19 kDa interacting protein (BNIP3) is a unique member of the 
Bcl-2 family members that is upregulated under hypoxic conditions (Chen et al. 1997; 
Cizeau et al. 2000). Forced overexpression of BNIP3 induces cell death characterized 
by localization at the mitochondria, opening of the permeability transition pore, loss 
of membrane potential and reactive oxygen species (ROS) production (Yande Velde 
et al. 2000). BNIP3 is also implicated in ischemia-induced apoptosis in rat 
cardiomyocytes (Kubasiak et al. 2002; Regula et al. 2002).
BNIP3 structure is similar to other Bcl-2 family members since it contains a 
C-terminal transmembrane domain that targets the protein to mitochondria and is 
required to induce cell death (Vande Velde et al. 2000). The BNIP3 protein also 
contains a BH3 domain as determined by sequence consensus with others BH3 
domains in the Bcl-2 family members, BNIP3-induced cell death is blocked by 
overexpression of Bcl-2, however, Bcl-2 fails to associate with the BH3 domain of 
BNIP3 instead Bcl-2 associates with the transmembrane domain of BNIP3 (Vande 
Velde et al. 2000).
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1.6.4 Role of Apoptosis in the Vasculature
Apoptosis is a normal physiological process, playing important roles in both 
development and maintenance of a wide variety of tissues, including the vasculature. 
It is also an essential component in the vascular response to tissue insult or injury. 
The critical role of apoptosis is evident throughout life and consequently, 
dysfunctions in apoptosis manifest themselves not only in developmental 
abnormalities, but also in a wide range of adult pathologies.
Apoptosis plays a critical role in normal vasculogenesis and aberrations in 
this process can result in embryonic lethality. Decreased apoptosis can result in 
increased development of endocardial cushions, and subsequently increased cardiac 
valve formation, whilst overabundance of apoptosis in the heart of developing mice 
has been shown to result in embryonic lethality (White et al. 2004). Apoptosis is 
also one of the mechanisms of neonatal vascular remodelling during the transition 
from foetal to neonatal circulation. Apoptosis is involved in the regression of the 
human umbilical vessels and the ductus arteriosus, and in the remodelling of the 
branching great arteries during the neonatal period (Kim et al. 2000). In addition, 
apoptosis has been shown to be involved in the post-natal morphogenesis of the 
atrioventricular node and Bundle of His, and aberrations in this process could 
predispose to tachyarrhythmias or bradyarrythmias in adulthood (James 1994).
The pathogenesis of various forms of vascular diseases involves 
dysregulation of both apoptosis and proliferation within the cells of the vasculature. 
Many vascular diseases involve an accumulation of cells within the intimal space. 
This was initially accredited to perturbations in cellular proliferation however, the 
importance of apoptosis in vascular remodelling and lesion formation is now 
recognized (Bai et al. 1999; Pollman et al. 1999).
Apoptosis can contribute to the pathogenesis of vascular disease through 
several potential mechanisms. The transition of a fatty streak to an atherosclerotic 
plaque is characterized by the appearance of focal and diffuse regions of cell death. 
The SMC of these fatty acid streaks express increased levels of the pro-apoptotic 
protein Bax, which increases the susceptibility of the cells to undergo apoptosis 
(Kockx et al. 1998). Apoptosis also occurs in advanced atherosclerotic lesions 
resulting in the formation of hypocellular fibrous zones and a lipid-rich core (Geng et 
al. 1996). It has also been extensively documented that SMC isolated from 
atherosclerotic arteries undergo apoptosis more frequently than their counterparts
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isolated from healthy vessels (Bennett et al. 1995). Apoptosis can influence the 
structure of the atherosclerotic plaque, causing thinning of the fibrous cap, rendering 
the plaque more prone to rupture (Walsh et al. 2000). In addition, increased 
apoptosis can also cause activation of tissue factor, which may increase the 
thrombogenicity of the lesion (Mallat et al. 1999). It is postulated that the 
development of atherosclerotic lesions are regulated by forces governing cellular 
proliferation and migration, in addition to plaque remodelling due to apoptotic cell 
death. Similarly, the development of restenotic lesions following balloon 
angioplasty or atherectomy of diseased arteries is thought to be due, at least in part, 
to impaired apoptotic signalling (Kraemer 2002).
Many studies have documented increased YSMC apoptosis following balloon 
injury. This increase in apoptosis occurs both early after injury, with a 70% 
increase in apoptosis evident 30 minutes post-injury, and can also occur in the 
neointima from 7 - 3 0  days post-injury (Han et al. 1995; Bochaton-Piallat et al. 1996; 
Perlman et al. 1997). It is also postulated that apoptosis plays an important role in 
the development of vascular lesions, as exuberant balloon injury-induced apoptosis 
has been found to result in enhanced neointimal formation (Rivard et al. 1999). 
However, the mechanisms that regulate neointimal SMC apoptosis remain 
incompletely understood.
Cardiac myocyte apoptosis is a feature of many pathological disorders 
including myocardial infarction and congestive heart failure (Cook et al. 1999; Kang 
and Izumo 2000), with Bcl-2 family proteins becoming increasingly recognized as 
important modulators of cardiac myocyte apoptosis. Bcl-2 is expressed in both the 
developing and adult hearts, is up-regulated following coronary occlusion in rat 
hearts and myocardial infarction in human hearts (Kajstura et al. 1995; Misao et al. 
1996; Liu et al. 1998). The pro-apoptotic protein Bax is also up-regulated 
following coronary occlusion and is over-expressed in spontaneously hypertensive 
rats, which may contribute to increased apoptosis (Fortuno et al. 1998; Liu et al.
1998). Therefore, the possibility of limiting cardiac myocyte loss by inhibiting 
apoptosis, possibly through interference with the level of expression of members of 
the Bcl-2 family, may have important therapeutic implications in the treatment of 
heart failure.
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1.6.5 Apoptosis in the atherosclerotic plaque
Apoptosis has been observed at many stages of the development of an 
advanced atherosclerotic plaque (Kockx et al. 1998). Atherosclerotic plaques 
typically consist of a lipid-rich core in the central portion of a thickened tunica 
intima, containing lipids, connective tissue, and dead cells or cell debris. The 
lipid-core is bound on its luminal aspect by a fibrous cap, at its edges by what is 
termed the “shoulder” region, and on its abluminal side by the base of the plaque 
(Libby 1995). Apoptosis is important in the progression of atherosclerotic lesions, 
resulting in the formation of a mature lesion containing a dense ECM and a relatively 
sparse cell population. Apoptosis is concentrated in the lipid-rich core of the plaque 
and occurs in both macrophage/foam cells and VSMC. However, the high 
percentage of apoptosis in the lesion does not translate to a decrease in tissue volume, 
therefore it is postulated that the system of phagocytosis of apoptotic cells operates 
poorly in an atherosclerotic plaque. Several mechanisms may be responsible for 
this intracellular accumulation of lipids which may decrease the ability of 
macrophages and SMC to phagocytose apoptotic cells. Increased apoptosis of 
macrophages in the lesion decreases the population of apoptotic scavenging cells and 
cross-linking of macromolecules can result in the stabilization of apoptotic cells 
within the lesion (Aeschlimann and Thomazy 2000). The presence of apoptotic 
cells or bodies has recently been shown to increase calcification and fibrosis of 
atherosclerotic lesions (Geng and Libby 2002).
Atherosclerosis is considered to be a relatively benign disease as long as 
complicating thrombosis can be prevented. Thrombosis underlies the most acute 
complication of atherosclerosis, notably unstable angina and acute myocardial 
infarction in the coronary circulation. The lipid-rich core of an atherosclerotic 
lesion contains large amounts of tissue factor, which is a powerful coagulant that 
stimulates thrombus formation when in contact with the blood (Wilcox et al. 1989; 
Schroeder and Falk 1995; Libby 2001; Libby and Schonbeck 2001). Most 
thrombus formations are due to a fracture in the protective fibrous cap of the 
atherosclerotic plaque, which usually occurs at the “shoulder” region. Therefore the 
integrity of the fibrous cap fundamentally determines the stability of a plaque, and its 
clinical implications.
In 1995, Libby et al., dubbed VSMC the “guardians of the integrity of the 
fibrous cap”. As its name implies, the fibrous cap is made up of a dense fibrous
38
ECM, primarily composed of collagens and elastin. It is now well established that 
the fibrous cap can undergo continuous remodelling, which is largely influenced by 
YSMC. YSMC synthesize and assemble the interstitial collagen, which accounts 
for the bulk of the ECM of the fibrous cap. Therefore, apoptosis of VSMC and a 
subsequent reduction in cell number can seriously compromise the integrity of the 
fibrous cap. In addition, the integrity of the fibrous cap can be weakened by the 
breakdown of existing ECM proteins through induction of proteolytic enzymes, such 
as matrix metalloproteinases, by inflammatory cells (Libby 2001). SMC of the 
arterial plaque also produce matrix metalloproteinases, however, these enzymes 
primarily effect SMC migration and vascular remodelling (Plutzky 1999).
The realization that the probability of the atherosclerotic plaque rupture, 
rather than the severity of plaque stenosis, determines its clinical implications led to 
the classification of atherosclerotic plaques as stable or vulnerable plaques. Most 
myocardial infarctions, for example, occur in lesions of less than 70% stenosis, with 
plaque rupture being the underlying pathological event (Falk et al. 1995)
The stable atherosclerotic plaque is not considered likely to rupture, and as 
such, is clinically not as serious as its “vulnerable” counterpart. The stable plaques 
are described as hard, sclerotic plaques, with a high VSMC and collagen content, a 
subsequently thick fibrous cap, and a limited amount of lipid-laden inflammatory 
cells. In contrast, the vulnerable plaque usually has a large lipid-core, a thin fibrous 
cap, a high density of inflammatory cells, particularly at the “shoulder region” where 
rupture often occurs and a paucity of VSMC. An atherosclerotic plaque is considered 
vulnerable when its lipid-rich core accounts for more than 40% of the total plaque 
volume (Schroeder and Falk 1995; Plutzky 1999; Corti et al. 2002).
Three major factors determine the vulnerability of the fibrous cap; these are 
lesion characteristics (location, size and consistency), blood flow characteristics, and 
consequent vessel wall stress or “cap fatigue”. Inflammation is also a key factor in 
plaque disruption. Inflammatory cells are a source of plaque tissue factor, and 
lesion thrombogenicity correlates with its tissue factor content (Moreno et al. 1996). 
In addition, inflammatory cells can secrete cytotoxic substances and proteolytic 
enzymes that induce VSMC apoptosis and degradation of the fibrous ECM. 
Mechanical forces experienced by blood vessels are critical in determining both 
plaque formation and disruption (Schroeder and Falk 1995).
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The pathogenesis of atherosclerosis is a complex multifactorial process of 
vascular wall injury and atheroma formation due to dynamic local and systemic 
factors. Shear stress, especially when blood flow is disturbed, plays an important 
role in the pathogenesis of the atherosclerotic plaque especially where flow 
conditions are disturbed with low or oscillatory shear stress. The combination of 
altered arterial haemodynamics are around curvatures, arterial branch ostia and 
bifurcations (Resnick et al. 2003) where secondary flows occur. Systemic risk factors 
promote atherosclerotic lesion initiation, progression and ultimately, development of 
complicated plaques. Atherogenesis is promoted by decreased shear stress which is 
associated with reduction in several vascular wall functions including endothelial 
nitric oxide synthase (eNOS) production, vasodilatation and endothelial cell repair. 
These are coupled with increases in reactive oxygen species (ROS), endothelial 
permeability to lipoproteins, leukocyte adhesion, apoptosis, smooth muscle cell 
proliferation and collagen deposition (Gimbrone et al. 2000).
1.7 Oxygen Levels in vivo and in Cell Culture
Oxygen is an excellent electron acceptor and acts in this capacity as an 
essential component of multiple biologic redox processes, in particular cellular 
respiration (Gnaiger 2001; Gnaiger 2003; Nohl et al. 2003). Knowledge about the 
exact levels of extra- and intracellular oxygen tensions that occur in organisms is not 
comprehensive which is largely due to technical challenges in making meaningful 
measurement (Dewhirst et al. 1994). There is great heterogeneity both between and 
within tissues. Extreme examples of the latter are the upper respiratory tract where 
cells are directly in contact with air containing 21% oxygen, and the medulla of the 
kidney, where extracellular levels approximate to 1% oxygen or below (Maxwell 
2003). Also rather striking is that tissues in the body are not equally resistant to the 
potentially harmful effects of sustained low oxygenation (hypoxia); for example, 
synaptically active neurons are relatively easily damaged by minor changes in 
oxygen supply (Olson and McKeon 2004), while neutrophils (at least ex vivo) have 
an increased lifespan in hypoxia (Walmsley et al. 2005)
Cells tolerate a broad range of oxygen tensions in vitro yet very little is 
known about how the oxygen levels they experience relate to physiologic conditions. 
However, it has recently become evident that varying oxygen tension in the gas 
phase over the range from 21 to approximately 0.5% has very potent effects on gene
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expression in many different cell types (Liu and Simon 2004). Many of these 
changes occur at the level of gene transcription and involve the transcription factor 
hypoxia-inducible factor (HIF) as a master regulator (Semenza 2000). Although 
variable from one cell type to another, HIF activation is usually just detectable and 
has some effect on gene expression under standard culture conditions. However, 
below approximately 5% oxygen, it is progressively activated, reaching a maximum 
atO.5%-1%.
To date, there are over 50 well-characterized HIF target genes, and the list is 
growing rapidly. It has been estimated that over 1% of all mammalian genes are 
regulated by HIF (Semenza 2000; Liu and Simon 2004). Target genes that have 
already been identified influence almost all aspects of cell behaviour. Accordingly, 
HIF is implicated in many processes relevant to human health such as embryonic 
development, inflammatory responses, wound healing, stroke and cancer (Semenza 
et al. 2000; Maxwell et al. 2001; Cramer et al. 2003; Melillo 2004). The ability to 
mount major adaptive changes to alterations in oxygen supply via HIF is conserved 
as far back as the nematode Caenorhabditis elegans (Jiang et al. 2001), which is 
entirely consistent with this pathway being a cornerstone of animal physiology.
Hypoxia-responsive transcrip tion  factors
Transcription factors Functions
HIF Vasodilatation
(Hypoxia-inducible factor) Glycolysis
Angiogenesis
NF k. B Innate immunity
(Nuclear factor kappa-B) Stress responses
Cell survival and development
CREB Inflammation
(Cyclic AMP response element Metabolism
binding protein) Signal transduction 
Stress responses
AP-1 Inflammation
Activating protein-1 Metabolism 
Signal transduction 
Stress responses
AP-1 Apoptosis
Activating protein-1 Proliferation
Differentiation
Inflammation
Angiogenesis
p53 Apoptosis 
Tumours growth 
Interact with HIF-1 a
Table 1.2 Hypoxia-responsive transcription factors
T able adap ted  from  E oin  P. C um m ins and C orm ac T. Taylor, 2005
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1.7.1 Hypoxia-responsive transcription factors
There are various transcription factors that have been demonstrated to be 
hypoxia-responsive and contribute to the complex transcriptional profile activated by 
this important physiological and pathophysiological stimulus (Table 1.2).
1.7.2 Multiple Mechanisms of Hypoxia Response Acting through HIF-la
HIF-1 is a heterodimeric transcription factor, composed of a HIF-la subunit 
and a protein known as the aryl hydrocarbon receptor nuclear translocator (ARNT) 
which is also named as 111F-1 [ifWang and Semenza 1995). Both HIF-1 subunits are 
members of the basic helix-loop-helix (bHLH)/PER-ARNT-SIM (PAS) domain 
family of transcription factors (Wang et al. 1995). The activity of HIF-1 is 
primarily regulated by a two-step mechanism of post-translational modification of 
HIF-la, increasing both protein stability and transactivation capacity. By contrast, 
ARNT is insensitive to changes in oxygen availability.
Regulation of HIF-la stability is mediated by a region that is referred to as 
the oxygen-dependent degradation domain (ODDD) (Huang et al. 1998). At 
normoxic condition (oxygen supply to cells in vitro corresponds to the atmospheric 
pressure), the degradation domain of H IF-la interacts with the product of the von 
Hippel-Lindau tumour suppressor gene (pVHL), which functions as a multisubunit 
ubiquitin-protein ligase, promoting HIF-la degradation by the proteasome (Maxwell 
et al. 1999; Cockman et al. 2000; Kamura et al. 2000; Ohh et al. 2000; Tanimoto et al.
2000). Interaction between pVHL and H IF-la is dependent on hydroxylation of two 
conserved proline residues, Pro 402 and Pro 564, within the ODDD. Hydroxylation 
and subsequent pVHL-HIF-la interaction and ubiquitination of HIF-la, are inhibited 
under hypoxic conditions, resulting in accumulation of the HIF-la protein (Fig. 
1.11).
Under hypoxic conditions (a reduction in the normal oxygen supply to cells 
either in the tissue or in culture where cells are being exposed to oxygen 
concentrations below the ambient level in the atmosphere), the 02-dependent 
hydroxylation of HIF-la is decreased, which prevents its degradation. A further level 
of 02-dependent regulation exists: the hydroxylation of an asparagine residue by 
factor inhibiting HIF-la (FIH) blocks the interaction of HIF-la with p300/CBP 
transcriptional co-activator proteins, thereby decreasing transcription of 
HIF-la-regulated gene at norrrioxia.
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Fig. 1.11 H IF-la Regulatory Pathway
Kol A. Zarember and harry L.Malech; J  Clin Invest 115: 1702-1704 (2005)
P: proline residues 402 & 564; vHL: von Hippel Lindau protein; FIH: factor 
inhibiting HIF-la; Ub:ubiquitination.
When H IF-la levels increase in response to hypoxia in tissues, functional 
HIF-1 regulates transcription at HREs (hypoxia response elements) of target gene 
regulatory sequences, which results in the transcription of genes such as vascular 
endothelial growth factor (VEGF); endothelial nitric oxide synthases (eNOS); 
platelet derived growth factor (PDGF); and glucose transporter GLUT-1 and thereby 
enhances local vascularization and systemic oxygen transport.
Among the bHLH-PAS protein family, the other members were identified by 
data base searches for cDNA sequences encoding structurally related protein. The 
amino acid important functional domains in H IF-la are highly conserved in HIF-2a 
(Tian et al. 1997; Wiesener et al. 1998; O'Rourke et al. 1999). In contrast to HIF-2a, 
HIF-3a also exhibits conservation with HIF-la and HIF-2a in the HLH and PAS
43
domains, and an oxygen-dependent degradation domain, but does not possess a 
similar hypoxia-inducible transactivation domain (Gu et al. 1998). However, 
although HIF-3a. is homologous to HIF-la, it might be a negative regulator of 
hypoxia-inducible gene expression (Shimo et al. 2001). As for all the class I subunits, 
HIF-la, -2a and -3a, each heterodimerize is with one of the class II subunits, ARNT 
(HIF-ip), ARNT 2 or ARNT 3.
HIF-la and HIF-1 (3 mRNA are expressed in most human and rodent tissues 
(Wenger et al. 1996; Wiener et al. 1996). In contrast, HIF-2a, HIF-3a, ARNT 2 and 
ARNT 3 show a more restricted pattern of expression to specific cell types (Jain et al. 
1998; Tian et al. 1998). It appears that HIF-la plays a very general role by 
signalling the existence of hypoxia to the transcriptional machinery in the nucleus of 
all cells, whereas HIF-2a and HIF-3a play more limited or specialized role in O2 
homeostasis which is still unclear (Wenger 2000; Fedele et al. 2002).
1.7.3 Protein hydroxylation as an oxygen-sensing mechanism
Recent major advances have shown that prolyl hydroxylation and acetylation, 
by controlling HIF-1 a-pVHL physical interaction, are critical in the regulation of 
H IF-la steady-state levels (Ivan et al. 2001). The proline residues subjected to 
hydroxylation reside in the H IF-la ODDD which is strongly conserved between the 
H IF-la isoforms (Jeong et al. 2002).
In mammalian cells, three isoforms, prolyl-hydroxylase 1(PHD1), PHD2 and 
PHD3, have been identified and shown to hydroxylate in vitro the key proline 
residues (Pro402 and Pro564) of HIF-la (Epstein et al. 2001). PHDs are 
dioxygenases that utilize oxygen as co-substrate providing the molecular basis for the 
oxygen-sensing functions of these enzymes. In addition, the prolyl hydroxylation 
reaction requires 2-oxoglutarate and iron as cofactors, thereby accounting for the 
well known ‘hypoxia-mimic’ effects of iron chelators and transition metals on 
HIF-la induction. Each PHD isoform differs in the relative abundance of their 
mRNA, howerer, all three show a ubiquitous pattern of expression (Lieb et al. 2002; 
Cioffi et al. 2003).
A separate hydroxylation reaction targets an asparagine residue in the carboxy 
terminal part of HIF (termed CTAD), preventing the recruitment of transcriptional 
coactivators (Hewitson et al. 2002; Stolze et al. 2004). This asparagynil 
hydroxylation is carried out by the enzyme FIH, which, like the PHD enzymes, is an
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iron- and 2-oxoglutarate-dependent oxygenase. Both the FIH and PHD reaction 
rates are exquisitely influence by oxygen concentration, many circumstances may 
influence the HIF response in one way or another such as altering the transcription of 
the hydroxylase enzymes themselves (del Peso et al. 2003), the PHD/FIH enzymes 
act as the oxygen sensors, thus regulating HIF stability and activity (Fig. 1.12).
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Fig. 1.12 Regulation of HIF by the level of oxygenation
M iguel A  E steb an  and  P a tr ick  H  M axw ell; E x p e r t  R e v .  P r o t e o m i c s  2 : 307-314  (2005)
PHD: prolyl hydroxylase domain; CTAD: C-terminal portion of HIF
1.7.4 H IF-la Plays a Complex Role in Mediating Hypoxia-Induced Apoptosis.
HIF-la can induce apoptosis via two mechanisms: firstly, it can increase the 
stability of product of the tumour suppressor gene p53 which regulates proteins such 
pro-apoptotic Bax and p21 causing growth arrest (Chen et al. 2003); and secondly, 
up-regulation of transcription of Nip3/BNIP3 (Bcl2/adenovirus E1B 19kf)a 
Interacting Protein 3) a pro-apoptotic member of the Bcl2 family of cell death factors, 
induces apoptosis by binding to and inhibiting the anti-apoptotic proteins Bcl-2 and
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Bc1-xl (Bruiclc 2000). However, while severe and prolonged hypoxia may result in 
reduced cell proliferation and increased apoptosis, cells can often adapt to acute and 
mild hypoxia and survive.
Hypoxic pulmonary vasoconstriction is an important mechanism for 
matching ventilation and perfusion (Gerritsen and Bloor 1993). The ability of 
hypoxia to induce the transcription and production of vasoconstrictions such 
platelet-derived growth factor-B (PDGF-B) and ET-1 may represent one molecular 
mechanism whereby low oxygen tension mediates vasoconstriction regionally 
(Kourembanas et al. 1990; Kourembanas et al. 1991; Kourembanas et al. 1993). It 
is also possible that the decrease in eNOS transcripts and enzyme by hypoxia may 
also contribute to the vasoconstrictor response to hypoxia, by inhibiting production 
of the counteracting vasodilator NO which itself can prevent the induction of 
vasoconstrictor gene transcription by hypoxia (Kourembanas et al. 1993).
Chronic hypoxia elicits a unique tissue vascular pathology. PDGF-B and 
ET-1 induction by hypoxia may mediate much of the structural remodelling that 
characterizes the tissue response to chronic hypoxia. Both are potent 
vasoconstrictors, strong mitogens for fibroblast and smooth muscle cells and also 
serve as fibroblast chemoattractants (Seppa et al. 1982; Berk et al. 1986; Komuro et 
al. 1988; Takuwa et al. 1989; Bobik et al. 1990; Dzau and Gibbons 1991; Peacock et 
al. 1992). Media conditioned by hypoxic endothelial cells has been show recently 
to inhibit chemoattractant and mitoegenic activity towards fibroblast and this activity 
was due to secreted ET-1 and PDGF (Dawes et al. 1994). Reciprocally, NO, the 
production of which is inhibited by hypoxia, inhibits fibroblast and smooth muscle 
cell mitogenesis, as well as endothelial cell migration, mitogenesis and proliferation 
(Garg and Hassid 1989; Garg and Hassid 1990; Nakaki et al. 1990; Nunokawa and 
Tanaka 1992; Scott-Burden et al. 1992; Sarkar et al. 1995; Lau and Ma 1996).
1.7.5 Hypoxia and Diabetic Vascular Disease
Hyperglycaemia and hypoxia are suggested to play essential 
pathophysiological roles in the complications of diabetes, which may result from a 
defective response of the tissues to low oxygen tension.
Exposure to acute/mild hypoxia can up-regulate HIF-la expression to 
increase proliferation which helps normal tissues and tumours to survive under 
hypoxic conditions. Exposure to severe and prolonged hypoxia may result in reduced
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cell proliferation and increased apoptosis leading to increased cell death.
Chronic complications of diabetes are a major health problem and it has 
become a priority to characterize further, their pathophysiological mechanisms to 
develop novel, rational therapeutic strategies. Even though prolonged exposure of 
the tissues to hyperglycaemia seems to be primary causative factor, some other 
factors may play a role, as intensive blood glucose control reduces chronic 
complications but does not prevent them altogether (DCCT 1993; UKPDS 1998). It 
has become increasingly evident that hypoxia plays an important role in all diabetes 
complications (Cameron et al. 2001).
The possibility that hyperglycaemia and hypoxia may interact via a common 
metabolic imbalance to initiate and/or exacerbate complications of diabetes is 
suggested by the correspondence of several redox, metabolic, and pathophysiological 
changes evoked by either condition alone (Nyengaard et al. 2004).
A biochemical event with diabetes is the formation of glycosylated products 
(Brownlee et al. 1988). Proteins constitute the principal substrate of this reaction 
which generates glycoproteins in the extracellular compartment, plasma membrane, 
cytoplasm, and ultimately, in the nucleus (Haltiwanger et al. 1997; Ramamurthy et al.
1999). Glycosylation and phosphorylation activate several transcription factors 
(Jackson and Tjian 1988) including p53 (Shaw et al. 1996). The processes of 
glycosylation and phosphorylation are tightly and dynamically regulated which affect 
the activation and stability of the p53 protein (Hupp and Lane 1994; Shaw et al. 1996; 
Ashcroft et al. 1999). There is direct competition between glucose and phosphate at 
a single amino acid residue on p53 which results in a decrease in the level of 
phosphorylation when glycosylation occurs (Hart et al. 1995; Haltiwanger et al. 
1997). Moreover, p53 reduces the expression of genes opposing cell death, such as 
Bcl-2, and up-regulates genes promoting apoptosis such as Bax (Miyashita and Reed 
1995).
It is well known that the major complication of diabetes is atherosclerosis; a 
disease of large and medium-sized muscular arteries characterized by endothelial 
dysfunction, vascular inflammation, and the build up of lipids, cholesterol, calcium, 
and cellular debris within the intima of the vessel wall. This build up results in 
plaque formation, vascular remodelling, acute and chronic luminal obstruction, 
abnormalities of blood flow and diminished oxygen supply to target organs.
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Atherosclerosis highlights the fact that the more deeply situated parts of the 
arterial wall depend on diffusion to satisfy their need for oxygen and nutrients. 
When atherosclerotic lesions develop, the arterial wall thickness increases and 
diffusion capacity is impaired. At the same time, oxygen consumption is 
augmented (Morrison et al. 1972; Bjornheden and Bondjers 1987) and an energy 
imbalance may occur. Local metabolic disturbances may be envisioned that may 
endanger regression or even result in progression of the atherosclerotic process, with 
the formation of a necrotic core.
Risk factors for atherosclerosis impair erythrocyte deformability, leading to a 
non-ischemic microcirculatory derangement involving shunting of erythrocytes 
through large capillaries, metarterioles, and arteriovenous anastomoses. The result 
is a non-homogenous microcirculatory blood flow and a consequently altered tissue 
level oxygen tension which leads to focal areas of tissue-level hypoxia within the 
avascular media worsened by a variety of other effects which diminish trans-intimal 
and trans-adventitial oxygen delivery.
Arterial medial hypoxia initiates a pathophysiological cycle with release of 
growth factors and cytokines. These growth factors and cytokines stimulate 
macrophage migration and activation, intimal and adventitial proliferation, 
endothelial permeability, and platelet adherence and degranulation resulting in 
atheroma formation. Because intimal proliferation further worsens medial hypoxia 
by decreasing transintimal oxygen delivery, a pathophysiological positive feedback 
loop is completed. Disruption of the normal intimal connective tissue architecture 
and underlying necrosis diminish the artery's capacity for endothelial support, 
resulting in endothelial ulceration with consequent luminal thrombosis. These 
endpoints manifest clinically as myocardial infarction and non-hemorrhagic stroke. 
Medial hypoxia also causes medial necrosis with consequent aneurysm formation or 
rupture which results in hemorrhagic stroke and ruptured aortic aneurysms 
(Simanonok 1996).
In response to this decrease in oxygen availability, atherosclerotic plaques 
undergo angiogenesis in an attempt to re-perfuse the plaque and maintain cell 
viability. Formation of these new vessels however, can be detrimental to the plaque 
as: (i) it can lead to increased entry of leukocytes and macrophages resulting in 
weakening and breakdown of the fibrous cap and (ii) due to the weak and unstable 
nature of the new vessels, neovascularisation may result in plaque haemorrhage and
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thrombosis (Tenaglia et al. 1997). Both diabetes and hypertension have been shown 
to produce tissue hypoxia.
Vascular homeostasis is subject to adaptation upon exposure of the 
endothelium to hypoxia and for this; it must be able to detect either the lack of 
oxygen itself or metabolic consequences of oxygen deprivation. During hypoxia, 
the transcription factor HIF-la binds to hypoxic response elements (I IRE) in the 
promoter or enhancer regions of various hypoxia-inducible genes including vascular 
endothelial growth factor (VEGF), eNOS, platelet derived growth factor (PDGF) and 
the glucose transporter GLUT-1 (Semenza 2002), promoting angiogenesis, glycolysis 
and growth factor signalling.
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Chapter 2
M aterials & M ethods
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2.1 Materials
All reagents used were of the highest grade commercially available and obtained by 
the following suppliers:
AGB Scientific (Dublin, Ireland)
Whatmann Chromatography paper
Amersham Pharmacia Biotech (Buckinghamshire, UK)
ECL Hybond nitrocellulose membrane, ECL Hyperfilm, Rainbow molecular weight 
marker, broad range (6-175kDa)
AXXORA (UK) Ltd.
Bnip3L antibody
BD Bioscience (USA)
Vybrant™ CFDA SE Cell Tracer Kit (V-12883), Vybrant™ Apoptosis Assay Kit #2, 
H IF-la antibody, Bcl-xl antibody, PS Round Bottom Tube W/Cap, FACS Flow
Bio Sciences Ltd (Dun Laoghaire, Ireland)
DMEM, dNTP’s, DEPC-treated water, Trizol® reagent
Cell Signalling TECHNOLOGY®
Cleaved Caspase-3 antibody, Bax antibody
PALL Corporation (Dun Laoghaire, Ireland)
Biotrace nitrocellulose membrane
Promega (UK)
Taq DNA Polymerase, MLV-RT, Rnase H, Oligo dT, Luciferase Reporter Reagents, 
WizardR Plus Midipreps DNA purification kit, 100 bp DNA ladder.
Sigma Chemical Company (Poole, Dorset, England)
ß-glycerophosphate, ß-mercaptoethanol, Acetic Acid, Acetone, Agarose, Ammonium 
Persulphate, Acrylaminde/bis-Acrylamine, Bovine Serum Albumin, Brefeldin A,
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Brightline Haemocytometer, Bromophenol blue, Calcium Chloride, CHAPSO, 
Chloroform, DMEM, DMSO, DTT, EDTA, EGTA, Ethidium Bromide, Foetal 
Bovine Serum, Glycerol, Glycine, Hanks Balanced Salt Solution, Hydrochloric acid, 
Isopropanol, Lauryl Sulphate, Leupeptin, N-Acetyl-Asp-Glu-Val-Asp-pNitroanilide, 
Methanol, Mineral oil (molecular grade), Penicillin-Streptomycin (100X), Ponceau S, 
Potassium Chloride, Potassium Iodide, Potassium Phosphate (Dibasic), 
p-Nitroaniline, Phosphatase inhibitor cocktail 1, Protease inhibitor cocktail, Sodium 
Acetate, Sodium Chloride, Sodium Doecly Sulphate, Sodium Hydroxide, Sodium 
Nitrite, Sodium Orthovanadate, Sodium Phosphate, Sodium Pyrophosphate, 
Sulphuric Acid, Tetracyline, TEMED, Tris Acetate, Tris Base, Tris Chloride, Triton 
X-100, Trypsin-EDTA solution (10X), Tween 20
Qiagen (West Sussex, UK)
SYBR Green® PCR Kit
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2.2 Cell Culture and Transfections
2.2.1 Cell Maintenance
Bovine Aortic Endothelial Cells (BAEC) and Bovine Aortic Smooth Muscle 
Cells (BASMC) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with 10% (v/v) Fetal Bovine Serum (FBS), 100 units/ml penicillin, 
100 pg/ml streptomycin sulfates, and 1% L-glutamine in a 37°C humidified 
atmosphere containing 5% CO2. When confluent, cell monolayers were washed with 
Hanks Balanced Salt Solution (HBSS), 1ml of 1 x trypsin diluted with HBSS added 
and the flasks returned to the incubator to allow cells to detach, 7 mis of media was 
then added to the flasks and the cells pipetted gently to resuspend. Cells were either 
passaged 1:4 into flasks to maintain the cell line or seeded into dishes for 
experimental analysis.
2.2.2 DNA Transfections using LipofectAMINE™
On the day prior to transfection, 75cm2 flasks of BAEC or BASMC were 
passaged 1:8 into 6 well plates and cells left overnight to plate down. For each well 
to be transfected, 2pg DNA and 5(0,1 of LipofectAMINE™ reagent were mixed gently 
with 0.24ml serum/antibiotic free DMEM and incubated at room temperature for 
15-45 mins in the dark. During the incubation, cell monolayers were washed with 
serum/antibiotic free DMEM and the medium replace with 0.76ml/well 
serum/antibiotic free DMEM. The DNA-LipofectAMINE™ mix was added 
dropwise to the cells and the plates returned to the incubator for 3hrs. Following 
incubation, the DNA-DMEM (serum/antibiotic free) were removed and replaced 
with fresh medium. Cells were analysed 24 hrs post-transfection.
2.2.3 siRNA Transfections using LipofectAMINE™ 2000
On the day prior to transfection, 75cm2 flasks of BAEC and BASMC were 
passaged 1:8 into 6 well plates and cells left overnight to plate down. For each well 
to be transfected, 5 pi of 20 pmol siRNA and 5pi of LipofectAMINE™ 2000 reagent 
were mixed gently with 0.99ml serum/antibiotic free DMEM and incubated at room 
temperature for 20-30 mins. Prior to the addition of siRNA to cells, cells were 
washed with serum/antibiotic free DMEM. The siRNA-LipofectAMINE™2000 mix
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was then added to the cells and incubated for 3hrs. Following incubation the 
siRNA-LipofectAMINE™2000 mix was removed and replaced with fresh medium. 
Cells were analysed 5 days post-transfection.
2.3 Molecular Biology
2.3.1 Transformation of DNA
30-50ng of DNA was incubated with 50fj,l of competent XLl-blue cells on ice 
for 10 minutes. The cells were then placed for 5 minutes in a 37°C shaking 
waterbath before the addition of 0.5mls LB broth (1.0% tryptone, 0.5% yeast extract,
1.0% NaCl). The mix was then returned to the waterbath and incubated for 45 
minutes. 200(0,1 from each transformation was spread onto agar plates containing 
the appropriate antibiotic (Amp 50(ig/ml). Plates were incubated overnight at 37°C 
and transformed colonies selected the next day.
2.3.2 Preparation of Plasmid DNA
Transformed colonies were picked from agar plates and grown overnight in 
5-10 mis of LB broth containing appropriate antibiotic (Amp 50|ig/ml). DNA 
purification was by the Qiagen plasmid midi kit system as per the manufactures 
instructions. The concentration of DNA obtained was determined by measuring the 
absorbance at 260nm (A260) of a 1:50 dilution in DNase/ RNase free H2O, assuming 
that 1 absorbance unit was equivalent to 50|_ig/ml of double stranded DNA.
2.3.3 Preparation of Total RNA
Total RNA was isolated from BAECs and BASMCs using Trizol® reagent 
according to the manufacturer instructions. The pellet was air-dried and the RNA 
re-suspended in 30-50p.l of DNase/RNase free water. All total RNA preparations 
were stored at -80 °C.
2.3.4 Quantification of Total RNA in Samples
To determine the amount of total RNA, the sample was diluted 1:500 in 
DNase/RNase free water and spectrophotometric analysis carried out using the
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Shimadzu UV-160A dual spectrophotometer, blanked with DNase/RNase free water. 
The sample was measured, using a quartz cuvette, at wavelengths of 260 and 280 nm, 
and the concentration of the RNA in the sample carried out as follows;
Abs260nm x dilution factor x 40 = concentration of RNA (ng/ml)
The purity of the RNA was determined by calculating the ratio of absorbance at 
260nm to 280nm. A ratio of 1.9 to 2.0 was indicative of a highly purified preparation 
of RNA.
2.3.5 Reverse-Transcription (RT) of mRNA
mRNA was reverse transcribed from total RNA, prepared by the Trizol® 
method, using iScript™ cDNA Synthesis Kit according to the manufacturer 
instructions. All RT samples were stored at -80°C until needed for PCR.
2.3.6 Design of PCR Primer Sets
A number of web based programs, “Primer 3 Output” and “NCBI/BLAST” 
were utilized to design the primer sets used in this study (Appendix 1). The Primer 3 
program designs primers from the sequence input by the user. Primer pairs are then 
entered into the BLAST program to determine multiple-species sequence alignment, 
which allows primers to be designed from highly conserved areas. Primers were 
designed with -50% GC content; subsequently the annealing temperature for all sets 
was ~55°C.
2.3.7 Polymerase Chain Reaction (PCR)
Regions of the appropriate cDNA were amplified by polymerase chain 
reaction (PCR). A typical PCR contained 45.5pl Mastermix (36.5pl DNase/RNase 
free water, 5 pi PCR Buffer, 3 pi MgCL, 1 pi DNTPs), lp l lOpmol forward primers 
and lp l lOpmol reverse primers, 0.5pl Taq, 2pl sample cDNA from reverse 
transcription, overlaid with 50pi emersion oil. The reaction was initiated by a 
denaturing phase of 94°C for lmin, followed by 40 cycles of annealing (55°C for 2 
mins) and elongation (72°C for 3 mins). Reactions were placed on hold at 4°C until 
required.
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2.3.8 Quantitative Real Time PCR (QRTPCR)
Quantitative PCR was carried out using a Real time Rotor-GeneRG-3000™ 
lightcycler (Corbett Research). The principle of real time amplification detection is 
that the amount of fluorescence is proportional to the concentration of product in a 
reaction. Higher fluorescence indicates a higher concentration of a product. Each 
PCR reaction was set up as follows; SYBR-Green (12.5 (0.1), RNAse free water 
(8.5|il), cDNA (2.0|al), forward/reverse primer (l.Ofil each from 10|iM stocks).
Each sample was assayed in triplicate, and the program used for the primers was 
as follows; denaturing phase: 94°C; 20secs, annealing phase: 55°C; 30secs, 
elongation phase: 72°C; 30secs and run for 40 cycles.
2.3.9 Agarose Gel Electrophoresis
RT and QRTPCR products were analysed by agarose gel electrophoresis in 
which samples were prepared by the addition of a 1:3 dilution of loading buffer (15% 
Ficoll® 400, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 
lOmM Tris-Hcl pH 7.5, 50mM EDTA). Electrophoresis took place on a 2% (w/v) gel 
containing 0.5[ig/ml ethidium bromide at 80 V, 300 mA and 150 W for 20-30 
minutes in 1 x TAE buffer (40mM Tris-acetate, ImM EDTA, glacial acetic acid). 
When finished the gel was placed on an Ultra Violet Products UV transilluminator 
for visualization. A picture was taken using a Kodak DC290 digital camera for 
documentation.
2.4 Experimental Techniques
2.4.1 Preparation of Whole Cell Lysates
Confluent monolayers in 6-well dishes were washed three times with HBSS 
and solubilised by the addition of 0.25ml / well immunoprécipitation buffer (RIPA 
buffer [49.92mM HEPES (pH 7.5), 149.76mM NaCl, 1% (v/v) Triton X-100, 0.5% 
(w/v) sodium deoxycholate and 0.1% (w/v) SDS] supplemented with 0.1M NaF, 
5mM EDTA (pH8), 0.01M NaPC>4, 1.04mM AEBSF, 0.08|iM Aprotinin, 0.02mM 
Leupeptin, 0.04mM Bestatin, 0.015mM PepstatinA, 0.014mM E-64) and incubation 
at 4°C for 1 hour on a rotating wheel. Insoluble material was pelleted by
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centrifugation for 15 minutes at 13,000rpm and the supernatant removed to fresh 
microfuge tubes.
BSA standards ranging from 0-2mg/ml were used to obtain a best-fit straight 
line of A562 in a bichinchonic acid (BCA) based assay using the graph package 
“Prism 4.0”. Protein concentrations of 1 Ojj.1 samples of each unknown extract were 
calculated by comparison to the BSA standards.
10-30(ig of each sample was incubated at 95°C for 5 mins in sample 
solubilization buffer (SSB) ( 2%SDS, 10%glycerol, 0.8% (3-marcaptoethanol, 0.02% 
Bromophenol blue, 12% 0.25M TrisCl, pH 6.8) and separated by SDS-PAGE.
2.4.2 Preparation of Cell Lysates for Immunoprécipitation
For immunoprécipitation assays, following determination of protein 
concentration, 30-40|ig of lysate were added to microfuge tubes containing 20fil of 
protein A-Sepharose beads with 10% (w/v) IgG free BSA in the presence of the 
appropriate antibody at a concentration of 0.025|ig Ab/|ig protein. Total volume in 
the tube was brought up to 500(al using R1PA buffer to allow sufficient volume for 
mixing and samples were rotated at 4°C overnight. The following day, immune 
complexes were isolated by centrifugation at 6,000 rpm for 2 mins and washed twice 
(lml/wash) with immunoprécipitation buffer supplemented with 0.01% Triton X-100 
and twice with immunoprecipitaiton buffer alone. Immune complexes were eluted 
from the protein A-Sepharose by a 10 min incubation at 90°C with 25jal 
electrophoresis sample buffer (50mM Tris (pH 6.8), 10% (v/v) glycerol, 12% SDS, 
bromophenol blue). 20(il of each sample was separated by SDS-PAGE.
2.4.3 SDS-PAGE Electrophoresis
Samples were separated by SDS-PAGE using a 6% or 12% acrylamide 
resolving gel ([6% or 12% (v/v) from 40% acrylamide/bis acrylamide stock], 0.4M 
Tris (pH 8.8), 0.1% (w/v) SDS, 3% (v/v) glycerol, 0.01% (w/v), ammonium 
persulphate and 0.001% (v/v) TEMED) and 3% acrylamide stacking gel (3% (v/v) 
acrylamide [from 40% acrylamide/bis acrylamide stock], 0.1% (v/v) bisacrylamide, 
0.1M Tris (pH 6.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium persulphate and 
0.001% (v/v) TEMED). Electrophoresis of the samples was carried out alongside 
prestained Rainbow molecular weight markers (10-250 kDa) in a running buffer 
(27.4mM Tris, 0.19M glycine, 0.1% (w/v) SDS) at 150 Volts until the dye front
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reached the end of the gel, or if looking for larger proteins, until all but the 3 top 
markers remained on the gel only (250, 160, 105 lcDa). At this point electrophoresis 
was stopped and the proteins transferred to nitrocellulose.
2.4.4 Transfer of Proteins to Nitrocellulose Membrane
For small sized proteins (under 100 kDa), the transfer procedure was carried 
out using an Atto Ae-6657 semi-dry transfer apparatus in semi-dry transfer buffer 
(25mM Tris, 102mM Glycine, 20% Methanol, 0.1% SDS) and run at 90 V, 500 mA 
for 45mins. For large size protein (upon lOOkDa), a biorad system transfer apparatus 
was used in wet transfer buffer (25mM Tris, 192 mM Glycine, 20% Methanol, 0.5% 
SDS) and run at 100V, 500mA for lhr and 20 mins.
Upon completion of the transfer, the nitrocellulose membrane was removed 
and stained in Ponceau S solution for 5 min. The membrane was then rinsed briefly 
in ultra pure water to remove any background staining, and the image scanned using 
an Epson perfection 1200S seamier. The image was saved and subsequently used to 
assess equality of protein loading onto gel, and quality of protein transfer onto 
nitrocellulose membrane.
2.4.5 Immunoblotting
Nitrocellulose membranes were washed twice briefly in PBS and non-specific 
protein binding sites blocked by a 60 min incubation in Blotto (5%(w/v) skimmed 
milk powder, 0.2% (v/v) Triton X-100, in PBS) at room temperature. Following 
blocking, membranes were washed briefly in 1 X PBS and incubated with the 
appropriate dilution of primary antibody (Appendix 2) in fresh Blotto overnight at 
4°C. The following day, membranes were washed three times with Blotto and 
HRP-conjugated secondary antibody added in fresh Blotto for 1-3 hours at room 
temperature. Visualisation was detected by an enhanced chemiluminescent procedure 
(ECL).
2.4.6 Densitometric Analysis of Blot
Bands on a developed film were photographed using a Kodak DC290 digital 
camera. The image generated was then analysed using Kodak ID (version 3.5.4) 
densitometry imaging software. A mean densitometric value was generated for each 
band; these values were then corrected using ponceau controls for each lane. The
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corrected values were then expressed as fold increase over control, and graphically 
expressed using “Prism 4.0”
2.4.7 Detection of Apoptotic Cell Death
(a) Caspase Assay
A colourimetric caspase 3 assay was carried out on cell lysates (prepared as 
described in 2.4.1) to determine the level of caspase 3 activation in the sample, and 
therefore the level of apoptosis. Briefly, lOfil of caspase 3 substrate (2mM 
Ac-DEVD-pNA containing 10% DMSO in 20mM HEPES, 0.1% CHAPSO, 5mM 
DTT and 2mM EDTA) was added to 50|_il cell lysate, and diluted in assay buffer 
(20mM HEPES, 0.1% CHAPS, 5mM DTT and 2mM EDTA) to a final volume of 
lOOnl. Samples were incubated for 90 min and the absorbance measured at 405nm 
using a Tecan Spectra plate reader. Appropriate negative controls and blanks were 
included in the assay. A pNitroanilide (pNA) standard curve (0-200|_ig/|_il) allowed for 
the specific activity of caspase 3 to be calculated for each sample.
(b) FACS analysis using the Vybrant® Apoptosis Assay Kit #2
Following treatment, BAEC and BASMC monolayers were washed once in 
HBSS and harvested by trypsinisation. Cells were pelleted by centrifugation at 1000 
rpm for 5 mins and the supernatant removed. Cell pellets were washed by the 
addition of 1ml ice-cold 1 x PBS with 0.1% BSA and resuspended by gentle 
pipetting; followed by centrifugation at 1000 rpm for 5 mins. Following this wash, 
the supernatant was discarded and the cells resuspended in lOOp.1 of 1 x 
Annexin-Binding Buffer (lOmM HEPES, 140mM NaCl, 2.5 mM CaCl2; PH 7.4). 
0.4|Ltl Propidium Iodide (from lOO^g/ml working solution) and l(il AlexaFluor 488 
AnnexinV (in 25mM HEPES, 140mM NaCl, ImM EDTA, PH 7.4, plus 0.1% BSA) 
were added to the cell suspension and incubated at room temperature for 15 mins. 
After the incubation period, a further 100p.l of 1 x Annexin-Binding Buffer was 
added to the cells and mixed gently by pipetting. Samples were placed on ice and 
analysed by flow cytometry using a Becton Dickinson FACSCAN flow cytometer. 
Annexin V binds to phosphatidylserine located on the extracellular surface of 
apoptotic cells while PI is impermeable to live cells and apoptotic cells but stains 
necrotic cells with red fluorescence. Populations of cells are distinguished using 
flow cytometry where they are designated as viable (V), early apoptotic (EA), late
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apoptotic (LA) or necrotic (N) depending on the AnnexinV / PI staining.
2.4.8 Determination of Cell Proliferation
(a) Cell Counting
Cell counts were carried out using a Sigma bright line haemocytometer. 
Following trypsinisation and resuspension in DMEM, a drop of cell suspension was 
used to fill the haemocytometer counting chamber. Following visualization under 
10X magnification, the number of cells were counted in each of the four outer 
quadrants of the haemocytometer. The average of these four counts was equal to 
the number of cells x 104/ml of cell suspension.
(b) FACS analysis using the Vybrant® CFDA SE Cell Tracer Kit
BAECs and BSAMCs were seeded into 6-well-plates so as to reach 50% 
confluency 24hrs after plating. Having reached the desired confluency, the growth 
media was removed and cells washed x 1 with HBSS. A working solution of 5jj.M 
CFDA SE (carboxy-fluorescein diacetate succinimidyl ester) was prepared in an 
appropriate volume of HBSS to allow the addition of 1ml CFDA-HBSS per well. 
CFDA-HBSS was added to the wells and cells incubated for 15 minutes at 37°C. 
Following incubation, the CFDA-HBSS was removed and replaced with fresh, 
pre-warmed medium. Cells were incubated overnight, prior to treatment. CFDA SE 
passively diffuses into cells. It is colourless and non-fluorescent until its acetate 
groups are cleaved by intracellular esterases to yield highly fluorescent, 
amine-reactive carboxyfluorescein succinimidyl ester. The succinimidyl ester group 
reacts with intracellular amines, forming fluorescent conjugates that are well-retained. 
Upon cell division, the label is inherited by daughter cells causing sequential halving 
of the CFDA SE fluorescence, resulting in a cellular fluorescence histogram in which 
the peaks represent successive generations.
(c) Luciferase Assay
To analyse transactivation of luciferase tagged (Luc) reporter genes, cells 
were co-transfected with Luc (1.5|ig) and P-Galactosidase (P-Gal; 0.5(ig) (section 
2.2.2), and harvested 24 hrs post transfection. Cells were washed twice in HBSS, and 
incubated with 300(j,l/well of 1 X reporter Lysis Buffer (Promega) for 10 min at 37°C 
in a humidified atmosphere. Cells were then scraped from the wells, transferred to
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eppendorf tubes, and lysed by freeze-thawing once. The lysates were clarified by 
centrifugation at 3,000 rpm for 2 mins, and the supernatant saved in a fresh tube for 
analysis. Transactiviton of the luciferase tagged reporter genes was then analysed by 
luciferase assay as follows: 40|_il sample and 50|il luciferase assay buffer (Promega) 
were incubated at room temperature for 30 mins and light emission measured over a 
period of 60 sec, after a lag period of 10 sec. To determine transfection efficiency, 
samples were normalized to (3-Gal expression.
(d) P-Galactosidase Assay
A P-Galactosidase assay (High Sensitivity P-Galactosidase Assay, Stratagene) 
was carried out according to the manufacturers’ instructions to normalise for 
differing transfection efficiencies. P-Gal, which is expressed due to transfection with 
pCMV-LacZ, catalyzes the hydrolysis of chlorophenol red-P-D-galactopyranoside 
(CRPG) into galactose and the chromophore chlorophenol red, yielding a dark red 
solution, which can be quantified using a spectrophotometer at 595nm. 20(il of cell 
lysate was analysed in triplicate in a 96 well plate. 130(0.1 of 1 X CRPG substrate was 
added per well and the time recorded. The plate was then covered and incubated at 
37°C until the sample turned a dark red up to 72 hrs. The incubation time was 
recorded and the reactions terminated by the addition of 80(il Stop solution (0.5M 
Na2C03) to each well. The absorbance was then analysed at 595nm using a 
microplate spectrophotometer. A blank was set up for each experiment by 
substituting the 20[ri of sample for 20(il of IX report lysis buffer.
Luciferase assay was corrected for both P-Galactosidase activity and differing 
protein concentrations, and expressed as fold activation over the empty vector.
2.4.9 Statistical Analysis
All treatments were normalised to quiesced cells (serum starved control: C 
(t=0) and expressed as a fold increase or decrease compared to this value. Results 
are expressed as mean ± SEM. Statistical significance was assessed by Students 
paired and unpaired t-test or 2-way ANOYA, with significance values of p<0.01 and 
p<0.05.
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Effect of High Glucose on BAEC and BASMC Cell Fate 
(proliferation and apoptosis)
Chapter 3
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3.1 Introduction
Diabetes mellitus can cause a wide variety of vascular complications and 
cardiovascular dysfunction (DCCT 1993). The normal range of blood sugar level is 
between 80-110mg/dL (4.4-6.1 mM/L), when this level goes above 160mg/dL 
(8.9mM/L) which results in hyperglycaemia. This viewpoint was supported by the 
results of the large-scale study (DCCT 1993). Hyperglycaemia is an important 
etiologic factor in the development of vascular complications (Wilson et al. 1991), 
however the mechanisms of hyperglycaemia-related tissue damage and clinical 
complications still remain unclear.
It is widely accepted that atherosclerosis is accelerated by the coexistence of 
diabetes mellitus (Garcia et al. 1974; Melton et al. 1980) which could alter cell fate 
such as apoptosis, proliferation, differentiation, tube formation and migration. In this 
study, we focus on the effects on cell apoptosis and proliferation under high glucose 
conditions.
Apoptosis is particularly prominent in models of hyperglycaemic injury, 
affecting a significant proportion of vascular endothelium in tissue damage 
(Nakagami et al. 2001; Ceriello et al. 2002; Zou et al. 2002). Increased 
proliferation of vascular smooth muscle cells (VSMC) is a key feature in the 
atherosclerotic lesion (Hanke et al. 1990; O'Brien et al. 1993; Pickering et al. 1993; 
Ross 1999). It is well established that cell growth is a fundamental feature of 
intimal hyperplasia (Newby and Zaltsman 2000), and it is becoming clear that 
perturbation in the regulation of apoptosis is equally important (Haunstetter and 
Izumo 1998; Kockx and Knaapen 2000). Furthermore, apoptosis of VSMC is 
critically involved in the formation of the fibrous cap and fatty streak that is the 
lipid-rich core of the atheroma and may therefore contribute to the instability of 
advanced atherosclerotic plaques (Bennett et al. 1995; Geng and Libby 1995; Han et 
al. 1995; Isner et al. 1995; Crisby et al. 1997; Kockx et al. 1998). Excessive 
accumulation of VSMC in atherosclerosis suggests reduced apoptosis and excessive 
cell proliferation in the lesions, as apoptosis and cell proliferation are intimately 
coupled (Evan and Littlewood 1998). Although many studies have focused on the 
mechanisms of VSMC proliferation (Newby and Zaltsman 2000), the regulatory 
mechanisms of VSMC apoptosis have not been fully elucidated (McCarthy and 
Bennett 2000).
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The role o f byperglycaemia in atherosclerosis has been investigated in recent 
studies. Several findings support the concept that hyperglycaemia accelerates the 
development of atherosclerosis (West et al. 1983; Wilson et al. 1991). Although 
high glucose concentrations enhance proliferation in cultured VSMC, little is known 
about the effect of glucose on the regulation of apoptosis in VSMC.
Aim 1: To investigate the effects of high glucose (HG 25mM) on Bovine Aortic 
Endothelial Cell (BAEC) and Bovine Aortic Smooth Muscle Cell (BASMC) 
growth (proliferation vs apoptosis)
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3.2 Results
High glucose, a situation that mimics the hyperglycaemia of diabetes can 
influence macrovascular cell fate. Therefore, we initially examined the effect of high 
glucose (25mM) on bovine aortic endothelial cell (BAEC) and bovine aortic smooth 
muscle cell (BASMC) growth (proliferation vs apoptosis).
BAEC and BASMC were treated in normal growth media (10% FBS, NG 
5.5mmol/L glucose) and high glucose (10% FBS, HG 25mmol/L glucose) containing 
media for up to 7 days. Mannitol (10% FBS, 19.5 mmol/L) was used as an osmotic 
control in all experiments. Exposure of BAEC and BASMC to normal growth media 
resulted in an increase in cell number after the 7 day period as determined by cell 
counting. Concurrent treatment of BAEC and BASMC with HG media did not alter 
the growth curve of the cells. Mannitol osmotic control does not alter the growth 
curve in either cell type (Figure 3.1).
Due to the subjective nature of manual cell counting, we confirmed our 
proliferative findings by FACS analysis. BAEC and BASMC were stained with a 
fluorescent nuclear marker carboxyfluorescein diacetate, succinimidyl ester (CFDA 
SE) as described in the methods (2.4.8) prior to treatment in the absence or presence 
of HG (Figure 3.2). Proliferation was determined by a reduction in the fluorescent 
intensity of the dye following cell division and subsequent halving of the dye to 
daughter cells (Fig. 3.3).
BAEC and BASMC were exposed to normal growth media or high glucose 
containing media for 24, 48 or 72 hrs. In normal glucose media, BAEC and BASMC 
showed a significant increase of proliferation during the time period. However, 
treatment of BAEC and BASMC with HG was not seen to alter cell proliferation 
(Figs. 3.4 & 3.5).
Further analysis of cell proliferation was carried out by western blotting for 
Proliferating cell nuclear antigen (pCNA) which is a co-factor of DNA polymerase 
delta and is involved in the control of eukaryotic DNA replication by increasing the 
polymerase processibility during elongation of the leading strand. BAEC and 
BASMC were treated with either normal growth media or high glucose containing 
media for 24, 48, or 72 hours prior to harvesting in RIPA buffer. pCNA expression 
was determined by western blot as described in the methods (2.4.3). pCNA 
expression increased in normal culture media up to 72 hours in BAEC and BASMC.
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However, cells which were treated with high glucose showed no changes in 
pCNA expression, a marker of cell proliferation (Figs. 3.6 & 3.7).
Treatment of cells in the present of HG up to 72 hrs did not appear to affect 
the proliferation status of the cells. Therefore, we increased the exposure time to a 
period of 3, 5, or 7 days. Cell proliferation was measured by FACS analysis and 
western blot as previously described. BAEC and BASMC proliferation significantly 
increased over the 7 day period; however, exposure to HG was not seen to alter 
proliferation in any way (Figs. 3.8, 3.9, & 3.10).
These results, which correlate with cell counts, suggest that BAEC and 
BASMC proliferation were not affected by the presence of HG in 10% FBS during 
either short-term or long-term exposure.
Fetal bovine serum (FBS) is a common component of animal cell culture 
media which contains basic components, such as hormones and growth factors 
without cells, platelets and clotting factors. Since no change in proliferation was 
observed in normal serum containing media, we hypothesised that the effect of high 
glucose on BAEC and BASMC may be impaired by the presence of fetal bovine 
serum.
Therefore, BAEC and BASMC were treated with normal growth media 
containing 10% FBS and low serum media contained 0.5% FBS for 24 hours and the 
rate of cell proliferation determined by FACS analysis. A significant increase in 
proliferation was observed in cells treated with 10% FBS compared to 0.5% FBS. 
However, the exposure of BAEC and BASMC to HG in the presence of 0.5% FBS, 
failed to alter the proliferation profile of the cells (Figs. 3.11 & 3.12).
Concurrent western blot analysis for pCNA expression also showed no 
change in proliferation of cells cultured in 0.5% FBS in the presence of HG (Fig. 
3.13).
To determine the effects of high glucose on BAEC and BASMC apoptosis, 
cells were cultured in 10% or 0.5% FBS in the absence or presence of HG for 24, 48, 
or 72 hrs. Subsequent FACS analysis using a PI/Annexin V-based dual staining 
technique (2.4.7) distinguished a population of cells depending on their uptake of the 
two dyes (Fig. 3.14).
A basal range of apoptotic cells in normal growth media was approximately 
0.5% ~ 2% in both cell types. During the time course, the percentage of apoptotic 
cells in 10% FBS conditions was not significant different compared to t=0 control.
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High glucose does not alter this effect either in BAEC or on BASMC over the 72 hr 
treatment period. However, the percentage of apoptotic cells significantly increased 
when cultured in 0.5% FBS compared to t=0 control (BAEC 2.36-fold ± 0.26-fold 
t=24, 4.04-fold ± 0.27-fold t=48, 10.38-fold ± 0.76-fold t=72 vs 1.00 *p< 0.01; 
BASMC 3.74-fold ± 0.40-fold t=24, 6.28-fold ± 0.64-fold t=48, 11.05-fold ± 
0.84-fold t=72 vs 1.00 *p< 0.01) and 10%oFBS treated cells (BAEC 2.36-fold ± 
0.26-fold t=24, 4.04-fold ± 0.27-fold t=48, 10.38-fold ± 0.76-fold t=72 vs 1.18-fold ± 
0.12-fold #p< 0.01; BASMC 3.74-fold ± 0.40-fold t=24, 6.28-fold ± 0.64-fold t=48,
11.05-fold ± 0.84-fold t=72 vs 1.18-fold ± 0.12-fold #p< 0.01) This increase in 
apoptotic cells was not altered by the presence of HG (Figs. 3.15 & 3.16).
Regulation of caspase-3 activity (methods 2.4.7) was used to confirm the 
effects of serum starvation and HG on BAEC and BASMC apoptosis. BAEC and 
BASMC cultured in 10% FBS media containing normal glucose (5.5 mmol/L) or 
high glucose (25 mmol/L) for 24, 48 or 72 hours showed no significant change in 
caspase-3 activity compared to t=0 control. However, a significant increase in 
caspase-3 activity was observed in BAEC and BASMC cultured in 0.5% FBS when 
compared 10%FBS treated control cells. The addition of high glucose to cells 
cultured in 0.5% FBS showed no effect on the activity of caspase-3 when compared 
to cells cultured in alone 0.5% FBS (Figs. 3.17 & 3.18).
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Fig. 3.1 Effect of high glucose on macrovascular cell proliferation
Bovine aortic endothelial cells (A) and smooth muscle cells (B) cultured in 10% FBS 
were plated in 6-well-plates (5x103 cells/well) and exposed to high glucose 
concentrations (G: 25mM) for up to 7 days. Cells were counted at the indicated 
times and the cumulative data plotted. Cells cultured in  normal glucose (5mM: C) 
and those treated w ith 25mM mannitol (M) were used as controls. Data represents 
mean values from three independent experiments performed in triplicate.
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Fig 3.2 CFDA SE staining of BAEC and BASMCs
Cells were labelled w ith the fluorescent marker CFDA SE as described in the 
M ethods section 2.4.8. The nuclear localisation o f  the m arker (arrows) was captured 
by fluorescence microscopy (20x). (A) BAEC (B) BASMC.
69
Fig 3.3 Tracking of cell proliferation using CFDA SE labelling and flow
cytometry
Representative example o f control and CFDA SE stained macrovascular cells 
obtained by flow  cytometry. Cell division results in sequential halving o f CFDA 
SE fluorescence, resulting in a cellular fluorescence histogram in which the peaks 
represent successive generations. Unstained control represents unlabelled cells.
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Fig. 3.4 Time course of BAEC Proliferation by FACS Analysis
BAECs were cultured in 10% FBS for 24hr, 48hr and 72hrs in the absence or 
presence of high glucose (25mM). After these time points, cells were collected and 
analysed by FACS as described in the Methods section 2.4.8. (A) Comparison of
cell proliferation over the 72hr period (B) comparison of proliferation of normal 
glucose (5.5mM:C), high glucose (25mM:G) and mannitol (25mM:M) treated cells 
at 72hrs. Data are representative of at least 3 independent experiments.
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Fig. 3.5 Time course of BASMC Proliferation by FACS Analysis
BASMCs were cultured in 10% FBS for 24hr, 48hr and 72hrs in the absence or 
presence of high glucose (25mM). After these time points, cells were collected and 
analysed by FACS as described in the Methods section 2.4.8. (A) Comparison of
cell proliferation over the 72hr period (B) comparison of proliferation of normal 
glucose (5.5mM:C), high glucose (25mM:G) and mannitol (25mM:M) treated cells 
at 72hrs. Data are representative of at least 3 independent experiments.
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Effects of high glucose concentrations on pCNA expression in BAECs
BAECs cultured in 10% FBS were exposed to high glucose concentrations over a period of 72hrs. Cells were harvested and cell lysates 
resolved by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised by incubation with an anti-pCNA-specific antibody 
followed by HRP-conjugated anti-mouse secondary antibody. Blots were quantified by densitometric scanning and values represent 
mean ± SEM for three experiments. *p<0.05 vs t=0 control.
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Fig. 3.7 Effects of high glucose concentrations on pCNA expression in BASMCs
BASMCs cultured in 10% FBS were exposed to high glucose concentrations over a period of 72hrs. Cells were harvested and cell lysates 
resolved by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised by incubation with an anti-pCNA-specific antibody 
followed by HRP-conjugated anti-mouse secondary antibody. Blots were quantified by densitometric scanning and values represent 
mean ± SEM for three experiments. *p<0.01 vs t=0 control.
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Fig. 3.8 Extended time course of BAEC Proliferation by FACS Analysis
BAECs were cultured in 10% FBS for 3, 5 and 7 days in the absence or presence of 
high glucose (25mM). After these time points, cells were collected and analysed by 
FACS as described in the Methods section 2.4.8. (A) Comparison of cell
proliferation over the 7 day period (B) comparison of proliferation of normal glucose 
(5.5mM: C), high glucose (25mM: G) and mannitol (25mM: M) treated cells at 5 
days. Data are representative of at least 3 independent experiments
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Fig. 3.9 Extended time course of BASMC Proliferation by FACS Analysis
BASMCs were cultured in 10% FBS for 3, 5 and 7 days in the absence or presence 
of high glucose (25mM). After these time points, cells were collected and analysed 
by FACS as described in the Methods section 2.4.8. (A) Comparison of cell
proliferation over the 7 day period (B) comparison of proliferation of normal glucose 
(5.5mM: C), high glucose (25mM: G) and mannitol (25mM: M) treated cells at 5 
days. Data are representative of at least 3 independent experiments.
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Fig. 3.10 Effects of high glucose concentrations on pCNA expression after 
5 days treatment
(A) BA EC s and (B) B A SM C s cultured in 10% FBS were exposed to high glucose 
concentrations over a period o f  5 days. Cells were harvested and cell lysates 
resolved by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised  
by incubation with an anti-pCNA-specific antibody follow ed by HRP-conjugated 
anti-mouse secondary antibody. Blots were quantified by densitometric scanning 
and values represent m ean ±  SEM  for three experiments.
(A)
BAEC ------- 10%FBS
------- 0.5%FBS
t = 24 hrs
(B)
Fig. 3.11 Effccts of serum starvation on BAEC proliferation
BAECs were cultured in 10% or 0.5% FBS for 24hrs in the absence or presence of 
high glucose (25mM). After these time points, cells were collected and analysed by 
FACS as described in the Methods section 2.4.8. (A) Comparison of cell
proliferation over the 24hr period in 10%» or 0.5% FBS (B) comparison of 
proliferation of normal glucose (5.5mM: C), high glucose (25mM: G) and mannitol 
(25mM: M) treated cells at 24hrs in the presence of 0.5%» FBS. Data are 
representative of at least 3 independent experiments.
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Fig. 3.12 Effects of serum starvation on BASMC proliferation
BASMCs were cultured in 10% or 0.5% FBS for 24hrs in the absence or presence of 
high glucose (25mM). After these time points, cells were collected and analysed by 
FACS as described in the Methods section 2.4.8. (A) Comparison of cell
proliferation over the 24hr period in 10% or 0.5% FBS (B) comparison of 
proliferation of normal glucose (5.5mM: C), high glucose (25mM: G) and mannitol 
(25mM: M) treated cells at 24hrs in the presence of 0.5%» FBS. Data are 
representative of at least 3 independent experiments.
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Fig. 3.13 Effects of serum starvation and high glucose concentrations on 
pCNA expression
(A) BAECs and (B) BASMCs cultured in 0.5% FBS were exposed to high glucose 
concentrations over a period of 5 days. Cells were harvested and cell lysates 
resolved by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised 
by incubation with an anti-pCNA-specific antibody followed by HRP-conjugated 
anti-mouse secondary antibody. Blots were quantified by densitometric scanning 
and values represent mean ± SEM for three experiments.
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Fig. 3.14 Representative data obtained from FACS analysis for apoptosis
Cells were cultured in serum containing 10% or 0.5% FBS and subjected to FACS 
analysis and stained for apoptosis using the Vybrant® Apoptosis Assay Kit as 
described in the Methods section 2.4.7. Annexin V binds to phosphatidylserine 
located on the extracellular surface of apoptotic cells while PI is impermeable to live 
cells and apoptotic cells but stains necrotic cells with red fluorescence. 
Populations of cells are distinguished using flow cytometry and designated as viable 
(V), early apoptotic (EA), late apoptotic (LA) or necrotic (N) depending on the ratio 
of Annexin V :PI staining.
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Fig. 3.15 Effects of serum starvation and high glucose concentrations on BAEC apoptosis as detected by FACS analysis
BEACs were cultured in media containing 10% or 0.5% FBS for 24hrs, 48hrs and 72hrs in the absence or presence of high glucose 
(25mM). After these time points, cells were collected and analysed for apoptosis by FACS as described in the Methods section 
2.4.7. The values obtained for EA and LA cells were combined and plotted as a bar chart (n=3 ±  SEM. *p<0.05 compared to t=0 
control, #p<0.05 compared to 10% FBS control; normal glucose [5.5mM: C], high glucose [25mM: G] and mannitol [25mM:M]).
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Fig. 3.16 Effects of serum starvation and high glucose concentrations on BASMC apoptosis as detected by FACS analysis
BESMCs were cultured in media containing 10% or 0.5% FBS for 24hrs, 48hrs and 72hrs in the absence or presence of high glucose 
(25mM). After these time points, cells were collected and analysed for apoptosis by FACS as described in the Methods section 2.4.7. 
The values obtained for EA and LA cells were combined and plotted as a bar chart (n=3 ±  SEM, *p<0.05 compared to t=0 control, 
#p<0.05 compared to 10% FBS control; normal glucose [5.5mM: C], high glucose [25mM: G] and mannitol [25mM:M]).
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Fig. 3.17 Effects of serum starvation and high glucose concentrations on BAEC apoptosis as detected by Caspase-3 activity
BEACs were cultured in media containing 10% or 0.5% FBS for 24hrs, 48hrs and 72hrs in the absence or presence of high glucose 
(25mM). After these time points, cells were harvested and a colourimetric caspase 3 assay carried out on cell lysates as described in 
the Methods section 2.4.7. A pNitroanilide (pNA) standard curve (0-200[¿g/fil) allowed for the specific activity of caspase 3 to be 
calculated for each sample and expressed as pmol pNA released/min/mg. Data are representative of at least 3 independent experiments ± 
SEM *p<0.05 compared to 10% FBS control; normal glucose [5.5mM: C], high glucose [25mM: G] and mannitol [25mM:M]).
ooLfi
A
£  t3
< i  fO JJ i  tt03 M
D.^
8R  CL
u  -oaa.
W5
5 -
4 -
3 -
2 -
7 1
6 -
:imw
c
v_
M
10% FBS
C
<w.
I
M
nnn I I aan
0.5% FBS 
________ '
10% FBS 
v.________
M
- j
C G M C
«■ -» v_
0.5% FBS 
_________ *
10% FBS
T l T
0.5% FBS
T=24 T=48 T=72
Fig. 3.18 Effects of serum starvation and high glucose concentrations on BASMC apoptosis as detected by Caspase-3 activity
BESMCs were cultured in media containing 10% or 0.5% FBS for 24hrs, 48hrs and 72hrs in the absence or presence of high glucose 
(25mM). After these time points, cells were harvested and a colourimetric caspase 3 assay carried out on cell lysates as described in the 
Methods section 2.4.7. A pNitroanilide (pNA) standard curve (0-200(ig/|al) allowed for the specific activity of caspase 3 to be calculated 
for each sample and expressed as pmol pNA released/min/mg. Data are representative of at least 3 independent experiments ± SEM 
*p<0.05 compared to 10% FBS control; normal glucose [5.5mM: C], high glucose [25mM: G] and mannitol [25mM:M]).
3.3 Discussion
It is well established that prolonged hyperglycaemia may be a key contributor 
in the development o f vascular complications in diabetes leading to vascular disease. 
An important feature o f vascular disease is abnormal growth, proliferation, migration 
and hypertrophy o f macrovascular and microvascular cells, however, the precise 
molecular events linking hyperglycaemia with the abnormal macro- and 
microvascular cell functions remain poorly characterized.
Many studies have shown that hyperglycaemia can accelerate vascular 
endothelial and smooth muscle cell proliferation by activation o f various pathways, 
such as reactive oxygen species (ROS) (Srivastava 2002), protein kinase C (PKC) 
(Patel et al. 1999), mitogen-activated protein kinases (MAPKs) (Amiri et al. 1999) 
and N F-kB activation (Fujita et al. 2002). The majority o f studies focusing on the 
pathogenic mechanism o f glucose in promoting vascular lesion formation have 
highlighted the proliferative effects o f glucose on VSMC growth (Newby and 
Zaltsman 2000).
In this study, we focused on the effects o f using pathophysiological levels of 
glucose (25mM) as detected in diabetic patients (Cai et al. 2002). We found that 
there was no notable change in BAEC and BASMC proliferation when compared to 
high glucose treated 10%FBS media in 24hrs or up to 7 days which is not consistent 
with previous studies. Various concentrations o f glucose ranging from 22-60mmol/L 
has been using to stimulate proliferation in different cell types which causes either an 
increase or decrease in the proliferative effect during short-term (Sheu et al. 2005) or 
long-term (Esposito et al. 2001) exposure.
Short-term hyperglycaem ia (45mmol/L glucose) produces oxidative damage 
and apoptosis which has been shown up to 6 hours in dorsal root ganglia neurons 
(Vincent et al. 2005). Studies on Bovine aortic and human microvascular 
endothelial cells also demonstrated a significant increase in cell number when 
exposed to high glucose (30mmol/L glucose) containing media compared with 
normal growth media (5.5mmol/L glucose) after 24 hours. However, this effect 
was not detectable at 48 hours. Long-term (8 weeks) exposure to high glucose did 
not modify the growth curve that was comparable to that o f cells grown in low 
glucose containing media. High glucose induced a change in cell morphology after 
long-term compared w ith low glucose treated cells (Esposito et al. 2001).
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As we described previously, FBS contains hormone and growth factors which 
can regulate cell growth. Since low serum conditions are used to quiesce the cells 
and deprive them of essential growth factors, one could expect that the addition of an 
energy substrate such as glucose could lead to an increase in proliferation of these 
cells. We have examined the effects of high glucose under low serum conditions 
(0.5% FBS) and shown no additive effect of HG treatment to BAEC and BASMC 
proliferation.
The reported effects of hyperglycaemia on endothelial and smooth muscle 
cells which are mixed and very dependent upon experimental conditions have been 
shown in several studies (Weimann et al. 1984; Umeda et al. 1991; Santilli et al. 
1992; Kusuhara et al. 1997; Morishita et al. 1997). It has been shown that 
hyperglycaemia enhances proliferation of bovine carotid artery endothelial cells 
under low serum (0.5%FBS) stimulation but inhibited in the presence of 10% serum 
(Hayashi et al. 1991). In contrast, hyperglycaemia also inhibits the rate of 
proliferation in macrovascular endothelial cells under serum free media (0% FBS) 
and low serum media (2% FBS) over 2 days exposure (Santilli et al. 1992; Morishita 
et al. 1997)
Apoptosis is a finely regulated process that plays an important role in 
regulating cell number (Thompson 1995). More recently, apoptosis has been 
implicated in the development of arteries. Several studies have focused on apoptosis 
during limb vessel development (Cho et al. 1995) and apoptosis during the 
remodelling of human ductus arteriosis (Slomp et al. 1997). However, apoptosis is 
not limited to cell elimination during embryonic development. In recent years, 
apoptosis has been implicated in cardiovascular disease.
Recent studies have suggested that vascular remodelling and lesion formation 
are determined in part by the balance between cell proliferation and apoptotic cell 
death (Gibbons and Dzau 1994; Isner et al. 1995). It has been reported that reduction 
in blood flow in animal models resulted in reduction in VSMC number by apoptosis 
(Cho et al. 1997; Kumar and Lindner 1997). Acute arterial injury is followed by 
rapid induction of medial cell apoptosis from 30 minutes to 4 hours (Perlman et al. 
1997; Pollman et al. 1999). In humans, restenosis after angioplasty has been reported 
to be associated with a decrease in VSMC apoptosis (Isner et al. 1995). A further 
example of apoptosis comes from aneurysm formation with advanced atherosclerosis 
(Henderson et al. 1999). Apoptosis of VSMC is increased in aortic aneurysms and is
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associated with an increase in expression of a number of pro-apoptotic molecules. 
These studies support the concept that apoptosis is a pivotal regulator of cell number 
in the vessel wall.
The main intracellular effectors of apoptosis are a family of cysteine 
proteases known as caspases. Caspases are activated by cleavage of pro-caspases in a 
sequential manner during apoptosis. Caspase-3 is an effector caspase that plays a role 
in cell death induced by a variety of stimuli (Thornberry and Lazebnilc 1998).
Rupture of atherosclerotic plaques is associated with a thinning of the 
VSMC-rich fibrous cap overlying the core. Rupture occurs particularly at the plaque 
shoulders, which exhibit lack of VSMCs and the presence of inflammatory cells. 
Apoptotic VSMCs are evident in advanced human plaques including the shoulder 
regions, prompting the suggestion that VSMC apoptosis may hasten plaque rupture. 
Indeed, increased VSMC apoptosis occurs in unstable versus stable angina lesions 
(Bennett 2002).
The disappearance of macrophages by apoptosis could have a positive effect 
on plaque stabilization. The death of macrophages would lead to decreased 
breakdown of collagen fibers. On the contrary, the disappearance of SMC from the 
fibrous cap or other vulnerable regions of the plaque could lead to destabilization of 
the plaque (Davies 1996; Libby et al. 1996).
A previous study showed that hyperglycaemia attenuated the rate of serum 
withdrawal-induced apoptosis on rat aortic A7r5 cells and attenuated capsase-3 
activity, and also increased the abundance of transcript and protein levels of Bcl-2 
and Bcl-xi (Li et al. 2005).
We investigated the apoptotic level of BAEC and BASMC in normal growth 
media (10%FBS) and low serum media (0.5%FBS) by FACS analysis. It is not 
surprising that low serum media induced apoptosis on both cell types. However there 
was no significant alteration observed when adding in high glucose. The percentage 
of apoptotic cells is varied in different cell types (0.2-10%) and is dependant on the 
environment. In our studies in BAEC and BASMC, the basal percentage of apoptotic 
cells is approximately 0.2-2%.
The significance of apoptosis in atherosclerosis appears to depend on the 
stage of the plaque , localization, and cell types involved (Kockx and Knaapen 2000). 
Glucose-induced suppression of apoptosis appears to be of particular importance in 
the initial events of vascular injury and thickening of the media of the vessels. It is
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well documented that high glucose and advanced glycation end products increase 
NF-kB activity in rat VSMC (Lander et al. 1997; Yemeni et al. 1999) and Bcl-X]has 
been identified as an N F-kB -dependent transcriptional target (Barkett and Gilmore
1999). Therefore, high glucose concentrations are likely to have an effect on the 
activity of NF-kB activation and Bcl-Xi expression, leading to apoptotic suppression 
in VSMC.
It is well established that the rate of apoptosis not only depends on the 
relative balance between pro- and anti-apoptotic signals but also on the target cells. 
Initial reports have shown that prolonged treatment of human umbilical vein 
endothelial cells with high glucose lead to increase DNA fragmentation and higher 
prevalence of apoptosis, while fibroblast were unaffected by sexposure to high 
glucose and no increase in apoptosis was observed (Baumgartner-Parzer et al. 1995). 
Moreover, the cellular mechanism by which the effect of high glucose modulates 
apoptotic events in the retina clearly appeared to be tissue-specific and cell-specific 
within tissues (Podesta et al. 2000).
Cellular responses to high glucose are numerous and varied ultimately 
resulting in functional changes and cell death. High glucose causes mitochondrial 
membrane depolarization and loss of uncoupling protein, resulting in increased 
oxidative stress as well as release of cytochrome c and activation of caspases 
(Leinninger et al. 2004; Vincent et al. 2004). Caspase-3 activity was also examined 
in this study and a similar effect was found when compared to FACS analysis. 
According to the studies by Leninger and Vincent which indicate caspase-3 
activation pathway is causally involved in hyperglycaemia-induced myocardial 
apoptosis when exposed to 60 mmol/L glucose, whereas there was no significant 
alteration when treated with 33mmol/L glucose (Cai et al. 2002); we hypothesise that 
physiological high glucose concentrations (25mM) may not be sufficient to induce 
cell apoptosis.
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4.1 Introduction
Arterial wall hypoxia and associated vascular cell proliferation have been 
implicated in the development of atherosclerosis (Bjornheden et al. 1999; Lee et al.
2000) and has also been shown to be mitogenic to cultured pulmonary artery smooth 
muscle and endothelial cells (Dempsey et al. 1997; Lou et al. 1997; Cooper and 
Beasley 1999). Prevalence of tissues hypoxia and increased VSM cell proliferation is 
reported in experimental models of diabetes and hypertension (Miller and Wilson 
1984; Bunkenburg et al. 1992; Alipui et al. 1993; Santilli et al. 1993; Sowers and 
Epstein 1995; Oikawa et al. 1996). Elevated glucose concentrations in media have 
been shown to produce both hypertrophic and hyperplastic effects in cultured porcine 
aortic smooth muscle cells (Natarajan et al. 1992) which hypoxia potentiates the 
effect of high glucose on the proliferation of VSM and mesangial cells (Sodhi et al. 
2001; Sodhi et al. 2001). Therefore, these results strongly suggest an important role 
for hypoxia in accelerated cell proliferation in diabetes; however the mechanisms 
responsible for the accelerated cell growth and progression into cardiovascular 
disease in diabetes remain to be clearly defined.
Apoptosis is the dominant mechanism of cell death in rats undergoing 
coronary artery occlusion (Kajstura et al. 1996). Apoptosis may also make a major 
contribution to overall cell death in the infarcted human heart (Morrell et al. 1997) 
and is an important pathological feature of the hypoxic myocyte (Wardell 1977) and 
the reperfused myocardium (Brown and Sernia 1994; Cooper and Beasley 1999).
Apoptosis can be induced in response to hypoxia (Tanaka et al. 1994). The 
severity of hypoxia determines whether cells become apoptotic or adapt to hypoxia 
and survive. A hypoxic environment devoid of nutrients prevents the cell undergoing 
energy dependent apoptosis and cells become necrotic. Apoptosis regulatory proteins 
are delicately balanced (Yamamoto et al. 2001; Mayorga et al. 2004). Hypoxia is a 
common phenomenon and cells can adapt to this environmental stress so; that after 
repeated periods of hypoxia, selection for resistance to hypoxia induced apoptosis 
occurs.
Aim 2: To Investigate the Effects of Hypoxia (2% O2) on BAEC and BASMC 
growth (proliferation vs apoptosis) in the absence or presence of HG (25mM).
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4.2 Results
We have established that the addition of high glucose concentrations (25mM) 
to BAEC and BASMC cultured in either 10% or 0.5% FBS has neither positive or 
negative effect on the balance between cell proliferation and apoptosis. Consequently, 
we introduced a known stimulus of cell apoptosis, hypoxia, to determine the effect 
on BAEC and BASMC growth (apoptosis vs proliferation).
A Ruskinn Invivo2 400 Hypoxia Workstation was used to study the effects of 
lowering oxygen tensions in vitro. Using this apparatus, we exposed BAEC and 
BASMC to hypoxia at the level of 2% O2 (Fig. 4.1).
BAEC and BASMC were cultured in 10% FBS for 5 days in either normoxic 
(5% CO2 , 95% air) or hypoxic (2% O2 , 5% CO2 , 93% N2) conditions and the effects 
on proliferation and apoptosis were measured as described previously. FACS analysis 
for proliferation showed that BAEC and BASMC proliferation was significantly 
decreased in cells exposed to hypoxic conditions when compared to normoxic 
control (Fig. 4.2). Concurrent western blot analysis for pCNA expression confirmed 
the hypoxia-induced decrease in BAEC (4.63 ± 0.50-fold n=3 vs 8.97-fold ± 
0.24-fold n=3; *p<0.01) and BASMC (2.49-fold ± 0.12-fold n=3 vs 7.92-fold ± 
0.61-fold n=3; *p<0.01) proliferation when compared to normoxic control (Fig. 4.3).
We detected hypoxia induced apoptosis by using FACS analysis, 
representative data has been shown (Fig. 4.4(A)). When we compared hypoxia 
induced apoptosis to serum deprivation induced apoptosis (Fig. 3.14), significantly 
more early apoptotic and late apoptotic cells were detected suggesting that hypoxia is 
a greater stimulator of cellular apoptosis compared to serum deprivation.
Exposure of cells to hypoxic conditions increased the percentage of apoptotic 
cells in both BAEC and BASMC when compared to normoxic control (BAEC 
(21.83% ± 2.46% n=3 vs 2.71% ± 0.43% n=3 *p<0.01; and BASMC 26.79% ± 
1.14% n=3 vs 5.41% ± 1.12% n=3; *p<0.01) (Fig. 4.4(B)).
Concurrent caspase-3 activity also showed the hypoxia induced apoptosis in 
BAEC (2.96-fold ± 0.20-fold n=4 vs 1.21-fold ± 0.08-fold n=4; *p<0.01) and 
BASMC (4.12-fold ± 0.37-fold n=4 vs 1.21-fold ± 0.06-fold n=4; *p<0.01). This 
result was also confirmed in caspase-3 protein expression by western blot in which 
hypoxia was seen to significantly enhance caspase-3 expression in BAEC (1.73-fold 
± 0.11-fold n=3 vs 0.48-fold ± 0.07-fold n=3; *p<0.01) and BASMC (2.79-fold ± 
0.30-fold n=3 vs 0.87-fold ± 0.05-fold n=3; *p<0.01) (Fig. 4.5).
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Having established the effects of hypoxia on BAEC and BASMC 
proliferation and apoptosis, we then investigated the effects of hyperglycaemia under 
these same conditions.
BAEC and BASMC were exposed to normoxic or hypoxic conditions with 
high glucose (25mM) or mannitol (19.5mM) for 5 days prior to analysis of 
proliferation and apoptosis as previously described using FACS analysis, we 
determined that under normoxic conditions, high glucose did not alter proliferation 
of BAEC or BASMC as detailed in our earlier studies (Chapter 3). However, under 
hypoxic conditions, high glucose induced a marked increase in proliferation of 
BAEC and BASMC when compared to normal glucose and mannitol treated control 
cells (Figs. 4.6 & 4.7).
This increase in proliferation was confirmed by western blot for pCNA. 
BAEC and BASMC were harvested after 5 days treatment and cell lysates resolved 
by SDS-PAGE. Similar to FACS analysis, there was no change of pCNA expression 
on BAEC and BASMC under normoxic conditions with either normal glucose or 
high glucose. In contrast, pCNA expression of BAEC and BASMC were 
significantly increased in the presence of high glucose under hypoxic conditions 
when compared to hypoxic control (BAEC 7.33-fold ± 0.49-fold n=3 vs 4.63 ± 0.50 
n=3 *p<0.01; BASMC 5.07-fold ± 0.50-fold n=3 vs 2.49-fold ± 0.12-fold n=3; 
*p<0.01) (Fig. 4.8).
Although high glucose increases BAEC and BASMC proliferation under 
hypoxic conditions, this increase did not return proliferation to the level of normoxic 
day 5 control (BAEC 7.33-fold ± 0.49-fold n=3 vs 8.97-fold ± 0.24-fold n=3 #p<0.05; 
BASMC 5.07-fold ± 0.50-fold n=3 vs 7.92-fold ± 0.61-fold n=3; #p<0.05) (Fig. 4.9).
This increase in the presence of high glucose on BAEC and BASMC 
proliferation under hypoxic condition was confirmed by FACS analysis. When 
compared to hypoxic control, BAEC and BASMC proliferation in the presence of 
high glucose significantly increased under hypoxic conditions, however, when 
compared to normoxic control, high glucose treated BAEC and BASMC (green line) 
under hypoxic condition did not reach the same level of normoxic control (Figure 
4.9).
FACS analysis for BAEC and BASMC apoptosis showed that high glucose 
did not alter cellular apoptosis under normoxic conditions as previously described. 
When cells were exposed to hypoxic conditions, the percentage of apoptotic cells
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was significantly increased on BAEC and BASMC compared to normoxic control 
(BAEC 21.83% ± 2.46% n=3 vs 2.71% ± 0.43% n=3 #p<0.01; BASMC 26.79% ± 
1.14% n=3 vs 5.41% ± 1.12% n=3; #p<0.01). However, hypoxia induced apoptosis 
was inhibited on BAEC (10.06% ± 2.35% n=3 vs 21.83% ± 2.46% n=3; *p<0.05) 
and BASMC (12.32% ± 1.38% n=3 vs 26.79% ± 1.14% n=3; *p<0.01) in the 
presence of high glucose when compared to hypoxic control (Fig. 4.10).
Increased caspase-3 activity based on pmol pNA released/min/mg protein was 
detected in BAEC and BASMC exposed to hypoxic conditions compared to 
normoxic control (BAEC 2.96-fold ± 0.20-fold n=4 vs 1.21-fold ± 0.08-fold n=4 
*p<0.01; BASMC 4.12-fold ± 0.37-fold n=4 vs 1.21-fold ± 0.06-fold n=4; *p<0.01). 
However, the presence of high glucose in hypoxia treated cells resulted in a 
significant decrease in caspase-3 activity when compared to hypoxic controls (BAEC 
1.83-fold ± 0.19-fold n=4 vs 2.961 ± 0.1952 n=4 *p<0.01; BASMC 2.72-fold ± 
0.22-fold n=4 vs 4.12-fold ± 0.37-fold n=4;*p<0.05) when compared to hypoxic 
control (Figure 4.11).
Expression of caspase-3 protein levels by western blot showed no change in 
caspase-3 protein expression under normoxic conditions in either BAEC or BASMC. 
High glucose did not alter caspase-3 protein expression under normoxic conditions. 
Similar to caspase-3 activity, protein levels were increased under hypoxic conditions 
when compared to normoxic control (BAEC 1.73-fold ± 0.11-fold n=3 vs 0.48-fold ± 
0.07-fold n=3 #p<0.01; BASMC 2.79-fold ± 0.30-fold n=3 vs 0.87-fold ± 0.05-fold 
n=3; #p<0.01). The presence of high glucose under hypoxic conditions significantly 
decreased caspase-3 expression levels compared to hypoxic control (BAEC 1.09-fold 
± 0.11-fold n=3 vs 1.73-fold ± 0.11-fold n=3 *p<0.05; BASMC 1.35-fold ± 0.09-fold 
n=3 vs 2.79-fold ± 0.30-fold n=3; *p<0.01) (Fig. 4.12).
Further analysis for apoptosis examined the regulation of pro- and 
anti-apoptotic proteins. Bcl-X| which belongs to the Bcl-2 family is an anti-apoptotic 
protein involved in regulating cell apoptosis. Bcl-X| protein expression was detected 
by western blot in BAEC and BASMC. Under normoxic conditions, high glucose 
showed no effect on Bcl-Xi expression in either BAEC or BASMC after 5 days 
treatment. Bcl-Xi expression was significantly decreased under hypoxic conditions 
when compared to normoxic control (BAEC 5.85-fold ± 0.87-fold n=4 vs 11.78-fold 
± 0.50-fold n=4 #p<0.01; BASMC 2.61-fold ± 0.36-fold n=3 vs 4.99-fold ± 0.27-fold 
n=3; #p<0.01). However this effect was reversed in the presence of high glucose
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when compared to hypoxic control (BAEC 9.55-fold ± 0.71-fold n=4 vs 5.85-fold ± 
0.87-fold n=4 *p<0.05; BASMC 5.64-fold ± 0.17-fold n=3 vs 2.61-fold ± 0.36-fold 
n=3; *p<0.01) (Fig. 4.13).
In parallel, we examined the expression of the pro-apoptotic protein Bax; 
another member of the Bcl-2 family. Bax protein expression was measured by 
western blot as previously described. No change in Bax protein expression was found 
under normoxic conditions in either BAEC or BASMC when cells treated in high 
glucose media; under hypoxic condition, Bax expression was inhibited when 
compared to normoxic control (BAEC 1.12-fold ± 0.09-fold n=3 vs 1.58-fold ± 
0.11-fold n=3 #p<0.05; BASMC 1.11-fold ± 0.07-fold n=3 vs 1.52-fold ± 0.13-fold 
n=3; #p<0.05). However, high glucose enhanced the expression of Bax under 
hypoxic condition on BAEC (1.48-fold ± 0.08-fold n=3 vs 1.12-fold ± 0.09-fold n=3; 
*p<0.05) and BASMC (1.63-fold ± 0.07-fold n=3 vs 1.11-fold ± 0.07-fold n=3; 
*p<0.01) when compared to hypoxic control (Fig. 4.14).
bcl-xl and bax gene expression in BAEC and BASMC was determined using 
quantitative RealTime RT-PCR (QRTPCR) following treatment. PCR product was 
resolved by 2% agarose gel. We found that mRNA levels of bcl-xl and bax did not 
change at 24 hours or after the 5 days treatment period (Figs. 4.15 & 4.16).
As both the pro- and anti-apoptotic proteins were seen to increase in the 
absence or presence of high glucose under normoxic conditions, we compared the 
increased ratio of Bcl-Xi/Bax expression. We found that Bcl-Xi expression has a 
(11.78-fold ± 0.50-fold n=4,p<0.01) increase over t=0 control when compared to a 
(1.58-fold ± 0.11-fold n=3,p<0.01) increase of Bax expression over t=0 control on 
BAEC and has a (4.99-fold ± 0.27-fold n=3,p<0.01) increase over t=0 control when 
compared to a (1.52-fold ± 0.13-fold n=3,p<0.01) increase of Bax expression over 
t=0 control on BASMC.
Although high glucose increased both Bax and Bcl-Xi expression under 
hypoxic conditions, we found that Bcl-X| expression has a 1.63-fold ± 0.13-fold 
increase over hypoxic control when compared to a 1.32-fold ± 0.08-fold increase of 
Bax expression over hypoxic control on BAEC and has a 2.16-fold ± 0.06-fold 
increase over hypoxic control when compared to a 1.61-fold ± 0.06-fold increase of 
Bax expression on BASMC.
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Figure 4.1 Ruskinn Invivo2 400 Hypoxia Workstation
This workstation has two semidetached chambers, one of which enables the 
investigator to carry out cell culture under direct vision, and the other in a same 
controlled oxygen environment in which samples are allow to be removed without 
disturbing the oxygen level of the main chamber. The unit has built-in sensor for 
oxygen which is supplied with separate feeds of compressed air, nitrogen and carbon 
dioxide. Temperature is controlled by thermostatic monitoring and maximum 
humidity is limited by controlled condensation.
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Figure 4.2 Hypoxia decreases BAEC and BASMC proliferation by FACS 
analysis
BAECs (A) and BASMCs (B) were cultured in 10% FBS for 5 days in either 
normoxic (5% C 02, 95% air) or hypoxic (2% 0 2, 5% C 02, 93% N2) conditions. 
After these time points, cells were collected and analysed by FACS as described in 
the Methods section 2.4.8. Data are representative of at least 3 independent 
experiments.
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Figure 4.3 Hypoxia inhibits macrovascular pCNA expression
BAECs (top) and BASMCs (bottom) were exposed to normoxic (5% 0 2, 95% air) or 
hypoxic (2% 0 2, 5% C 02, 93% N2) conditions over a period of 5 days. Cells were 
harvested and cell lysates resolved by SDS-PAGE. Proteins were transferred to 
nitrocellulose and visualised by incubation with an anti-pCNA-specific antibody 
followed by HRP-conjugated anti-mouse secondary antibody. Blots were quantified 
by densitometric scanning and values represent mean ± SEM for three experiments; 
*p<0.01 compared to normoxic controls.
98
(A) (B)
vovo
H
I f
Fropidium Iodide 
Fluorescence
\ N LA
A
V EA
Normoxia Annexin V 
Fluorescence
■s s- 
■3 S
u -su 9
1 “O %-
a  ^
£ e
¡■I
30 -1
20
10 -
C(t=0)
0
*~r
N H
j
N
V_
H
BAEC BASMC
Treatment
Figure 4.4 Hypoxia induces apoptosis in macrovascular cells
BAECs were cultured in media containing 10% FBS and exposed to either normoxic (5% C02, 95% air) or hypoxic (2% O2 , 5% CO2 , 
93% N2 ) conditions for 5 days. Cells were collected and analysed for apoptosis by FACS as described in the Methods. (A) representative 
example of FACS andalysis for hypoxia-induced apoptosis (B) The values obtained for EA and LA cells were combined and plotted as a 
bar chart (n=3, ±  SEM, *p^0.01 compared to normoxic controls).
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Figure 4.5 Hypoxia increases Caspase-3 activity and expression in 
macrovascular cells
BAECs and BASMCs were cultured in media containing 10% FBS for 5 days. Cells 
were then harvested for (A) Caspase-3 western blot (BAEC: top; BASMC: bottom) 
or (B) colourimetric caspase 3 assay as described in the Methods. Data are 
representative of at least 3 independent experiments ± SEM compared to normoxic 
controls; *p<0.01
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Figure 4.6 Effect of high glucose on hypoxia-induced proliferation in BAECs
BAECs were labelled with CFDA SE and cultured in 10% FBS for 5 days under (A) 
normoxic or (B) hypoxic conditions in the absence or presence of high glucose. Cells 
were then collected and analysed by FACS as described in the Methods. Panels show 
comparisons of cell proliferation over the 5 day period in 10% FBS with normal 
glucose (5.5mM: C), high glucose (25mM: G) and mannitol (25mM: M). Data are 
representative of at least 3 independent experiments.
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Figure 4.7 Effect of high glucose on hypoxia-induced proliferation in
BASMCs
BASMCs were labelled with CFDA SE and cultured in 10% FBS for 5 days under 
(A) normoxic or (B) hypoxic conditions. Cells were then collected and analysed by 
FACS as described in the Methods. Panels show comparisons of cell proliferation 
over the 5 day period in 10% FBS with normal glucose (5.5mM: C), high glucose 
(25mM: G) and mannitol (25mM: M). Data are representative of at least 3 
independent experiments.
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Effects of high glucose on hypoxia-induced decrease in pCNA 
expression
BAECs (A) and BA SM C s (B) were cultured in 10% FBS under norm oxic or hypoxic  
conditions for 5 days; in the absence or presence o f  high glucose (25mM ). Cells 
were harvested and cell lysates resolved by SDS-PAGE. Proteins were transferred to 
nitrocellulose and visualised by incubation with an anti-pCNA-specific antibody 
follow ed by HRP-conjugated anti-mouse secondary antibody. Blots were 
quantified by densitometric scanning and values represent mean ±  SEM for three 
experiments. #p<0.01 compared to t=0 control, *p<0.05 (BAEC), * p<0.01 (BASM C) 
compared to hypoxic control.
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Fig. 4.9 High Glucose in the Presence of Hypoxia Does Not Return Cell 
Proliferation to Normoxic Levels
BAECs (A) and BASMCs (B) were labelled with CFDA SE and cultured in 10% 
FBS for 5 days under normoxic or hypoxic conditions. Cells were then collected and 
analysed by FACS as described in the Methods. Panels show comparisons of cell 
proliferation over the 5 day period in 10% FBS with normal glucose (5.5mM; 
Normoxia and Hypoxia), or high glucose (25mM: Hypoxia + Glue). Data are 
representative of at least 3 independent experiments.
OinVi
£
3
<3o
BASMC Normoxia
t=5 days ----- Hypoxia
—  Hypoxia + Glue
FL1 -Height
104
(A)
30-1
a  *3 
U £  20
w s
« Ift II 
<3* « 10>
o-iJ= P -
C (t=0) c
v _
M
- J
#
X
™r
C
*
X
-r~
G
“T—
M
Normoxia Hypoxia
Treatment
(B)
30-1
« 2 
U % .a § 
© " -*■* o  
fr II o +■* Ph u 
<  g»
2 0 -
10-
in LQ
C (t=0) c G M
Normoxia
_ r _
C
-r~
G M
Hypoxia
Treatment
Figure 4.10 Effects of high glucose on hypoxia-induced increase in apoptosis
BAECs (A) and BASMCs (B) were cultured in media containing 10% FBS in the 
absence or presence of high glucose (25mM) and exposed to either normoxic (5% 
C 02, 95% air) or hypoxic (2% 0 2, 5% C 02, 93% N2) conditions for 5 days. Cells 
were collected and analysed for apoptosis by FACS as described in the Methods. The 
values obtained for EA and LA cells were combined and plotted as a bar chart (n=3, 
± SEM, #p<0.01 compared to normoxic control; *p<0.05 (BAEC), *p<0.01 
(BASMC) compared to hypoxic control).
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Figure 4.11 Effect of high glucose on hypoxia-induced Caspase-3 activity
(A) BAECs and (B) BASMCs were cultured in media containing 10% FBS for 5 
days, in the absence or presence of high glucose (25mM) under normoxic or hypoxic 
conditions. Cells were harvested and a colourimetric caspase 3 assay carried out on 
cell lysates as described in the Methods. A pNitroanilide (pNA) standard curve 
(0-200|j.g/(j.1) allowed for the specific activity of caspase 3 to be calculated for each 
sample and expressed as pmol pNA released/min/mg. Data are representative of at 
least 3 independent experiments ± SEM. #p<0.01 compared to normoxic control; 
*p<0.01 (BAEC), *p<0.05 (BASMC) compared to hypoxic control (normal glucose 
[5.5mM: C], high glucose [25mM: G] andmannitol [25mM:M]).
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Figure 4.12 Effect of high glucose on hypoxia-induced Caspase-3 expression
(A) BAECs and (B) BASMCs were cultured in 10% FBS in the absence or presence 
of high glucose and exposed to normoxic or hypoxic conditions for 5 days. Cells 
were harvested and cell lysates resolved by SDS-PAGE. Proteins were transferred 
to nitrocellulose and visualised by incubation with an anti-Caspase-3-specific 
antibody followed by HRP-conjugated anti-rabbit secondary antibody. Blots were 
quantified by densitometric scanning and values represent mean ± SEM for three 
experiments, #p<0.01 compared to normoxic control, * p<0.05 (BAEC, * p<0.01 
(BASMC) compared to hypoxic control.
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Figure 4.13 Effect of hypoxia and high glucose on expression of the 
anti-apoptotic protein Bcl-xL
BAECs (A) and BASMCs (B) cultured in 10% FBS were exposed to high glucose 
concentrations over a period of 5 days under either normoxic or hypoxic conditions. 
Cells were harvested and cell lysates resolved by SDS-PAGE. Proteins were 
transferred to nitrocellulose and visualised by incubation with an anti-Bcl-xL-specific 
antibody followed by HRP-conjugated anti-mouse secondary antibody. Blots were 
quantified by densitometric scanning and values represent mean ± SEM for three 
independent experiments, § p<0.01 vs t=0 control; # p<0.01 vs normoxic control; * 
p<0.05 (BAEC), p<0.01 (BASMC) vs hypoxic control.
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Figure 4.14 Effect of hypoxia and high glucose on expression of the 
pro-apoptotic protein Bax
BAECs (A) and BASMCs (B) cultured in 10% FBS were exposed to high glucose 
concentrations over a period of 5 days under either normoxic or hypoxic conditions. 
Cells were harvested and cell lysates resolved by SDS-PAGE. Proteins were 
transferred to nitrocellulose and visualised by incubation with an anti-Bax-specific 
antibody followed by HRP-conjugated anti-rabbit secondary antibody. Blots were 
quantified by densitometric scanning and values represent mean ± SEM for three 
independent experiments, § p<0.01 vs t=0 control; # p<0.05 vs normoxic control; * 
p<0.05 (BAEC), p<0.01 (BASMC) vs hypoxic control.
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Figure 4.15 Effect of hypoxia and high glucose on Bcl-xL and Bax gene 
expression
BAECs cultured in 10% FBS were exposed to high glucose concentrations over a 
period of 5 days under either normoxic or hypoxic conditions. Cells were harvested, 
RNA extracted and QRTPCR carried out using specific primer sets for (A) Bcl-xL 
and (B) Bax as described in the methods. The resultant PCR products were resolved 
by agarose gel electrophoresis (2%). Data are representative of at least three 
independent experiments showing similar results.
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Figure 4.16 Effect of hypoxia and high glucose on Bcl-xL and Bax gene 
expression
BASMCs cultured in 10% FBS were exposed to high glucose concentrations over a 
period of 5 days under either normoxic or hypoxic conditions. Cells were harvested, 
RNA extracted and QRTPCR carried out using specific primer sets for (A) Bcl-xL 
and (B) Bax as described in the methods. The resultant PCR products were resolved 
by agarose gel electrophoresis (2%). Data are representative of at least three 
independent experiments.
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4.3 Discussion
The present study demonstrates that hypoxia inhibits BAEC and BASMC 
proliferation and induces apoptosis compared with normoxia. However, high glucose 
significantly reverses this effect by increasing cell proliferation and decreasing cell 
apoptosis under hypoxic conditions. These findings suggest an important interaction 
between hypoxia and hyperglycaemia in vascular cells.
In our present study, hypoxia inhibits the proliferation of BAEC and BASMC 
which is consistent with previous observations (Benitz et al. 1986; Bai et al. 1997; 
Zhen et al. 2003). In contrast, hypoxia was found to induce cell proliferation in 
tumour cells such as follicular B-lymphoma (Shimizu et al. 1995) and others cell 
types such as rat mesangial cells and osteopontin (Sahai et al. 1997; Sahai et al. 1997; 
Sodhi et al. 2001). Increasing or decreasing cell proliferation under hypoxic 
conditions also depends on the oxygen level. 1% O2 has been shown to inhibit 
proliferation and 3% O2 increase proliferation in rat airway smooth muscle cells with 
lower oxygen level such as 0.5%-1 % easily decreasing cell proliferation when 
compared with 2%-3% oxygen (Cogo et al. 2003).
Hypoxia inhibits cellular proliferation in a time-dependent manner (Galvin et 
al. 2004) which ranges from 5 mins (Liu et al. 2001) to 280 days (Stock and Vacanti
2001). Our initial hypoxic studies were carried out over a time period of 72 hours. 
However, we found no significant changes in cell proliferation until we extended the 
treatment period out to 5 days.
Hyperglycaemia and hypoxia are two major factors in diabetes. Some studies 
have shown an interaction between these two factors in which hyperglycaemia 
impairs hypoxia induced proliferation (Catrina et al. 2004; Nyengaard et al. 2004) or 
exaggerates cell growth (Sodhi et al. 2001).
In our present study, we found that high glucose increased cell proliferation in 
BAEC and BASMC under hypoxic conditions; however, this increase of 
proliferation did not reach the same levels as normoxic conditions; suggesting that 
although hyperglycaemia can upregulate cell growth under hypoxic conditions, this 
effect could not replace the normal cell growth in the vascular cells. This abnormal 
proliferation and response in the presence of high glucose to hypoxia may have a 
profound effect on the healing process in diabetes, particularly because 
hyperglycaemia is correlated to ischemia. Without an appropriate proliferative 
response, the subsequent phases of cell proliferation and matrix deposition are
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delayed because the neovasculature is required for the deposition of matrix in healing 
process (Nissen et al. 1998; Singer and Clark 1999). On the other hand, acute 
hypoxia can induce cell apoptosis in minutes (Yu et al. 2004) with cell loss occurring 
at an early stage, decreasing cell proliferation in part.
Apoptosis clearly occurs in the myocardium during and after ischemia (Fliss 
and Gattinger 1996; Bialik et al. 1997; Haunstetter and Izumo 1998), although the 
relative contribution of apoptotic and non-apoptotic cell death in hypoxic cardiac 
injury is still unclear (Anversa and Kajstura 1998; Haunstetter and Izumo 1998). 
Many recent studies have indicated that either ischemia or hypoxia alone (Itoh et al. 
1995; Saraste et al. 1997) or in combination with reoxygenation (Gottlieb et al. 1994; 
Fliss and Gattinger 1996; Aikawa et al. 1997) can trigger apoptosis. The mechanism 
by which hypoxia induces apoptosis remains unclear, although it is probably 
analogous to the pathways by which other cellular stresses initiate apoptosis. Cellular 
stresses, such as growth factor withdrawal, UV irradiation, or treatment with 
actinomycin D, glucocorticoids, or chemotherapeutic agents, cause apoptosis via a 
mitochondria-dependent release of cytochrome c and subsequent activation of the 
Apaf-l-caspase 9 complex or apoptosome (Green and Reed 1998).
Caspase 9 subsequently cleaves and activates downstream effector caspases 
such as caspase 3, which then mediate the biochemical features of apoptotic cell 
death (e.g. PARP and lamin cleavage). The triggers for cytochrome c release may 
include reactive oxidant species, increased cytoplasmic calcium concentration, 
decreased ATP levels, as well as activation or increased expression of the 
proapoptotic proteins p53 and Bax (Green and Reed 1998).
It has been shown that hypoxia induces cell apoptosis in many studies 
(Torres-Roca et al. 2000; Wu et al. 2004). In addition, hypoxia also inhibits the 
apoptosis of tumour cells (Kim et al. 2004). Some studies also show that hypoxia 
does not induce cell death (Galvin et al. 2004) and severe chronic hypoxia alone does 
not cause apoptosis of cardiac myocytes in culture (Webster et al. 1999).
In our study, we found that hypoxia significantly increased the percentage of 
apoptotic BAEC and BASMC when compared with normoxic control. Obvious 
protection against hypoxia-induced apoptosis was found in cells treated with high 
glucose. Therefore, it is logical to conclude that hyperglycaemia blocks one or more 
steps in the apoptotic pathway.
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The regulation of apoptosis within the cell can be simplified into two major 
pathways (Roucou et al. 2001). One is initiated from death receptors at the cell 
surface and is mainly regulated by the tumour necrosis factor super family and 
includes, for example, the fas/CD95 receptor. Upon ligand binding to the death 
receptor, the receptor activates the apoptosis signalling pathway through activation of 
caspase-8 (Ashkenazi and Dixit 1998).
The other pathway is triggered by disruption of the mitochondria. Genotoxic 
agents, ischemia, oxidative stress, growth factor withdrawal, and many other stimuli 
require mitochondria to activate caspases. Unlike caspase-8, caspase-9 is involved in 
the mitochondrial pathway response to extracellular cues and internal insults. The 
pro-apoptotic signals regulate cytochrome c release from mitochondria and further 
activate caspase-9 through interaction with Apaf-1 (Green and Reed 1998; Zou et al. 
1999). Both death receptor and mitochondrial pathways converge at the level of 
caspase-3 activation.
To further define the potential molecular mechanisms by which high glucose 
treatment modulates hypoxia induced apoptosis, we investigated the expression of 
pro- and anti-apoptotic proteins in BAEC and BASMCs.
Recently, Bcl-2 family proteins have been proved to be critical regulators of 
apoptosis. Bcl-2 was originally identified as a translocation breakpoint in human 
B-cell lymphoma (Reed 1995). It is now clear that Bcl-2 belongs to a large family of 
homologous proteins that can either promote or suppress apoptosis. The ratio 
between Bcl-2 to Bax and Bcl-Xi to Bax determines cell survival or death after 
apoptotic stimuli. The expression pattern and role of different members of the family 
appear to be cell specific (Evan and Littlewood 1998).
The significance of apoptosis in atherosclerosis appears to depend on the 
stage of the plaque, localization, and cell types involved (Kockx and Knaapen 2000). 
Glucose-induced suppression of apoptosis under hypoxia appears to be of particular 
importance in the initial events of vascular injury and thickening of the media of the 
vessels. It is well documented that high glucose and advanced glycation end products 
increased NF-kB activity in rat VSMCs (Lander et al. 1997; Yemeni et al. 1999). 
Bcl-X| has been identified as an NF-KB-dependent transcriptional target (Barkett and 
Gilmore 1999). In our study, we found that high glucose increased the Bcl-Xi protein 
expression under hypoxic conditions which suggests that high glucose concentrations 
are likely to have an effect on the activity of NF-kB activation leading to apoptosis
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suppression in BAEC and BASMC. This notion remains to be tested directly and 
could provide a possible mechanism by which these cells become resistant to 
apoptosis in the presence of glucose in hypoxia.
Several studies have shown that anti-apoptotic protein Bcl-2 and Bcl-Xi levels 
are dramatically either increased or decreased under hypoxic conditions, whereas the 
levels of the pro-apoptotic factors Bax and Bad remain unaltered (Schaffer et al. 
2000; Yamamoto et al. 2004; Li et al. 2005). We focused on the expression of an 
anti-apoptotic molecule Bcl-X| which is a Bcl-2 related gene can function as a Bcl-2 
independent regulator of apoptosis and a pro-apoptotic molecule Bax which 
heterodimerizes with Bcl-X| in mammalian cells.
Bcl-xi and Bax are homologous proteins that have opposing effects on cell 
growth and death, with Bcl-X| serving to prolong cell survival and Bax acting as an 
accelerator of apoptosis (Reed 1994). This present study revealed a significant 
decrease in Bcl-X| by hypoxic treatment which was reversed in the presence of high 
glucose. As our present data demonstrated marked down-regulation of Bcl-Xi 
induced by hypoxia, the apoptosis induced by hypoxia may be due to an 
inappropriate decrease in anti-apoptotic factors.
Bax protein expression was also decreased under hypoxic conditions in our 
studies other than remaining unaltered; this finding is not consistent with previous 
reports (Kim et al. 2004; Yamamoto et al. 2004; Li et al. 2005). Recent studies 
demonstrated that the translocation of Bax from the cytoplasm to the mitochondrial 
membrane is critical to induce apoptosis (Murphy et al. 1999; Putcha et al. 1999). 
After delivery of death signals such as hypoxia to cells in culture, Bax moves to the 
mitochondria and other membrane sites and triggers a catastrophic transformation of 
mitochondrial function which suggests that Bax translocation from cytosol to the 
mitochondrial membrane occurred under a physiological condition, thereby leading 
to pathological tissue destruction (Yamamoto et al. 2004). Our data showed that 
high glucose upregulated protein expression of Bax under hypoxic conditions. It is 
important to note that while only total protein amounts of Bax were measured, our 
data cannot rule out the possibility that phosphorylated Bax is affected by 
hypoxia/hyperglycaemia. Moreover, Bax protein in cytosolic fractions was 
decreased and mitochondrial fractions was increased under hypoxic conditions in 
epithelial cells (Yamamoto et al. 2004). The time course of changes in Bcl-Xi and 
Bax were different. Translocation of Bax to mitochondria occurred within 48 hours,
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while a decrease in Bcl-Xi occurred after 48 hours (Yamamoto et al. 2004). It is 
probable that the acute hypoxia-induced apoptotic process (within 48 hours) may 
depend on Bax, whereas the chronic hypoxia-regulated cell death process (over 5 
days) may depend on Bcl-X]
Therefore, we then compared the ratio of Bcl-X|/Bax at the level of protein 
expression in the cells. We found a 9.5-fold increase of Bcl-X| levels when compared 
to a 1.48-fold increase of Bax levels under hypoxic conditions in BAEC and a 
5.6-fold increase of Bcl-Xi level when compared 1.6-fold increase of Bax level under 
hypoxic condition in BASMC (over t=0 control).
Considering the ratio of Bcl-X|/Bax in the cells at different oxygen status, it 
appears that there is a phenomenon of levelling since the greater expression of Bcl-2 
seems to neutralise and then block Bax function at the mitochondrial level.
In regard to cellular survival, the down-regulation of Bax under hypoxic 
conditions is important in chronically hypoxic cells which would render cells 
resistant to a variety of apoptotic stimuli. The evidence that Bax participates in 
hypoxia-induced cell death implies that its role in this pathway would be abolished in 
cells that adapt to survive under hypoxic conditions. The down-regulation of Bax 
would provide a survival advantage, as activation of Bax inactivates Bcl-2 and Bcl-Xi 
(Letai et al. 2002). It has been shown that the down-regulation of Bax under 
hypoxic conditions was HIF-1-independent in human colon carcinoma cells which 
was not associated with decreased levels of bax mRNA and the observed reduction in 
Bax protein did not reflect increased proteosomal degradation (Erler et al. 2004) A 
global decrease in translation efficiency would be expected to contribute to the 
reduced expression of many proteins including Bax. Further studies are required to 
validate and expand this hypothesis.
It is well known that activation of Bax appears to involve subcellular 
translocation from the cytosol to mitochondria (Saikumar et al. 1998; Mikhailov et al.
2003). The signal directing the translocation remains to be elucidated. Regulatory 
proteins such as Bid have been reported to be involved in the modulation of cellular 
function, and localisation of Bax (Eskes et al. 2000; Nomura et al. 2003; Tsuruta et al.
2004). It is believed that cytosolic Bax fails to homodimerize in the presence of 
protective levels of Bcl-2 or Bcl-Xi, indicating a block at the death signal. Exploring 
various stimuli of Bax translocation could be important to understand the cell death 
system (Yamamoto et al. 2004). This should be further investigated to clarify the
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exact role of Bax in this model, as it may serve as a point for various apoptotic 
signals.
Interestingly, a similar protective effect of chronic hyperglycaemia on 
cardiomyocytes was also reported in a model of hypoxia-induced apoptosis and 
necrosis (Schaffer et al. 2000).
Caspase-3 activity and caspase-3 protein expression were decreased 
following exposure to high glucose concentration under hypoxic conditions in our 
study. To date, over a dozen caspases have been identified, and about two-thirds of 
these have been suggested to function in apoptosis (Adams and Cory 1998). 
Caspase-3 is an effector enzyme for induction of DNA damage and for ensuring 
apoptotic cell death. Caspase function is positively or negatively modified by Bcl-2 
family proteins, including Bcl-X|, and Bax (Roucou et al. 2001). Our data also 
suggest that upregulation of Bax and Bcl-Xi may also play a key role in the reduction 
of caspase-3 activity in BAEC and BASMC.
It has been recently demonstrated that the anti-apoptotic gene bcl-xl is 
unregulated within intimal VSMCs in animal models and human specimens of 
vascular disease (Pollman et al. 1998). Moreover, it has been shown that down 
regulation of Bcl-Xi expression within intimal cells using antisense oligonucleotides 
induces YSMC apoptosis and regression of vascular lesions. A study also showed 
that acutely disrupting Bcl-2 expression in VSMCs altered cell cycle activity through 
the execution of the apoptosis pathway (Perlman et al. 2000). These findings indicate 
that Bcl-xl and Bcl-2 are important determinants of cell viability and lesion 
formation.
Our study demonstrates that there is no altered expression of bcl-xl and Bax 
mRNA by high glucose treatment in both cell types in hypoxia during 24hour and 5 
days, while the expression of bcl-xl and Bax was not affected by both high glucose 
and mannitol treatments. Therefore, we propose that glucose-induced apoptosis 
suppression in BAEC and BASMC is partly due to upregulation of Bcl-X] and Bax 
protein expression as RNA levels did not change after the treatment period. The 
mechanisms for Bcl-2 and Bcl-X| anti-apoptotic function may include binding to 
Apaf-1 to prevent the activation of caspase cascade, altering mitochondrial 
membrane potential, and inhibiting cytochrome c release from mitochondria 
(Chinnaiyan et al. 1997; Decaudin et al. 1997; Kharbanda et al. 1997).
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Although the present and previous studies clearly support the notion that 
chronic hyperglycaemia could provide protection against hypoxia-induced cell 
apoptosis and elevate cell proliferation, surviving cells should be considered as an 
important issue, since this elevated mortality rate of the diabetic patient after a 
myocardial infarction is greater than that of non-diabetic patients (Aronson et al.
1997). This elevated mortality rate has been largely attributed to the development of 
a cardiomyopathy. The present study suggests that the increased risk of developing 
hypoxia-induced morbidity, cell proliferation and apoptosis is linked to the 
preexisting diabetic cardiomyopathy (Aronson et al. 1997). This scenario would 
imply that chronic hyperglycaemia and hypoxia act as an alternative way in which on 
the one hand, they render the cell resistant to a hypoxic insult and one the other hand, 
the surviving cells exhibit abnormal contractile and transport properties which 
increase the risk of eventually developing severe heart failure.
Taken together, our findings suggest that BAEC and BASMC exposure to 
high glucose under hypoxic condition leads to increased anti-apoptotic and 
pro-proliferative events by altering the fine balance between the expression of 
anti-apoptotic and pro-apoptotic proteins and by increasing the expression of 
proliferating cell nuclear antigen. The relative concentration of these proteins is an 
important determinant of their final impact on cell fate, and promotion of 
anti-apoptotic and pro-proliferative events may play an important role in the 
development of macro vascular complications in diabetes.
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Chapter 5
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5.1 Introduction
All organisms possess mechanisms to maintain oxygen homeostasis, which 
are essential for survival. The hypoxia-inducible factor-1 (HIF-1), conserved during 
evolution from worms to flies to vertebrates, is central to adaptation to low oxygen 
availability.
HIF-1, a master regulator, in turn regulates transcription of many genes 
involved in cellular and systemic responses to hypoxia, including breathing, 
vasodilation, anaerobic metabolism, erythropoiesis and angiogenesis. Therefore, hif 
represents a master gene in oxygen homeostasis during embryonic development and 
postnatal life in both physiological and pathophysiological processes (Semenza
1998).
Although oxygen availability regulates multiple steps on HIF-1 
transcriptional activation, the dominant control mechanism occurs through 
oxygen-dependent proteolysis of HIF-a (Huang et al. 1996). The most extensively 
studied isoform of the a-subunits is ubiquitous HIF-la.
The regulation of HIF-1 a expression and activity in vitro occurs at multiple 
levels, including mRNA expression (Wiener et al. 1996; Yu et al. 1998; Bergeron et 
al. 1999), protein expression (Wang et al. 1995; Jiang et al. 1996; Pugh et al. 1997; 
Salceda and Caro 1997; Huang et al. 1998; Kallio et al. 1999), nuclear localization 
(Kallio et al. 1998) and transactivation (Jiang et al. 1997; Pugh et al. 1997; Kallio et 
al. 1998; Ema et al. 1999). The most intensively studied has been the regulation of 
steady-state HIF-la protein level.
Studies have shown the interaction between hyperglycaemia and 
hypoxia-inducible factor-1 a (Catrina et al. 2004; Nyengaard et al. 2004), even 
though hypoxia is the main regulator of HIF-la, several other factors such as insulin 
and advanced glycosylation end products (AGE) (Zelzer et al. 1998; Feldser et al. 
1999; Treins et al. 2001) influence H IF-la expression and function also.
We therefore studied the effect of hyperglycaemia on the regulation of 
H IF-la function under hypoxic conditions at the protein and mRNA level and 
investigated the interaction between high glucose and HIF-la on BAEC and 
BASMC fate.
Aim 3: To Investigate the role H IF-la as a target for hyperglycaemia (25mM 
HG) in hypoxia-induced apoptosis and proliferation
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5.2 Results
Hypoxia activates a number of genes which are important in the cellular 
adaptation to low oxygen conditions and this elegant response is principally mediated 
through HIF-1. Only active as a heterodimer, HIF-1 is composed of HIF-la and 
HIF-1 [3. While HIF-1 P is readily found in cells under all oxygen conditions, HIF-la 
is virtually undetectable in normal oxygen conditions. For the HIF-1 transcriptional 
complex to be functional, HIF-la levels must be induced.
Our initial studies investigated the expression of HIF-la in BAEC and 
BASMC under conditions of normoxia and hypoxia. BAEC and BASMC were 
exposed to either normoxia or hypoxia for 5 days. Whole cell lysates were 
immunoprecipitated and analysed by western blot. Under normoxic conditions, no 
HIF-la protein could be detected by western blot analysis of whole cell extracts in 
either BAEC or BASMC. In contrast, strong expression of HIF-la protein level was 
observed under hypoxic conditions in both cell types (Figure 5.1).
Concomitantly, we examined the mRNA expression of HIF-la under the 
same conditions on BAEC and BASMC. RNA was extracted and subjected to 
QRTPCR using pre-optimized primers (Appendix 1). PCR product was resolved by 
2% agarose gel and normalized to 18S RNA. No change in mRNA was observed in 
either normoxia or hypoxia in both cell types corresponding with previous studies. 
High glucose did not alter mRNA expression under either condition suggesting that 
HIF-la expression is controlled at the protein level in response to hypoxia as has 
been previously described (Figure 5.2).
Having confirmed the expression of HIF-la under our experimental 
conditions, we examined the activity of HIF-la by luciferase assay. BAEC and 
BASMC were transfected with a luciferase reporter construct containing multiple 
copies of a hypoxia response element (HRE) upstream of the luciferase gene 
(HRE-Luc). Cells were exposed to normoxic or hypoxic conditions for 24 hours. 
Hypoxic treatment of cells over-expressing HRE-Luc showed a significant increase 
in luciferase activity when compared normoxic controls (BAEC 3.48-fold ± 
0.21-fold n=3 vs 1.05-fold ± 0.06-fold n=3 *p<0.01; BASMC 3.37-fold ± 0.29-fold 
n=3 vs 1.21-fold ± 0.12-fold n=3 *p<0.01) which confirmed that hypoxic regulation 
of H IF-la expression can result in activation of genes contain HRE sequences 
(Figure 5.3).
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Having shown that hypoxia can regulate HIF-la expression and activity and 
that hyperglycaemia can attenuate the proliferative and apoptotic response to hypoxia; 
we went on to investigate the role of HIF-la in hypoxia/hyperglycaemic-induced cell 
fate changes. BAEC and BASMC were cultured in either normoxia or hypoxia for 5 
days in the absence or presence of high glucose and whole cell lysates extracted and 
analyzed by immunoprécipitation using an HIF-la-specific antibody. HIF-la 
expression was not detectable under normoxic condition with normal media or high 
glucose treated media. However, hypoxia dramatically increased HIF-la expression 
under hypoxic condition. This expression was significantly inhibited in the present of 
high glucose when compared to hypoxic controls (BAEC 0.51-fold ± 0.06 n=3 vs
1.00-fold n=3; *p<0.01) and BASMC (0.59-fold ± 0.07-fold n=3 vs 1.00-fold n=3; 
*p<0.01) (Fig. 5.4).
To detect HRE-Luc activity of BAEC and BASMC under either normoxic or 
hypoxic conditions in the presence of high glucose, cells were transfected with a 
luciferase reporter and exposed for 24 hours. A significant increase activity was 
found under hypoxic conditions when compared to normoxic controls (BAEC 
3.48-fold ± 0.21-fold n=3 vs 1.05-fold ± 0.06-fold n=3 #p<0.01; BASMC 3.37-fold ± 
0.29-fold n=3 vs 1.21-fold ± 0.12-fold n=3 #p<0.01). High glucose did not alter this 
effect under normoxic conditions. However, this activity was significantly reversed 
following treatment with high glucose under hypoxic conditions when compared to 
hypoxic controls (BAEC 1.25-fold ± 0.10-fold n=3 vs 3.48-fold ± 0.21-fold n=3 
*p<0.01; BASMC 1.21-fold ± 0.12-fold n=3 vs 3.37-fold ± 0.29-fold n=3 *p<0.01). 
This data suggests that glucose-dependent rescue of hypoxia-treated BAEC and 
BASMC is via inhibition of a HIF-la-dependent mechanism (Fig. 5.5).
In our studies, we have shown that high glucose enhanced proliferation, 
inhibited apoptosis and decreased HRE-Luc activity in BAEC and BASMC under 
hypoxic conditions. We therefore question if this effect is HIF-la-dependent. Firstly, 
we knocked down H IF-la gene expression by HIF-la siRNA (siHIF-la) using 
pre-optimized primers (Appendix 1) and detected transfection efficiency using 
QRTPCR. BAEC and BASMC were transiently transfected with siHIF-la and 
scrambled siRNA (siScram) for 3 hours and recovered in 10% FBS overnight. Total 
RNA from cell pellets was extracted and PCR product was quantitated by QRTPCR 
analysis. HIF-la mRNA expression was significantly suppressed by siHIF-la 
(BAEC 23% ± 3.61% n=3 vs 102% ± 11.72% n=3 *p<0.01; BASMC 34% ± 2.03%
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n=3 vs 101% ± 6.36% n=3; *p<0.01) when compared to siScram. There was no 
significant change of none-transfected control on BAEC (100% n=3 vs 102% ±
11.72% n=3) and BASMC (100% n=3 vs 101.3% ± 6.36% n=3) when compared to 
siScram (Fig. 5.6).
Based on this successful siRNA transfection, BAEC and BASMC were 
transiently transfected with siHIF-la or siScram for 3 hours and recovered overnight 
in 10% FBS. Cells were then exposed to high glucose in normoxia or hypoxia for 5 
days. Proliferation was measured by FACS analysis. Under normoxic condition, 
siHIF-la did not show any effect in the presence of high glucose, the effect of 
transfected siScram control was correlated to siFIIF-la transfected control. Under 
hypoxic condition, siHIF-la transfected cells showed a significant increase 
proliferation when compared siScram transfected control on both cell type. However, 
due to -77% knocked off HIF-la on BAEC and -67% on BASMC, 
hyperglycaemia-induced cell proliferation was impaired on both cell types when 
compared to siHIF-la hypoxic control. This data suggests that hyperglycaemia 
upregulates cells proliferation under hypoxic conditions is HIF-la-dependent (Fig. 
5.7).
Although HIF-la mRNA was not knocked down to approximately the same 
level in both BAEC (-77%) and BASMC (-67%), a slight increase in proliferation 
was observed in siHIF-la BASMC under hypoxic conditions in the presence of high 
glucose; an effect that was not observed in BAEC (Fig. 5.8).
Concurrently, we examined the effect of apoptosis under the same conditions. 
BAEC and BASMC were transiently transfected with siHIF-la or siScram for 3 
hours and recovered in 10% FBS overnight, cells were then exposed to high glucose 
in either normoxia or hypoxia for 5 days. Cells were collected and the percentage of 
apoptotic cells was determined by FACS analysis. Under normoxic conditions, there 
was no change in apoptosis between siHIF-la and siScram transfected cells, high 
glucose did not modify this effect of apoptosis on BAEC and BASMC. Under 
hypoxic condition, hypoxia-induced apoptosis was significant increased in siScram 
transfected cells when compared to normoxic siScram transfected control cells 
(BAEC 21.34% ± 1.37% n=3 vs 6.46% ± 0.78% n=3 §p<0.01; BASMC 25.77% ± 
1.2% n=3 vs 6.51% ± 0.33% n=3 §p<0.01). However, this effect was significantly 
inhibited by siHIF-la transfected cells (BAEC 15.34% ± 0.36% n=3 vs 21.34% ± 
1.37% n=3 #p<0.05; BASMC 16.20% ± 1.23% n=3 vs 25.77% ± 1.20% n=3 #p<0.01)
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when compared to siScram transfected hypoxic control. Since there was still 23% 
(BAEC) and 33% (BASMC) of HIF-la mRNA in the siHIF-la transfected cells, 
hyperglycaemia showed significant inhibition of apoptosis (BAEC 11.54% ± 0.94% 
n=3 vs 15.34% ± 0.36% n=3 *p<0.05; (BASMC 11.88% ± 0.63% n=3 vs 16.20% ± 
1.23% n=3 *p<0.05) when compared to HIF-la siRNA transfected hypoxic control 
(Figs. 5.9 & 5.10).
Similar results were observed by examining caspase-3 activity in BAEC and 
BASMC. Cells were treated under the same conditions for 5 days and caspase-3 
activity assay was measured. Under normoxic conditions, high glucose had no effect 
on caspase-3 activity in either siHIF-la or siScram transfected BAEC and BASMC. 
Under hypoxic conditions, caspase-3 activity significantly increased in siScram 
transfected cells (BAEC 4.45-fold ± 0.31-fold n=3 vs 1.45-fold ± 0.17-fold n=3 
§p<0.01; BASMC 3.34-fold ± 0.19-fold n=3 vs 1.44-fold ± 0.06-fold n=3; §p<0.01) 
when compared to normoxic siScram transfected control. However, this 
hypoxia-induced caspase-3 activity was significantly decreased in siHIF-la 
transfected cells (BAEC 3.01-fold ± 0.09-fold n=3 vs 4.45-fold ± 0.31-fold n=3 
#p<0.05; BASMC 2.23-fold ± 0.12-fold n=3 vs 3.34-fold ± 0.19-fold n=3; #p<0.01) 
when compared to siScram transfected hypoxic control. High glucose showed a 
significant decreased in caspase-3 activity in siHIF-la transfected BAEC (2.27-fold 
± 0.19-fold n=3 vs 3.01-fold ± 0.09-fold n=3; *p<0.05) and BASMC (1.65-fold ± 
0.09-fold n=3 vs 2.23-fold ± 0.12-fold n=3; *p<0.05) when compared to HIF-la 
siRNA transfected hypoxic control (Figs. 5.11 & 5.12).
To further investigate the role of the apoptotic proteins, BNIP3L was 
introduced to this study. To examine BNIP3L protein expression in either normoxia 
or hypoxia in the presence of high glucose, BAEC and BASMC were exposed to 
either normoxic or hypoxic conditions with high glucose for 5 days and whole cell 
lysates were analyzed by immunoprécipitation. BNIP3L protein expression was not 
observed under normoxic conditions which correspond with previous studies. Under 
hypoxic conditions, the expression of BNIP3L protein was significantly increased in 
BAEC and BASMC. However, this expression was significantly inhibited by high 
glucose when compared to hypoxic control (BAEC 0.74-fold ± 0.05-fold n=3 vs
1.00-fold n=3 *p<0.01; BASMC 0.59-fold ± 0.05-fold n=3 vs 1.00-fold n=3; 
*p<0.01). This data suggests that hyperglycaemia may impair hypoxia-induced 
apoptosis via the inhibition of the pro-apoptotic protein BNIP3L (Fig. 5.13).
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Fig. 5.1 Hypoxia Induces H IF-la Protein Expression
BAECs (A) and BASMCs (B) were cultured in 10% FBS under normoxic or hypoxic 
conditions for 24 hours. Cells were harvested and cell lysates immunoprecipitated 
using an HIF-la-specific antibody. Proteins were resolved by SDS-PAGE. and 
transferred to nitrocellulose. Visualisation of H IF-la was by incubation with an anti- 
H IF-la -specific antibody followed by HRP-conjugated anti-mouse secondary 
antibody.
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Fig. 5.2 Hypoxia and High Glucose Concentrations Do Not Alter HIF-la 
mRNA Expression
(A) BAEC and (B) BASMC cultured in 10% FBS were exposed to high glucose  
concentrations for 48hrs or 5 days under either norm oxic or hypoxic conditions. 
Cells were harvested, RNA extracted and QRTPCR carried out using specific primer 
sets for H IF-la as described in the methods. The resultant PCR products were 
resolved by agarose gel electrophoresis (2%). Data are representative o f  at least 
three independent experiments showing similar results.
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Fig. 5.3 Hypoxia Regulates Hypoxia Response Element Activation
BAECs and BASMCs were transiently transfected with an HRE-Luc reporter 
construct prior to treatment in the absence or presence of hypoxia for 24hrs. Cells 
were harvested and Luciferase assay carried out as described in the Methods. 
Values represent mean ± SEM for three experiments; *p<0.01 compared to normoxic 
control.
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Fig. 5.4 Effect of High Glucose on Hypoxia-Induced HIF-la Protein 
Expression
BAECs (A) and BASMCs (B) were cultured in 10% FBS under normoxic or hypoxic 
conditions for 24 hours. Cells were harvested and cell lysates immunoprecipitated 
using an HIF-la-specific antibody. Proteins were resolved by SDS-PAGE and 
transferred to nitrocellulose. Visualisation of H IF-la was by incubation with an anti- 
H IF-la -specific antibody followed by HRP-conjugated anti-mouse secondary 
antibody. Blots were quantified by densitometric scanning and values represent mean 
± SEM for three experiments; *p<0.01 compared to hypoxic control.
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Fig. 5.5 High Glucose Inhibits Hypoxia-Induced Activation of HRE’s
BAECs and BASMCs were transiently transfected with an HRE-Luc reporter 
construct prior to treatment in the absence or presence of hypoxia for 24hrs. Cells 
were harvested and Luciferase assay carried out as described in the Methods. 
Values represent mean ± SEM for three experiments; # p<0.01 compared to 
normoxic control, *p<0.01 compared to hypoxic control.
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Fig. 5.6 Knockdown of H IF -la  mRNA using Small Interfering (si) RNA
BAEC’s (A) and BASMC’s (B) were transiently transfected with scrambled siRNA 
or siRNA specific to the bovine sequence of H IF-la (Appendix 1). Cells were 
harvested, RNA extracted and QRTPCR carried out using specific primer sets for 
HIF-la. The resultant PCR products were resolved by agarose gel electrophoresis. 
Data are representative of at least three independent experiments showing similar 
results. *p<0.01 compared to scrambled control (NT: non-transfected)
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Figure 5.7 Effect of high glucose on hypoxia-induced proliferation in siRNA 
Transfected BAECs
BAECs were transiently transfected with siHIF-la and labelled with CFDA SE prior 
to culture in 10% FBS for 5 days under (A) normoxic or (B) hypoxic conditions. 
Cells were then collected and analysed by FACS as described in the Methods. Panels 
show comparisons of cell proliferation over the 5 day period in 10% FBS with 
normal glucose (5.5mM: Control), high glucose (25mM: Glucose) and mannitol 
(25mM: Mannitol). Data are representative of at least 3 independent experiments.
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Fig. 5.8 Effect of high glucose on hypoxia-induced proliferation in siRNA 
Transfected BASMCs
BASMCs were transiently transfected with siHIF-la and labelled with CFDA SE 
prior to culture in 10% FBS for 5 days under (A) normoxic or (B) hypoxic conditions. 
Cells were then collected and analysed by FACS as described in the Methods. Panels 
show comparisons o f cell proliferation over the 5 day period in 10% FBS with 
normal glucose (5.5mM: Control), high glucose (25mM: Glucose) and mannitol 
(25mM: Mannitol). Data are representative of at least 3 independent experiments.
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Fig. 5.9 Effect of High Glucose on Hypoxia-induced Apoptosis in siRNA-transfected BAECs
BAECs were transiently transfected with siHIF-la prior to treatment in the absence or presence of high glucose under normoxic or hypoxic 
conditions for 5 days. Cells were collected and analysed for apoptosis by FACS as described in the Methods. The values obtained for EA 
and LA cells were combined and plotted as a bar chart (n=3, ± SEM, §p<0.01 compared to normoxic scrambled control; #p<0.05 compared 
to hypoxic scrambled control; *p<0.05 compared to hypoxic siHIF-la control).
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Fig. 5.10 Effect of High Glucose on Hypoxia-induced Apoptosis in siRNA-transfected BASMCs
BASMCs were transiently transfected with siHIF-la prior to treatment in the absence or presence of glucose under normoxic or hypoxic 
conditions for 5 days. Cells were collected and analysed for apoptosis by FACS as described in the Methods. The values obtained for EA 
and LA cells were combined and plotted as a bar chart (n=3, ± SEM, §p<0.01 compared to normoxic scrambled control; #p<0.01 compared 
to hypoxic scrambled control; *p<0.05 compared to hypoxic siHIF-la control).
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Figure 5.11 Effect of High Glucose on Hypoxia-induced Caspase-3 activity in siRNA Transfected BAECs
BEACs were transiently transfected with siH IF-la and cultured in media containing 10% FBS for 5 days, in the absence or presence of 
high glucose (25mM) under normoxic or hypoxic conditions. Cells were harvested and a colourimetric caspase 3 assay carried out on 
cell lysates as described in the Methods. A pNitroanilide (pNA) standard curve (0-200|ig/^il) allowed for the specific activity of 
caspase 3 to be calculated for each sample and expressed as pmol pNA released/min/mg. Data are representative of at least 3 
independent experiments ± SEM; §p<0.01 compared to normoxic scrambled control; #p<0.05 compared to hypoxic scrambled control; 
*p<0.05 compared to hypoxic siH IF-la control
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Figure 5.12 Effect of High Glucose on Hypoxia-induced Caspase-3 activity in siRNA Transfected BASMCs
BASMCss were transiently transfected with siH IF-la and cultured in media containing 10% FBS for 5 days, in the absence or presence of 
high glucose (25mM) under normoxic or hypoxic conditions. Cells were harvested and a colourimetric caspase 3 assay carried out on cell 
lysates as described in the Methods. ApNitroanilide (pNA) standard curve (0-200|ig/|il) allowed for the specific activity of caspase 3 to 
be calculated for each sample and expressed as pmol pNAreleased/min/mg. Data are representative of at least 3 independent experiments 
± SEM; §p<0.01 compared to normoxic scrambled control; #p<0.01 compared to hypoxic scrambled control; *p<0.05 compared to 
hvpoxic siH IF-la control
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Fig. 5.13 Hypoxia and  H igh Glucose Regulate Pro-Apoptotic BNIP3L 
Protein Levels
BAECs (A) and BASMCs (B) were cultured in 10% FBS under normoxic or hypoxic 
conditions in the absence or presence of HG (25mM) for 5 days. Cells were 
harvested and cell lysates immunoprecipitated using a BNIP3L-specific antibody. 
Proteins were resolved by SDS-PAGE and transferred to nitrocellulose. Visualisation 
o f H IF -la  was by incubation with an anti- H IF -la  -specific antibody followed by 
HRP-conjugated anti-rabbit secondary antibody. Blots were quantified by 
densitometric scanning and values represent mean ± SEM for three experiments; 
*p<0.01 compared to hypoxic control.
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5.3 Discussion
H I F - l a  is  a  m a s t e r  g e n e  c o n t r o l l i n g  t h e  h y p o x i c  r e s p o n s e  i n  m a m m a l i a n  c e l ls  
a n d  t h u s  p l a y s  a n  i m p o r t a n t  r o l e  i n  c e l l  a p o p t o s is  a n d  p r o l i f e r a t i o n .  W e  h a v e  f o u n d  
t h a t  h y p e r g l y c a e m i a  r e g u la t e s  c e l l  a p o p t o s is  a n d  p r o l i f e r a t i o n  u n d e r  h y p o x i c  
c o n d i t i o n s ;  w e  t h e r e f o r e  s t u d i e d  t h e  e f f e c t  o f  h y p e r g l y c a e m i a  o n  h y p o x i a  in d u c e d  
H I F - l a  e x p r e s s i o n  a n d  a c t i v i t y .
I n  t h is  s t u d y ,  w e  d e m o n s t r a t e d  t h a t  i n h i b i t i o n  o f  t h e  e x p r e s s i o n  o f  H I F - l a  a t  
t h e  m R N A  l e v e l  r e s u l t e d  i n  a n  a s s o c ia t e d  d e c r e a s e d  p r o t e i n  l e v e l s  w h i c h  i n  t u r n  
in c r e a s e d  h y p o x i a - i n d u c e d  p r o l i f e r a t i o n  a n d  d e c r e a s e d  h y p o x i a - i n d u c e d  a p o p t o s is .  
W e  a ls o  s h o w e d  t h a t  h y p e r g l y c a e m i a  c a n  i n h i b i t  h y p o x i a - i n d u c e d  H I F - l a  e x p r e s s i o n  
a t  t h e  p r o t e i n  l e v e l .
T h i s  o b s e r v a t i o n  s u g g e s ts  a  m e c h a n i s m  o f  c r o s s  c o u p l i n g  b e t w e e n  t w o  o f  t h e  
m o s t  i m p o r t a n t  d e t e r m i n a t e s  o f  t h e  c h r o n i c  c o m p l i c a t i o n s  i n  d i a b e t e s :  
h y p e r g l y c a e m i a  a n d  h y p o x i a .  B o t h  h y p e r g l y c a e m i a  a n d  h y p o x i a  h a v e  b e e n  
s u g g e s t e d  t o  b e  i m p o r t a n t  c a u s a t iv e  f a c t o r s  f o r  d i a b e t i c  r e t i n o p a t h y  ( B u r s e l l  e t  a l .  
1 9 9 6 ) ,  n e u r o p a t h y  ( N e w r i c k  e t  a l .  1 9 8 6 ) ,  a r t e r io s c le r o s is  ( S a n t i l l i  e t  a l .  1 9 9 3 ) ,  k i d n e y  
d is e a s e  ( M e l i n  e t  a l .  1 9 9 7 )  a n d  d i a b e t i c  f o o t  u l c e r s  ( K a l a n i  e t  a l .  1 9 9 9 ) .  M o r e o v e r ,  
b l o o d  g l u c o s e  w a s  s h o w n  t o  b e  i n  l i n e a r  r e l a t i o n  w i t h  f a t a l  o u t c o m e  a f t e r  a n  a c u t e  
h y p o x i c  c h a l l e n g e  s u c h  a s  a c u t e  m y o c a r d i a l  i n f a r c t i o n  ( M a l m b e r g  e t  a l .  1 9 9 9 ) ,  
s u g g e s t i n g  a  p o t e n t i a l  d e l e t e r i o u s  i n f l u e n c e  o f  h y p e r g l y c a e m i a  o n  t h e  c a p a c i t y  o f  
t is s u e  t o  a d a p t  t o  l o w  o x y g e n  t e n s io n s .
W e  f i r s t l y  in v e s t i g a t e d  t h e  H I F - l a  p r o t e i n  a n d  m R N A  e x p r e s s i o n  u n d e r  
n o r m o x i c  a n d  h y p o x i c  c o n d i t i o n s .  H I F - l a  p r o t e i n  l e v e l s  w e r e  o n l y  d e t e c t e d  u n d e r  
h y p o x i c  c o n d i t io n s  a n d  h i g h  g l u c o s e  d i d  n o t  h a v e  a n y  e f f e c t  o n  H I F - l a  p r o t e i n  l e v e l  
u n d e r  n o r m o x i c  c o n d i t i o n s .  I n  c o n t r a s t ,  h i g h  g lu c o s e  s i g n i f i c a n t l y  i n h i b i t s  H I F - l a  
p r o t e i n  e x p r e s s i o n  u n d e r  h y p o x i c  c o n d i t i o n ,  h o w e v e r ,  h i g h  g lu c o s e  d o e s  n o t  r e g u la t e  
H I F - l a  m R N A  t r a n s c r i p t i o n  w h i c h  a r e  c o r r e s p o n d  w i t h  p r e v i o u s  s t u d ie s  ( C a t r i n a  e t  
a l .  2 0 0 4 )  a n d  i t  is  a ls o  i n  a g r e e m e n t  w i t h  t h e  o b s e r v a t io n s  m a d e  o n  n o r m a l  r e t i n a l  
c e l l s ,  w h e r e  h i g h  g l u c o s e  d o e s  n o t  i n f l u e n c e  t h e  n o r m o x i c  l e v e l s  o f  H I F - l a  p r o t e i n  
( P o u l a k i  e t  a l .  2 0 0 2 ) .  H o w e v e r ,  t h e  e f f e c t  o f  g l u c o s e  o n  H I F - l a  p r o t e i n  l e v e l s  s e e m s  
t o  b e  c e l l  d e p e n d e n t :  i n  c a n c e r  c e l l s ,  h i g h e r  l e v e l s  o f  H I F - l a  a r e  p r e s e n t  a t  n o r m a l  
g l u c o s e  c o n c e n t r a t io n s  t h a n  a t  l o w  g lu c o s e  c o n c e n t r a t io n s  ( L u  e t  a l .  2 0 0 2 ) .
I n  t h e  p r e s e n t  s t u d y ,  t h e  i m p a i r e d  e x p r e s s i o n  o f  H I F - l a  p r o t e i n  w i t h  t h e  
g l u c o s e - i n d u c e d  d e c r e a s e  i n  f u n c t i o n a l  a c t i v i t y  o f  H I F - l a  i n  h y p o x i c  c e l ls  p r o v i d e s
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a n  a l t e r n a t i v e  m e c h a n i s m  o f  r e g u l a t i o n  o f  H I F - l a  f u n c t i o n  b y  h i g h  g lu c o s e  d u r i n g  
h y p o x i a .
I n  t h e  c a s e  o f  c e l l u l a r  r e s p o n s e s  t o  h y p o g l y c a e m i a ,  a  l i n k  b e t w e e n  g lu c o s e  
c o n c e n t r a t io n s  a n d  h y p o x i a  s i g n a l l i n g  h a s  b e e n  o b s e r v e d .  E m b r y o n i c  c e l l s  d e f i c i e n t  
i n  H I F - l a  a r e  u n a b le  t o  u p r e g u l a t e  s e v e r a l  H I F - l a  t a r g e t  g e n e s  a t  l o w  g lu c o s e  
c o n c e n t r a t i o n  ( C a r m e l i e t  e t  a l .  1 9 9 8 ;  I y e r  e t  a l .  1 9 9 8 ;  R y a n  e t  a l .  1 9 9 8 ) .  H o w e v e r ,  
t h e  m o d u l a t i o n  b y  h y p o g l y c a e m i a  o f  H I F - l a  t a r g e t  g e n e s  s e e m s  t o  b e  d e p e n d e n t  o n  
t h e  c e l l  t y p e  v a r y i n g  f r o m  i n h i b i t i o n  t o  s t i m u l a t i o n  ( W i l l i a m s  e t  a l .  2 0 0 2 ) .
C o n s is t e n t  w i t h  a  n e g a t i v e  e f f e c t  o f  h i g h  g l u c o s e  c o n c e n t r a t io n s  o n  
h y p o x i a - i n d u c e d  p r o t e i n  s t a b i l i z a t i o n ,  h y p e r g l y c a e m i a  d e c r e a s e d  t h e  t r a n s c r i p t i o n a l  
a c t i v a t i o n  f u n c t i o n  o f  H I F - l a  a s  a s s e s s e d  b y  lu c i f e r a s e  r e p o r t e r  g e n e  a s s a y .  G lu c o s e  
h a s  b e e n  r e p o r t e d  t o  i n t e r f e r e  w i t h  h y p o x i a - d e p e n d e n t  a c t i v a t i o n  o f  t h e  l i v e r  p y r u v a t e  
k in a s e  p r o m o t e r  ( K r o n e s  e t  a l .  2 0 0 1 ) .  D u e  t o  t h e  h i g h  h o m o l o g y  b e t w e e n  H R E  a n d  
g l u c o s e  r e s p o n s iv e  e le m e n t s  o f  t h i s  p r o m o t e r ,  i t  h a s  b e e n  p r o p o s e d  t h a t  t h e  
c o r r e s p o n d i n g  t r a n s c r i p t i o n  f a c t o r s  H I F - l a  a n d  u p s t r e a m  s t i m u l a t i n g  f a c t o r s  s u c h  as  
V E G F ,  r e s p e c t i v e l y ,  c o u l d  c o m p e t e  f o r  b i n d i n g  t o  e i t h e r  r e s p o n s e  e l e m e n t s ,  t h e r e b y  
i n d u c i n g  a  d e c r e a s e  o f  t h e  c o g n a t e  a c t i v a t i o n  p a t h w a y  ( I y e r  e t  a l .  1 9 9 8 ) .
W e  h a v e  s h o w n  t h a t  h y p e r g l y c a e m i a  i n h i b i t s  h y p o x i a - i n d u c e d  a p o p t o s is ,  
e n h a n c e s  h y p o x i a - i n d u c e d  a n t i - p r o l i f e r a t i o n  a n d  i n t e r f e r e s  w i t h  H I F - l a  p r o t e i n  l e v e l ;  
t h e r e f o r e  w e  i n v e s t i g a t e d  i f  t h e s e  e f f e c t s  o f  h y p e r g l y c a e m i a  w e r e  H I F - l a  d e p e n d e n t .  
H I F - l a  m R N A  l e v e l  w a s  k n o c k e d  d o w n  a p p r o x i m a t e l y  7 0 %  i n  b o t h  c e l l  t y p e  u s in g  
s i R N A .  W e  o b s e r v e d  t h a t  h y p o x i a - i n d u c e d  a p o p t o s is  w a s  s i g n i f i c a n t l y  d e c r e a s e d  in  
H I F - l a  s i R N A  t r a n s f e c t e d  c e l l s  w h e n  c o m p a r e d  t o  h y p o x i c  c o n t r o l ,  h i g h  g lu c o s e  s t i l l  
i n h i b i t s  h y p o x i a - i n d u c e d  a p o p t o s is  o n  H I F - l a  s i R N A  t r a n s f e c t e d  c e l ls  w h e n  
c o m p a r e d  t r a n s f e c t e d  h y p o x i a  c o n t r o l  s in c e  t h e r e  w a s  s t i l l  - 3 0 %  H I F - l a  e x p r e s s i o n  
i n  t h e  c e l ls .  H o w e v e r ,  t h e  r a t i o  o f  w h i c h  h i g h  g l u c o s e  i n h i b i t s  H I F - l a  s i R N A  
t r a n s f e c t e d  c e l ls  a p o p t o s is  w a s  m u c h  s m a l l e r  t h a n  h i g h  g l u c o s e  i n h i b i t s  
n o n e - t r a n s f e c t e d  c e l ls  a p o p t o s is  u n d e r  h y p o x i c  c o n d i t i o n .
T h e  p r o l i f e r a t i o n  o f  H I F - l a  s i R N A  t r a n s f e c t e d  c e l l s  w a s  in c r e a s e d  w h e n  
c o m p a r e d  t o  n o n e - t r a n s f e c t e d  h y p o x i c  c o n t r o l .  S in c e  - 7 0 %  H I F - l a  m R N A  h a s  b e e n  
k n o c k e d  o f f ,  t h e r e  w a s  n o  s i g n i f i c a n t  in c r e a s e  p r o l i f e r a t i o n  b y  h i g h  g lu c o s e  o n  
H I F - l a  s i R N A  t r a n s f e c t e d  c e l l  u n d e r  h y p o x i a  w h i c h  s u g g e s ts  t h a t  h i g h  g lu c o s e  
i n h i b i t s  c e l l  a p o p t o s is  a n d  u p r e g u la t e s  c e l l  p r o l i f e r a t i o n  u n d e r  h y p o x i c  c o n d i t i o n  m a y  
v i a  a  H I F - l a - d e p e n d a n t  p a t h w a y .
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E x p r e s s i o n  o f  t h e  H I F - l a  s u b u n i t  is  p r e c i s e l y  r e g u l a t e d  b y  t h e  c e l l u l a r  O 2  
c o n c e n t r a t i o n ,  s u c h  t h a t  t h e  l e v e l  o f  H I F - l a  a n d  t h e  D N A  b i n d i n g  a c t i v i t y  o f  H I F 1  
in c r e a s e  e x p o n e n t i a l l y  a s  t h e  O 2  c o n c e n t r a t i o n  d e c r e a s e .  B y  b i n d i n g  t o  t h e  
h y p o x i a - r e s p o n s e  e l e m e n t  ( H R E )  p r e s e n t  i n  t h e  p r o m o t e r / e n h a n c e r  r e g i o n  o f  t a r g e t  
g e n e s ,  H I F 1  in c r e a s e s  t h e  e x p r e s s i o n  o f  t h e s e  t a r g e t  g e n e s  s u c h  a s  v a s c u la r  
e n d o t h e l i a l  g r o w t h  f a c t o r  A  ( V E G F - A ) ,  e r y t h r o p o i e t i n - 1 , h e m e  o x y g e n a s e  1 ( O X  1 ) ,  
g l u c o s e  t r a n s p o r t e r  1 ( G L U T  1 )  a n d  o t h e r  e n z y m e s  i n v o l v e d  i n  g l y c o l y s i s  ( W e n g e r  
a n d  G a s s m a n n  1 9 9 7 ;  I y e r  e t  a l .  1 9 9 8 )  i n  r e s p o n s e  t o  h y p o x i a .
H e r e  w e  s h o w e d  t h a t  h y p e r g l y c a e m i a  d e c r e a s e s  H R E  a c t i v a t i o n  u n d e r  
h y p o x i c  c o n d i t i o n  w h i c h  s u g g e s ts  t h a t  h y p e r g l y c a e m i a  in t e r f e r e s  w i t h  H I F - l a  b y  t h e  
i n h i b i t i o n  o f  b i n d i n g  t o  H R E  a n d  i n t e r a c t i n g  w i t h  t a r g e t  g e n e s .
H I F - l a  c a n  i n d u c e  a p o p t o s is  v i a  t w o  m e c h a n is m s .  F i r s t l y ,  i t  c a n  in c r e a s e  t h e  
s t a b i l i t y  o f  t h e  p r o d u c t  o f  t u m o u r  s u p p r e s s o r  g e n e  p 5 3 .  p 5 3  in d u c e s  a p o p t o s is  b y  
r e g u l a t i n g  p r o t e in s  s u c h  a s  B a x  o r  c a n  c a u s e  g r o w t h  a r r e s t  w h i c h  is  m e d i a t e d  b y  p 2 1  
i n  e n v i r o n m e n t a l  s t re s s  o r  D N A  d a m a g e .  R e c e n t l y ,  i t  w a s  s h o w n  t h a t  H I F - l a  d i r e c t l y  
b i n d s  t o  t h e  p 5 3  u b i q u i t i n  l i g a s e  b o t h  i n  v i v o  a n d  i n  v i t r o  t h e r e b y  s t a b i l i z i n g  p 5 3  
( C h e n  e t  a l .  2 0 0 3 ) .  H o w e v e r ,  a n o t h e r  r e p o r t  s h o w e d  a  d i r e c t  b i n d i n g  o f  p 5 3  t o  t h e  
O D D  d o m a i n  o f  H I F - l a  ( H a n s s o n  e t  a l .  2 0 0 2 ) .  H I F - l a  in t e r a c t s  w i t h  w i l d - t y p e  p 5 3  
b u t  n o t  w i t h  t u m o u r  d e r i v e d  m u t a n t  p 5 3  ( A n  e t  a l .  1 9 9 8 )  w h i c h  m a y  r e f l e c t  a  
d i f f e r e n c e  i n  b e h a v i o u r  o f  H I F - l a  i n  p h y s i o l o g i c a l  c i r c u m s t a n c e s  c o m p a r e d  w i t h  a  
t u m o u r  e n v i r o n m e n t .
S e c o n d l y ,  H I F - l a  c a n  i n i t i a t e  a p o p t o s is  b y  i n d u c i n g  h i g h  c o n c e n t r a t io n s  o f  
p r o - a p o p t o t i c  p r o t e in s  B c l - 2 / a d e n o v i r u s  E 1 B  1 9  k D a  i n t e r a c t i n g  p r o t e i n  3  ( B N I P 3 ) .  
B N I P 3  w a s  i n i t i a l l y  r e l a t e d  t o  m i t o c h o n d r i a l  f u n c t io n s  ( C h e n  e t  a l .  1 9 9 7 ;  R a y  e t  a l .  
2 0 0 0 )  a n d  h a s  b e e n  s h o w n  t o  f o r m  h e t e r o d i m e r s  w i t h  a n t i - a p o p t o t i c  B c l - 2  f a m i l y  
m e m b e r s  s u c h  a s  B c 1-x l  a n d  B c l - 2  a n d  m a y  p r o m o t e  a p o p t o s is  b y  s e q u e s t e r in g  t h e s e  
f a c t o r s  ( B o y d  e t  a l .  1 9 9 4 ;  C h e n  e t  a l .  1 9 9 7 ;  Y a s u d a  e t  a l .  1 9 9 8 ;  R a y  e t  a l .  2 0 0 0 )  a t  t h e  
l e v e l  o f  t h e  m i t o c h o n d r i a  ( V a n d e  V e l d e  e t  a l .  2 0 0 0 ) .
W e  s t u d i e d  B N I P 3  b e c a u s e  i t  h a s  b e e n  i m p l i c a t e d  i n  h y p o x i a - c o n t r o l l e d ,  
p r o - a p o p t o t i c  p r o c e s s e s  c o n t r o l l e d  b y  H I F - 1  ( B r u i c k  2 0 0 0 ) .  B N I P 3  p r o t e i n  l e v e l  
c o u l d  n o t  b e  o b s e r v e d  u n d e r  n o r m o x i c  c o n d i t i o n  a n d  B N I P 3  p r o t e i n  e x p r e s s i o n  w a s  
d r a m a t i c a l l y  in c r e a s e d  u n d e r  h y p o x i c  c o n d i t i o n  w h i c h  is  c o r r e s p o n d  w i t h  s e v e r a l  
s t u d ie s  ( B r u i c k  2 0 0 0 ;  G u o  e t  a l .  2 0 0 1 ;  S c h m i d t - K a s t n e r  e t  a l .  2 0 0 4 ) .  H o w e v e r ,  
h y p o x i a - i n d u c e d  B N I P 3  p r o t e i n  l e v e l  a c c u m u l a t i o n  w a s  s i g n i f i c a n t l y  i n h i b i t s  i n  t h e
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presence of high glucose in our study which suggest that high glucose decreased 
hypoxia-induced apoptosis by diminishing the expression of BNIP3.
Mitochondrial damage and release of cytochrome c from the mitochondria to 
the cytosol accompany apoptotic cell death induced by various stimuli (Liu et al. 
1996; Kluck et al. 1997; Nicholson and Thornberry 1997; Yang et al. 1997). Together 
with dATP, cytochrome c triggers the association of pro-caspase-9 with Apaf-1, the 
formation of a cytochrome c/dATP/caspase-9/Apaf-l complex leads to the cleavage 
and activation of caspase 9 which in turn cleaves and activates caspase 3 and 
executes apoptosis in various models.
Therefore, we investigated caspase-3 activity and found that the inhibition of 
hypoxia-induced caspase-3 activity in the present of high glucose is dependent on 
HIF-la mRNA expression which suggests that high glucose decreases caspase-3 
activation under hypoxic condition is via HIF-la-dependent pathway.
Taken together, in our study high glucose inhibits hypoxia-induced apoptosis 
and enhances hypoxia-induced anti-proliferation under hypoxic condition is 
HIF-1 a-dependent.
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C hapter 6
Discussion & Perspectives
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Vascular complications are a major cause of morbidity and mortality in 
diabetes and are the leading cause of death in adults with diabetes mellitus (Getz 
1993). Compared with other individuals with equivalent risk factors, people with 
diabetes have a four- to fivefold increase in mortality from vascular disease (Getz 
1993). The factors responsible for this increased risk of cardiovascular disease are 
not known, but studies in patients with types I and II diabetes have demonstrated that 
good metabolic control is able to prevent early changes of atherosclerosis and 
decrease the risk of coronary heart disease events and deaths (Kuusisto et al. 1994; 
Jensen-Urstad et al. 1996).
Abnormalities in vascular cells such as increased permeability, enhanced 
expression of cell adhesion molecules and a reduced response to nitric oxide (NO) 
are thought to contribute to both micro- and macrovascular complications of diabetes 
(Hink et al. 2001; Wautier and Wautier 2001). Injury to endothelial and arterial 
smooth muscle cells triggers the formation of fibrous lesions within high glucose 
exposure further aggravating their formation (Ross 1993). Results from the Diabetes 
Control and Complications Trial (DCCT 1993) and United Kingdom Prospective 
Diabetes Study (UKPDS 1998) indicated that it is persistent hyperglycaemia of 
uncontrolled diabetes that causes vascular complications, however, whether there is a 
direct effect of glucose on vascular cells or an indirect effect to the modification of 
other risk factors is not known.
Previous studies have demonstrated that high concentrations of glucose cause 
death of vascular cells as a result of increased apoptosis (Wu et al. 1999; Nakagami 
et al. 2001; Ido et al. 2002; Liu et al. 2004) and cause the inhibition of vascular cell 
growth (Lorenzi et al. 1987; Curcio and Ceriello 1992; Graier et al. 1995; Morishita 
et al. 1997; Kamal et al. 1998).
In our initial studies, we firstly investigated the effect of high glucose (HG 
25mM) on BAEC and BASMC apoptosis and proliferation and showed that 
hyperglycaemia alone in 10% FBS had no effect on proliferation and apoptosis. 
Experiments with mannitol excluded the possibility that the stimulus provided by HG 
is a function of hyperosmolarity which is consistent with previous findings (Lorenzi 
et al. 1985; Morishita et al. 1997; Morishita et al. 1997).
Previous studies using high glucose concentrations as stimuli for proliferation 
have examined these effects under low serum conditions ranging from 1-5% FCS 
(Oikawa et al. 1996; Sodhi et al. 2001). As low serum conditions are used to quiesce
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the cells and deprive them of essential growth factors, we expect that the addition of 
an energy substrate such as glucose will lead to an increase in proliferation and 
decrease in apoptosis of these cells. To investigate this further, we then examined the 
effect of high glucose in cells cultured in 0.5% FBS. Although 0.5% FBS 
significantly increased cell apoptosis and decreased cell proliferation, high glucose 
did not alter these effects which suggests that concentrated high glucose (25 mM) is 
not sufficient to alter cell fate at physiological levels. Mannitol, as an osmotic control, 
failed to alter cell proliferation and apoptosis in our study which again correlates 
with previous studies (Graier et al. 1995; Morishita et al. 1997; Kamal et al. 1998).
Even though prolonged exposure of the tissues to hyperglycaemia seems to 
be the primary causative factor (DCCT 1993; UKPDS 1998), it has become 
increasingly evident that hypoxia plays an important role in all diabetes 
complications (Cameron et al. 2001). In addition to deficient blood supply as a 
consequence of micro- and macrovascular disease, it has been postulated that 
hyperglycaemia induces a pseudohypoxia state which is based on the finding that 
high glucose concentrations induce a high NADH+/NAD+ ratio in cells even when 
the oxygen tension is normal (Williamson et al. 1993).
Several studies have also observed that diseases characterized by chronic 
hypoxic episodes are associated with glucose intolerance (Austin et al. 1994; Brooks 
et al. 1994; Hardin et al. 1997). However, the effect of hyperglycaemia under 
hypoxic condition has not been fully studied.
Therefore, we introduced hypoxia into cells as a known stimulator of changes 
in cell fate. Hypoxia induces cell apoptosis and decreases cell proliferation which has 
been shown in many studies (Graeber et al. 1996; Shimizu et al. 1996; Webster et al.
1999). In contrast in tumour cell lines, hypoxia inhibits cell apoptosis and enhances 
cell growth (Cuisnier et al. 2003). We demonstrated that hypoxia induced cell 
apoptosis and decreased cell growth in both BAEC and BASMC by FACS analysis 
and western blot. However, these effects were altered in the presence of high glucose 
in vitro. A recent study showed that hypoxia-induced apoptosis in rat neonatal 
cardiac myocytes was prevented by the presence of as little as ImM glucose in the 
medium (Malhotra and Brosius 1999). Glucose inhibited translocation of cytochrome 
c from mitochondria to the cytosol and cleavage of the death substrate poly 
ADP-ribose polymerase (PARP). Cleavage of PARP and DNA laddering were 
prevented by preincubation with caspase inhibitors indicating participation of
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activated caspase in the apoptotic process (Lin et al. 2000). The alternate substrates 
lactate, pyruvate and propionate provided no protection from apoptosis and the effect 
of extracellular glucose on apoptotic biochemical and morphological changes was 
eliminated when glycolysis was blocked, indicating that glycolysis was necessary for 
glucose-induced protection (Malhotra and Brosius 1999).
The Bcl-2 family members are major regulators of the apoptotic process, 
whereas caspase are the major executioners. The cell death-regulating activity of the 
Bcl-2 family members appears to depend on their ability to modulate mitochondrial 
function. Bcl-2 family members are divided into pro- and anti-apoptotic molecules 
and it is suggested that protein-protein interactions between Bcl-2 family members 
are a major player in controlling the apoptotic process (Antonsson and Martinou
2000). Bax may form homodimers to accelerate cell death or heterodimers with 
either Bcl-2 or Bcl-X| to inhibit cell death. Therefore, the change in the ratio of Bcl-2 
or Bcl-X| and Bax protein expression may attenuate the anti-apoptotic effect in 
apoptosis (Baghelai et al. 1999).
In our study, Bax and Bcl-X| proteins were expressed in a constitutive manner 
in BAEC and BASMC under normoxic conditions. Following hypoxia, Bax inserts 
into the mitochondrial membranes, while it is located in the cytosol and in peripheral 
association with intracellular membranes including mitochondria in normoxic 
conditions which suggests that Bax translocation from cytosol to the mitochondrial 
membrane occurred under a physiological condition, thereby leading to pathological 
tissue destruction (Yamamoto et al. 2004). Hyperglycaemia did significantly 
enhance the expression of Bax and Bcl-X| protein expression under hypoxic 
conditions when compared to hypoxic control, however; the ratio of increased Bcl-X| 
was found to be fivefold over Bax in BAEC and threefold over Bax in BASMC. This 
increased Bcl-X|/Bax ratio correlates with previous studies; suggesting that the 
increase in Bcl-X| protein expression is involved in the inhibition of hypoxia-induced 
apoptosis(Clark et al. 1999; Riva et al. 2001). These results reveal a direct link 
between hypoxia and the regulation of proteins implicated in the control of cellular 
death. Conversely, these results are different from those where short ischemia and 
reperfusion did not alter Bcl-2 expression, but overexpression of Bax changed the 
ratio of Bax over Bcl-2 in the favour of apoptotic cell death (Moley et al. 1998; 
Nakamura et al. 2000; Podesta et al. 2000; Nakagami et al. 2001).
Since no change in bcl-xl and Bax gene expression was found in our studies
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under either normoxic or hypoxic conditions in the absence or presence of high 
glucose, we propose that glucose inhibits cell apoptosis and enhances cell 
proliferation under hypoxic conditions in part by upregulation of Bcl-X| and Bax 
protein expression.
Bax promotes cytochrome c release (Appaix et al. 2000), which in turns 
activates caspase-9 and caspase-3 (Kluck et al. 1997; Yang et al. 1997; de Moissac et 
al. 2000). It was recently reported that caspases are important regulators of apoptosis 
and the release of cytochrome c from mitochondria activated caspase, especially 
caspase-3 (Green and Reed 1998). Our studies in which hyperglycaemia inhibits cell 
caspase-3 activation and caspase-3 protein expression in hypoxia to prevent cell 
apoptosis suggests that the protective action of high glucose appears to involved the 
caspase pathway via caspase-3, an effector molecule in the caspase-mediated cascade 
of apoptosis induction (Shi 2002).
Adaptive responses of cells to hypoxia are mediated by the hypoxia-induced 
factor-1 (HIF-1). Regulation of HIF-1 activity is critically dependent on the 
degradation of the HIF-1 a subunit which, when stabilized against degradation, 
upregulates genes involved in angiogenesis, glycolytic energy metabolism, cell 
proliferation and survival (Huang et al. 1998; Kallio et al. 1999; Bruick and 
McKnight 2001; Epstein et al. 2001; Ivan et al. 2002).
The issue of whether HIF-1 a is a pro- or anti-apoptotic protein is a matter of 
some debate (Piret et al. 2002) and there are published studies that are supportive of 
either viewpoint (Yu et al. 2004; Gwak et al. 2005; Luo et al. 2006). It has been 
shown that HIF-1 a may indirectly produce a pro-apoptotic effect either by 
upregulating the expression of proteins in the Bcl-2 family that are known to mediate 
cell death or by associating with and stabilizing these proteins. The tumour 
suppressor protein p53 can activate target genes that initiate cell death. The 
accumulation of wild-type p53 in response to hypoxia was shown to be 
HIF-la-dependent since p53 induction did not occur in a mutant hepatoma cell line 
that was incapable of synthesizing HIF-la, whereas transfection with HIF-la 
increased the amount of endogenous p53 in normoxic cells (An et al. 1998). Other 
investigator have demonstrated that hypoxic induction of the pro-apoptotic protein 
BNIP3 was mediated via HIF-la in renal carcinoma and Chinese hamster ovary cell 
lines (Sowter et al. 2001).
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In contrast to these observations, other evidence suggests that HIF-la may 
have a protective role in limiting hypoxia-induced apoptosis. One study showed that 
pancreatic cancer cell lines that constitutively expressed HIF-la were more resistant 
to apoptosis induced by hypoxia than were similar cell lines that lacked constitutive 
HIF-la expression (Akakura et al. 2001). In addition, the induction of HIF-la by 
hypoxia was shown to be protective against the apoptotic effect in a hepatoma cell 
line (Piret et al. 2002). Further evidence supporting an anti-apoptotic role for HIF-la 
was demonstrated when neutralizing antibody against vascular endothelial growth 
factor (VEGF), the major target gene protein transactivated by HIF-1, was shown to 
block the anti-apoptotic effect of hypoxia (Baek et al. 2000).
Although in all cell lines tested, exposure of cells to hypoxia rapidly 
increased HIF-la cellular protein levels; this expression is also induced by serum 
deprivation, hormones and growth factors in VSMC (Richard et al. 2000).
In our study, we observed that the HIF-la protein level under hypoxic 
conditions was altered by high glucose and HIF-la mRNA remained unchanged 
which supports previous reports that HIF-la activation is regulated at the protein 
level (Maxwell et al. 1999; Lee et al. 2004). Under hypoxic conditions, HIF-1 has 
been shown to upregulate the expression of a number of genes (Bunn and Poyton 
1996) among them those encoding glycolytic enzymes such as aldolase A and C 
(Ebert et al. 1996), lactate dehydrogenase A and phosphoglycerate kinase 1 (Firth et 
al. 1994). Moreover, during hypoxia, transportation of glucose into cells and 
glycolytic enzyme activity are enhanced and hypoxia upregulates expression of 
several key genes in the glycolysis pathway such as hexokinase 1 (HK1), 
phosphoglycerate kinase 1 (PGK1) and GLUT-1 which modulates glucose 
transportation and glycolysis under the control of HIF-la during hypoxia. (Chen et al. 
2001; Semenza 2003; Gao et al. 2004). It is important to note that in another model, 
hypoxic rat cardiomyocytes, glucose uptake and metabolism was found to be 
protective against hypoxia-induced apoptosis (Malhotra and Brosius 1999). The 
interaction of the signals of glucose and hypoxia was proposed also from 
experiments with mouse embryonic stem cells in which hypoglycaemia and hypoxia 
induced the expression of phosphoglycerate kinase 1, VEGF, lactate dehydrogenase 
and GLUT-1 (Krones et al. 2001).
When we exposed cells transfected with HIF-la siRNA to hypoxia, it was 
found that cell apoptosis was decreased and proliferation was increased; suggesting
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HIF-la mediates cell fate by functioning as a pro-apoptotic protein. However, the 
effect of cell apoptosis and proliferation mediated by hyperglycaemia was impaired 
in HIF-la siRNA transfected cells which suggest that alteration of hyperglycaemia 
on BAEC and BASMC cell fate (proliferation and apoptosis) is HIF-la-dependent. 
Furthermore, concurrent results found in caspase-3 activity suggest that caspase-3 
suppression was of particular mechanistic importance.
Moreover, HIF-la overexpression significantly enhanced the growth 
inhibitory and pro-apoptotic response to hypoxia, whereas application of siHIF-la 
markedly attenuated these features under hypoxic conditions in A549 cells (an 
alveolar epithelial cell line) (Krick et al. 2005) which correlates with our studies.
BNIP3 is a member of pro-apoptotic Bcl-2 family which has been shown to 
bind to Bcl-2 to inhibit its activity (Boyd et al. 1994), and BNIP3-Like (BNIP3L) 
and BNIP3 reveal a high degree of sequence conservation at the Bcl-2 homology 
(BH) 3 domain (Matsushima et al. 1998) and it has also been shown that BNIP3L 
directly targets the mitochondria to induce apoptosis-associated mitochondrial 
changes including membrane potential loss and cytochrome c release (Imazu et al. 
1999). According to our studies, BNIP3L protein level was not detected under 
normoxia which correlates with previous studies (Kubasiak et al. 2002; Kothari et al. 
2003; Schmidt-Kastner et al. 2004). As a pro-apoptotic protein, BNIP3L protein 
expression was significantly increased in hypoxia which supports previous studies 
that demonstrated that hypoxia-inducible expression of BNIP3L was HIF-dependent 
and caused apoptosis in neuroblastoma cells (Graeber et al. 1996). The response of 
BNIP3L to hypoxia in human cell lines was further characterized and BNIP3L was 
overexpressed in human tumours which implicated BNIP3L as an important mediator 
of HIF-1 signalling pathway leading to cell death (Mason et al. 2002). HIF-la is 
essential for BNIP3 transcriptional activation under hypoxia, it has been previously 
shown that rodent BNIP3 promoter is activated by HIF-la (Bruick 2000), however, 
direct interaction between BNIP3 promoter and HIF-la was not demonstrated. Our 
studies demonstrated that BNIP3L expression was inhibited by high glucose under 
hypoxic conditions which suggests that hyperglycaemic protection of 
hypoxia-induced apoptosis may occur via the inhibition of BNIP3L protein 
expression or the interaction of with HIF-la. Moreover, it has been shown that 
HIF-la could directly bind to an HRE site on the human BNIP3 promoter and this 
binding is required for activation of the human BNIP3 promoter (Kothari et al. 2003)
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(Fig. 6.1).
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Fig. 6.1 D iagram m atic representation of the effects of hypoxia and 
hyperglycaemia on BAEC and BASMC fate
M any genes contain h ypoxia response elements (HRE) w hich are required for 
transcriptional activation in response to reduced cellular 0 2 concentration (Semenza 
and W ang 1992). H ypoxia response elements containing functionally essential HIF-1 
binding sites w ith  the consensus sequence 5 ’ -R C G T G -3 ’ (Semenza et al. 1996) has 
been identified in over 50 genes including those encoding transferrin, V E G F, 
inducible nitric oxide synthase (iN OS), heme oxygenase 1 (HO 1), glucose 
transporter 1 (G L U T -1) (W enger and Gassmann 1997). Each o f  these proteins plays 
an important role in system ic, local, or intracellular O2 homeostasis: transferrin 
delivers iron to the bone marrow for incorporation into haemoglobin; V E G F  
mediates vascularization; iN O S and HO 1 synthesize N O  and C O  respectively, 
w hich modulate vascular tone; and induction o f  G LU T -1 and glycolytic enzymes 
allow s for increased anaerobic A T P  synthesis.
Taken w ith  our previous study that showed glucose inhibits H IF -la  protein 
expression; w e hypothesis that this reduction in H IF -la  expression results in 
decreased binding o f  H IF -la  to HIF-1 p (A R N T) thereby inhibiting the formation o f
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the functional HIF molecule that is required to bind to HRE’s to regulate gene 
expression.
It has been shown that hyperglycaemia inhibits hypoxia-induced stabilization 
of HIF-la protein levels against degradation and that mechanisms in addition to 
proline hydroxylation may be involved in primary human dermal fibroblasts and 
endothelial cells (Catrina et al. 2004). To further investigate how high glucose 
modulates HIF-la protein levels under physiological conditions to modulate 
macrovascular cell growth, inhibition of HIF-la proteosomal degradation could be 
carried out using proteosomal inhibitors to detect the hyperglycaemic effects on 
BAEC/BASMC cell fate in either normoxia or hypoxia.
Hyperglycaemia/hypoxia has shown parallel effects on BAEC and BASMC 
growth in mono-cultures in our present studies, however, as two different cell types, 
the dissimilarity of cell response to pathological conditions needs to be further 
investigated. Cyclic strain is a powerful stimulus and can also regulate cell fate 
decisions. Exposure of VSMC to cyclic strain leads to apoptosis via a p53 pathway, 
in contrast, cyclic strain can suppress EC apoptosis via. AKT phosphorylation (Mayr 
et al. 2002; Persoon-Rothert et al. 2002). The relationship between circumferential 
stress and the structure of the vascular wall has been well established in 
macrovascular cell types. Increases in arterial pressure are associated with VSMC 
hypertrophy and increases in extracellular matrix (ECM) production. Conversely 
decreases in arterial pressure result in vessel atrophy (Bomberger et al. 1980). To 
examine the relations between BAEC and BASMC, the effects of exposing 
BAEC/BASMC co-cultures to pulsatile flow under normoxic/hypoxic conditions 
warrants further investigation.
In addition to controlling a switch to glycolytic metabolism and induction of 
erythropoiesis and angiogenesis, hypoxia promotes the undifferentiated cell state in 
various stem and precursor cell populations and the latter process requires Notch 
signalling (Gustafsson et al. 2005) (Fig. 6.2). Notch signalling is an attractive 
candidate for this process as it functions to maintain the stem/progenitor cell state 
such as myogenesis (Nofziger et al. 1999; Dahlqvist et al. 2003) and hematopoiesis 
(Varnum-Finney et al. 2000) and it is central to modulating fate decisions 
(proliferation, migration, differentiation and apoptosis) during embryonic 
development of the vasculature.
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Fig. 6.2 D iagram m atic representation of the Notch Signalling Pathway
On binding of Notch ligand to receptor, cleavage by presenilin occurs and Notch IC 
is translocated to the nucleus. Notch IC then interacts with the CSL 
[CBF-l(RBP-jK)/Su (H)/Lagl] family of DNA binding proteins to form a 
transcriptional activator. This transcriptional activator turns on transcription of a 
set of target genes, including HRT-1, 2 and 3. Most Notch target genes encode 
transcriptional regulators. These are involved in modulating cell fate by affecting 
the function of tissue-specific basic helix-loop-helix transcriptional factors or 
through other molecular targets such as NF-kfl.
Studies within our own laboratory have shown that the Notch signalling 
pathway is fundamental in controlling the balance between VSMC proliferation and 
apoptosis (Sweeney et al. 2004; Morrow et al. 2005; Morrow et al. 2005). The link 
between hypoxia and Notch may have ramifications for other aspects of hypoxia, 
such as tumour development, in which deregulation of both HIF-la and Notch 
mediated signalling events have been implicated (Radtke and Raj 2003; Weng and 
Aster 2004). As many tumours show elevated expression of HIF-la caused by 
hypoxia inherent to growing tumours and genetic loss of VHL (Kondo and Kaelin
2001), it will be interesting to investigate whether the elevated levels of HIF-la are 
paralleled by increased Notch signalling and whether the ensuing Notch induction 
contributes to macrovascular cell growth (Fig. 6.3).
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The canonical HIF-la and Notch signalling pathways
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In conclusion, our results demonstrate that hyperglycaemia itself does not 
alter BAEC and BASMC cell fate (proliferation and apoptosis) in either full serum or 
low serum containing media under normoxic conditions. Hypoxia significantly 
induces cell apoptosis and decreases proliferation, which is impaired by 
hyperglycaemia via a HIF-la-dependent pathway. Hypoxia and hyperglycaemia, as 
two very important factors, suggest playing an essential pathophysiologial role in the 
progression of diabetic vascular diseases.
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Appendix 1
Primer Name AccessionNumber Species Primer Sequence
HIF-la NM_174339 Bovine
For: tea get att tgc gtg tga gg 
Rev: teg tgg tea eat gga tga gl
Bax U92569 Bovine For: tel gac ggc aac lie aac tg Rev: tgg gtg tee eaa agt agg ag
Bcl-Xi. AF245487 Bovine For: ggt att ggt gag teg gat eg Rev: aag agt gag ccc age aga ac
18S Ribosome AF176811 Bovine For: aaa egg eta cea cat cca ag Rev: cge tee caa gat cca act ac
H if-la siRNA NM_174339 Bovine 5’-gag acu gau gac caa caa ctt-3’
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Appendix 2
Antibody Dilution Secondary Antibody Dilution & Species
pCNA 1:80 1:4000 anti-mouse
Caspase-3
1:1000
1 :2000 anti-rabbit
B cI-Xl 1:200 1:1000 anti-mouse
Bax 1:1000 1:2000 anti-rabbit
H if-la 1:250 1:250 anti-mouse
BNIP3L 1:500 1:1000 anti-rabbit
2 1 2
Appendix 3
Caspase-3 activity =
Specific Activity =
nmol pNA / 100 »1 x dilution factor Molar Extinction Coefficient 
(10.5) x Volume (ml) x Time (mins)
Caspase-3 activity ('mnol pNA/min/ml~) = |.imol 
pNA/min/mg mg Protein x 0.1
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